Aims: To estimate the association of smoking status with rates of i) infection, ii) hospitalisation, iii) disease severity, and iv) mortality from SARS-CoV-2/COVID-19 disease.
Design: Living rapid review of observational and experimental studies with random-effects hierarchical Bayesian meta-analyses. Published articles and pre-prints were identified via MEDLINE and medRxiv.
Setting: Community or hospital. No restrictions on location.
Participants: Adults who received a SARS-CoV-2 test or a COVID-19 diagnosis.
Measurements: Outcomes were SARS-CoV-2 infection, hospitalisation, disease severity and mortality stratified by smoking status. Study quality was assessed (i.e. ‘good,’ ‘fair’ and ‘poor’).
Findings: v12 (searches up to 2021-07-18) included 547 studies with 87 ‘good’ and ‘fair’ quality studies included in unadjusted meta-analyses. 171 studies (31.3%) reported current, former and never smoking status with the remainder using broader categories. Recorded smoking prevalence among people with COVID-19 was generally lower than national prevalence. Current compared with never smokers were at reduced risk of SARS-CoV-2 infection (RR = 0.67, 95% Credible Interval (CrI) = 0.6-0.75, τ = 0.27). Data for former smokers were inconclusive (RR = 0.99, 95% CrI = 0.94-1.05, τ = 0.12) but favoured there being no important association (0% probability of RR ≥1.1). Former compared with never smokers were at increased risk of hospitalisation (RR = 1.27, CrI = 1.15-1.4, τ = 0.2), greater disease severity (RR = 1.69, CrI = 1.3-2.22, τ = 0.43) and mortality (RR = 1.59, CrI = 1.34-1.89, τ = 0.37). Current compared with never smokers were at increased risk of greater disease severity (RR 1.3, 95% CrI = 1.01-1.71, τ = 0.32). Data for current smokers on hospitalisation and mortality were inconclusive (RR = 1.1, 95% CrI = 0.97-1.24, τ = 0.23; RR = 1.13, 95% CrI = 0.9-1.4, τ = 0.41, respectively) but favoured there being no important associations (50% and 60% probability of RR ≥1.1, respectively).
Conclusions: Compared with never smokers, current smokers appear to be at reduced risk of SARS-CoV-2 infection and increased risk of greater disease severity, while former smokers appear to be at increased risk of hospitalisation, greater disease severity and mortality from COVID-19. However, it is uncertain whether these associations are causal.
v7 of this living review article has been published in Addiction
COVID-19 is a respiratory disease caused by the SARS-CoV-2 virus. Large age and gender differences in case severity and mortality have been observed in the ongoing COVID-19 pandemic (Guan, Ni, et al., 2020); however, these differences are currently unexplained. SARS-CoV-2 enters epithelial cells through the angiotensin-converting enzyme 2 (ACE-2) receptor (Hoffmann et al., 2020). Some evidence suggests that gene expression and subsequent receptor levels are elevated in the airway and oral epithelium of current smokers (Brake et al., 2020; G. Cai, 2020), which could put smokers at higher risk of contracting SARS-CoV-2. Other studies, however, suggest that nicotine downregulates the ACE-2 receptor (Oakes et al., 2018). These uncertainties notwithstanding, both former and current smoking is known to increase the risk of respiratory viral (Abadom et al., 2016; Denholm et al., 2010) and bacterial (Almirall et al., 1999; Feldman & Anderson, 2013) infections and is associated with worse outcomes once infected. Cigarette smoke reduces the respiratory immune defence through peri-bronchiolar inflammation and fibrosis, impaired mucociliary clearance and disruption of the respiratory epithelium (Dye & Adler, 1994). There is also reason to believe that behavioural factors (e.g. regular hand-to-mouth movements) involved in smoking may increase SARS-CoV-2 infection and transmission in current smokers. However, early data from the COVID-19 pandemic have not provided clear evidence for a negative impact of current or former smoking on SARS-CoV-2 infection or COVID-19 disease outcomes, such as hospitalisation or mortality (Vardavas & Nikitara, 2020). It has also been hypothesised that nicotine might protect against a hyper-inflammatory response to SARS-CoV-2 infection, which may lead to adverse outcomes in patients with COVID-19 disease (Farsalinos, Niaura, et al., 2020).
There are several reviews that fall within the scope of smoking and COVID-19 (Alqahtani et al., 2020; Berlin et al., 2020; Emami et al., 2020; Farsalinos, Barbouni, et al., 2020; Grundy* et al., 2020; Patanavanich & Glantz, 2020; Vardavas & Nikitara, 2020). We aimed to produce a rapid synthesis of available evidence pertaining to the rates of infection, hospitalisation, disease severity and mortality from SARS-CoV-2/COVID-19 stratified by smoking status. Given the increasing availability of data on this topic, this is a living review with regular updates. As evidence accumulates, the review will be expanded to include studies reporting COVID-19 outcomes by alternative nicotine use (e.g., nicotine replacement therapy or e-cigarettes).
Study design
This is a living evidence review which is updated as new evidence becomes available (Elliott et al., 2014). We adopted recommended best practice for rapid evidence reviews, which involved limiting the search to main databases and having one reviewer extract the data and another verify (Tricco et al., 2015). This study was not pre-registered but evolved from a report written for a UK medical society (Simons, Brown, et al., 2020). The most recent version of this living review is available here. Version 7 of this living review has been published in a peer-reviewed journal (Simons, Shahab, et al., 2020). A completed Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) checklist is included in Supplementary file 1.
Eligibility criteria
Studies were included if they:
Search strategy
The following terms were searched for in Ovid MEDLINE (2019-search date) as free text or Medical Subject Headings:
The following terms were searched for in titles, abstracts and full texts in medRxiv (no time limitations):
Additional articles/reports of interest were identified through mailing lists, Twitter, the International Severe Acute Respiratory and Emerging Infection Consortium (ISARIC) and the US Centers for Disease Control and Prevention (CDC). Where updated versions of pre-prints or public health reports were available, old versions were superseded.
Selection of studies
One reviewer screened titles, abstracts and full texts against the inclusion criteria.
Data extraction
Data were extracted by one reviewer and verified (i.e. independently checked against pre-prints and published reports) by another on i) author (year); ii) date published; iii) country; iv) study design; v) study setting; vi) sample size; vii) sex; viii) age; ix) smoking status (e.g. current, former, never, not stated, missing) and whether it was biochemically verified; x) use of alternative nicotine products (e.g. e-cigarettes); xi) SARS-CoV-2 testing; xii) SARS-CoV-2 infection; xiii) diagnosis of COVID-19; xiv) hospitalisation with COVID-19; xv) disease severity in those hospitalised with COVID-19; xvi) mortality; xvii) adjustment of smoking specific risk estimates for relevant covariates (e.g. age, sex); and xviii) whether a representative or random sampling method was used.
Quality appraisal
The quality of included studies was assessed to determine suitability for inclusion in meta-analyses. Studies were judged as ‘good’ quality if they: i) had <20% missing data on smoking status and used a reliable self-report measure that distinguished between current, former and never smoking status; AND ii) used biochemical verification of smoking status and reported results from adjusted analyses; OR reported data from a representative/random sample. Studies were rated as ‘fair’ if they fulfilled only criterion i) and were otherwise rated as ‘poor.’ The quality appraisal was conducted by one reviewer and verified by a second.
Evidence synthesis
A narrative synthesis was conducted. Data from ‘good’ and ‘fair’ quality studies were pooled in R v.3.6.3 (Team, 2013). In a living review where new data are regularly added to the analyses, it may be more appropriate to use a Bayesian (as opposed to frequentist) approach where prior knowledge is used in combination with new data to estimate a posterior risk distribution. A Bayesian approach mitigates the issue of performing multiple statistical tests, which can inflate family-wise error. A series of random-effects hierarchical Bayesian meta-analyses were performed with the brms (Bürkner, 2017) package to estimate the relative risk for each comparison with accompanying 95% credible intervals (CrIs). We first defined prior distributions for the true pooled effect size (µ) and the between-study heterogeneity (τ), with µ specified as a normal distribution with a mean equal to the derived point estimate from each comparison of interest in the immediately preceding version of this living review, and τ specified as a half-Cauchy distribution with a mean of 0 and standard deviation of 1. The half-Cauchy distribution was selected to reflect prior knowledge that high levels of between-study heterogeneity are more likely than lower levels. Markov Chain Monte Carlo methods (20,000 burn-ins followed by 80,000 iterations) were then used to generate a risk distribution for each study, in addition to a pooled effect for the posterior risk distribution. We report forest plots with the pooled effect for the posterior risk distribution displayed as the median relative risk with an accompanying 95% CrIs. We used the empirical cumulative distribution function (ECDF) to estimate the probability of there being a 10% reduction or 10% increase in relative risk (RR) (i.e. RR ≥1.1 or RR ≤0.9). Due to a lack of indication as to what constitutes a clinically or epidemiologically meaningful effect (e.g. with regards to onward disease transmission or requirements for intensive care beds), we deemed a 10% change in risk as small but important. Where data were inconclusive (as indicated by CrIs crossing RR = 1.0), to disambiguate whether data favoured no effect or there being a small but important association, we estimated whether there was ≥75% probability of RR ≥1.1 or RR ≤0.9.
Two sensitivity analyses were performed. First, a minimally informative prior for µ was specified as a normal distribution with a mean of 0 and standard deviation of 1 and τ as described above. Second, an informative prior as described above for µ was used with τ specified as a half-Cauchy distribution with a mean of 0.3 and standard deviation of 1 to reflect greater between-study heterogeneity.
To aid in the visualisation of smoking prevalence in the included studies, the weighted mean prevalence of current and former smoking was calculated for countries with ≥3 studies and plotted for comparison with national prevalence estimates. It should be noted that prevalence estimates in the included studies were not adjusted for age, sex, socioeconomic position, or geographic region within countries.
In the current review version (v12) with searches up to 2021-07-18, a total of 1940 records were identified, with 547 studies included in a narrative synthesis and 87 studies included in meta-analyses (see Figure 1).
Figure 1. PRISMA flow diagram of included studies.
Characteristics of included studies are presented in Table 1. Studies were conducted across 51 countries. 139 studies were conducted in the USA, 76 in China, 63 in the UK, 32 in Spain, 26 in Italy, 25 in France, 21 in Mexico, 18 in multiple countries, 12 in Switzerland, 11 in Iran, 10 in Turkey, 9 in Brazil, with 8 in India and 97 studies from 39 further countries. The majority of studies used observational designs (see Supplementary table S1). 326 (59.6%) were conducted in hospital settings, 129 studies (23.6%) included individuals from community and hospital settings, 88 studies (16.1%) were conducted exclusively in the community, with one study each conducted in a homeless shelter and a quarantine centre, and one study that did not state the study setting. Studies had a median of 576 (interquartile range = 170-2810) participants. The majority of studies (58.1%) used reverse transcriptase polymerase chain reaction (RT-PCR) for confirmation of SARS-CoV-2 infection, 9.7% used an antibody test to confirm prior infection and 4.4% of studies relied on a combination of RT-PCR, antigen or antibody assays.
Categorisation of smoking status was heterogeneous (see Table 1). 296 (54.1%) studies collected data on smoking status through routine electronic health records (EHRs), 211 (38.6%) studies used a bespoke case report form for COVID-19 and 40 (7.3%) studies did not state the source for information on smoking status. None of the studies verified smoking status biochemically. Notably, only 171 (31.3%) studies reported current, former and never smoking status (see Supplementary table S2a), with a further 26 studies reporting only ever and never smoking status (see Supplementary table S2b). The remaining 336 studies reported current, current/former or current and former smoking status but did not explicitly state whether remaining participants were never smokers or if data were missing on smoking status (see Supplementary table S2c). 188 studies explicitly reported the proportion with missing data on smoking status, which ranged from 0% to 97.6%.
Fifteen studies recorded the use of alternative nicotine products in current and/or former smokers but did not report COVID-19 outcomes stratified by alternative nicotine use (see Table 1).
Nine studies were performed in random or representative population samples and were rated as ‘good’ quality, and 131 studies were rated as ‘fair’ quality, of which 87 studies reported results stratified by smoking status for the outcomes of interest and could be included in meta-analyses. The remaining 407 studies were rated as ‘poor’ quality (see Table 1).
ref | Lead author | Date published | Country | Sample size | Study setting | Median (IQR) | Female % | Current smoker % | Current vaper % | Current smoker, current vaper % | Current smoker, former vaper % | Former smoker % | Former smoker, current vaper % | Former smoker, former vaper % | Current/former smokers % | Never smokers % | Never smoker, current vaper % | Never smoker, former vaper % | Never/unknown smokers % | Missing % | Study quality |
C. Huang et al. (2020) | Huang, Wang | 2020-01-24 | China | 41 | Hospital | 49 (41-58) | 27.0 | 7.3 | - | - | - | - | - | - | - | - | - | - | - | 92.7 | poor |
Jie Li et al. (2020) | Li | 2020-02-12 | China | 17 | Hospital | 45 (33-57) | 47.1 | 17.6 | - | - | - | - | - | - | - | - | - | - | - | 82.3 | poor |
Jin-jin Zhang et al. (2020) | Zhang, Dong | 2020-02-19 | China | 140 | Hospital | 57^ (25-87) | 46.3 | 1.4 | - | - | - | 5.0 | - | - | - | - | - | - | - | 93.6 | poor |
Yang et al. (2020) | Yang, Yu | 2020-02-24 | China | 52 | Hospital | 60 (47-73) | 37.0 | 3.8 | - | - | - | - | - | - | - | - | - | - | - | 96.2 | poor |
Guan, Ni, et al. (2020) | Guan, Ni | 2020-02-28 | China | 1,099 | Hospital | 47 (35-58) | 41.9 | 12.5 | - | - | - | 1.9 | - | - | - | 84.3 | - | - | - | 1.3 | fair |
W. Liu et al. (2020) | Liu, Tao | 2020-02-28 | China | 78 | Hospital | 38 (33-57) | 50.0 | - | - | - | - | - | - | - | 6.4 | - | - | - | - | 93.6 | poor |
Qi et al. (2020) | Qi | 2020-03-03 | China | 267 | Hospital | 48 (35-65) | 45.2 | 19.9 | - | - | - | - | - | - | - | - | - | - | 80.1 | 0.0 | poor |
Y. Huang et al. (2020) | Huang, Yang | 2020-03-05 | China | 36 | Hospital | 69 (60-78) | 30.6 | - | - | - | - | - | - | - | 11.1 | - | - | - | - | 88.9 | poor |
Xu et al. (2020) | Xu | 2020-03-08 | China | 53 | Hospital | NA | 47.2 | 11.3 | - | - | - | - | - | - | - | - | - | - | - | 88.7 | poor |
F. Zhou et al. (2020) | Zhou, Yu | 2020-03-11 | China | 191 | Hospital | 56 (46-67) | 38.0 | 5.8 | - | - | - | - | - | - | - | - | - | - | - | 94.2 | poor |
R. Liu et al. (2020) | Liu, Ming | 2020-03-12 | China | 41 | Hospital | 39 (30-48) | 58.5 | 9.8 | - | - | - | - | - | - | - | - | - | - | - | 90.2 | poor |
Mo et al. (n.d.) | Mo | 2020-03-16 | China | 155 | Hospital | 54 (53-66) | 44.5 | 3.9 | - | - | - | - | - | - | - | - | - | - | - | 96.1 | poor |
Y. Shi et al. (2020) | Shi, Yu | 2020-03-18 | China | 487 | Hospital | 46 (27-65) | 46.8 | - | - | - | - | - | - | - | 8.2 | - | - | - | - | 91.8 | poor |
Xiaoli Zhang et al. (2020) | Zhang, Cai | 2020-03-20 | China | 645 | Hospital | NA | 49.1 | 6.4 | - | - | - | - | - | - | - | - | - | - | - | 93.6 | poor |
Dong et al. (2020) | Dong, Cao | 2020-03-20 | China | 9 | Hospital | 44 (30-46) | 66.7 | 11.1 | - | - | - | - | - | - | - | - | - | - | - | 88.9 | poor |
S. Wan et al. (2020) | Wan | 2020-03-21 | China | 135 | Hospital | 47 (36-55) | 46.7 | 6.7 | - | - | - | - | - | - | - | - | - | - | - | 93.3 | poor |
X. Jin et al. (2020) | Jin | 2020-03-24 | China | 651 | Hospital | 46 (32-60) | 49.2 | 6.3 | - | - | - | - | - | - | - | - | - | - | - | 93.7 | poor |
R. Wang et al. (2020) | Wang, Pan | 2020-03-24 | China | 125 | Hospital | 41 (26-66) | 43.2 | - | - | - | - | - | - | - | 12.8 | - | - | - | - | 87.2 | poor |
Lian et al. (n.d.) | Lian | 2020-03-25 | China | 788 | Hospital | NA | 38.5 | 6.9 | - | - | - | - | - | - | - | - | - | - | - | 93.2 | poor |
Hu et al. (2020) | Hu | 2020-03-25 | China | 323 | Hospital | 61^ (23-91) | 48.6 | - | - | - | - | - | - | - | 11.8 | - | - | - | - | 88.2 | poor |
Guan, Liang, et al. (2020) | Guan, Liang | 2020-03-26 | China | 1,590 | Hospital | 49 (33-64) | 42.7 | - | - | - | - | - | - | - | 7.0 | 93.0 | - | - | - | 0.0 | poor |
T. Chen et al. (2020) | Chen | 2020-03-26 | China | 548 | Hospital | 62 (44-70) | 37.6 | 4.4 | - | - | - | 2.6 | - | - | - | - | - | - | - | 93.1 | poor |
Guo et al. (2020) | Guo | 2020-03-27 | China | 187 | Hospital | 59 (45-73) | 51.3 | 9.6 | - | - | - | - | - | - | - | - | - | - | - | 90.4 | poor |
CDCMMWR (2020) | Chow (US CDC) | 2020-03-31 | USA | 7,162 | Community and Hospital | NA | - | 1.3 | - | - | - | 2.3 | - | - | - | - | - | - | - | 96.4 | poor |
E. S. Kim et al. (2020) | Kim | 2020-04-01 | South Korea | 28 | Hospital | 43 (30-56) | 46.4 | 17.9 | - | - | - | - | - | - | - | - | - | - | - | 82.1 | poor |
Feng et al. (2020) | Feng | 2020-04-10 | China | 476 | Hospital | 53 (40-64) | 43.1 | 9.2 | - | - | - | - | - | - | - | - | - | - | - | 90.8 | poor |
C. Rentsch et al. (2020) | Rentsch | 2020-04-14 | USA | 3,528 | Community and Hospital | 66 (60-70) | 4.6 | 27.2 | - | - | - | 30.6 | - | - | - | 36.9 | - | - | - | 5.3 | fair |
Goyal et al. (2020) | Goyal | 2020-04-17 | USA | 393 | Hospital | 62.2 (49-74) | 39.3 | 5.1 | - | - | - | - | - | - | - | - | - | - | - | 94.9 | poor |
K. I. Zheng et al. (2020) | Zheng, Gao | 2020-04-19 | China | 66 | Hospital | 47^ (NA) | 25.8 | 12.1 | - | - | - | - | - | - | - | - | - | - | - | 87.9 | poor |
Gold et al. (2020) | Gold (US CDC) | 2020-04-20 | USA | 305 | Hospital | NA | 50.5 | 5.2 | - | - | - | - | - | - | - | - | - | - | - | 94.8 | poor |
Argenziano et al. (2020) | Argenziano | 2020-04-22 | USA | 1,000 | Hospital | 63 (50-75) | 40.4 | 4.9 | - | - | - | 17.9 | - | - | - | 77.2 | - | - | - | 0.0 | fair |
Richardson et al. (2020) | Richardson | 2020-04-22 | USA | 5,700 | Hospital | 63 (52-75) | 39.7 | - | - | - | - | - | - | - | 9.8 | 52.8 | - | - | - | 37.4 | poor |
Fontanet et al. (2020) | Fontanet | 2020-04-23 | France | 661 | Community and Hospital | 37 (16-47) | 62.0 | 10.4 | - | - | - | - | - | - | - | - | - | - | 89.6 | 0.0 | poor |
P. Shi et al. (2020) | Shi, Ren | 2020-04-23 | China | 134 | Hospital | 46 (34-58) | 51.5 | - | - | - | - | - | - | - | 10.4 | - | - | - | - | 89.5 | poor |
Hadjadj et al. (2020) | Hadjadj | 2020-04-23 | France | 50 | Hospital | 55 (50-63) | 22.0 | 2.0 | - | - | - | 18.0 | - | - | - | 80.0 | - | - | - | 0.0 | fair |
Liao et al. (2020) | Liao, Feng | 2020-04-24 | China | 1,848 | Hospital | 55 (48-61) | 54.7 | - | - | - | - | - | - | - | 0.4 | - | - | - | - | 99.6 | poor |
Gil-Agudo et al. (2020) | Gil-Agudo | 2020-04-24 | Spain | 7 | Hospital | 68 (34-75) | 28.6 | - | - | - | - | - | - | - | 42.9 | 57.1 | - | - | - | 0.0 | poor |
Q. Yao et al. (n.d.) | Yao | 2020-04-24 | China | 108 | Hospital | 52 (37-58) | 60.2 | 3.7 | - | - | - | - | - | - | - | - | - | - | - | 96.3 | poor |
Zuo, Yalavarthi, et al. (2020) | Zuo, Yalavarthi | 2020-04-24 | USA | 50 | Hospital | 61 (46-76) | 34.0 | - | - | - | - | - | - | - | 36.0 | - | - | - | - | 64.0 | poor |
Solís & Carreño (2020) | Solis | 2020-04-25 | Mexico | 650 | Hospital | 46 (NA) | 42.1 | 9.4 | - | - | - | - | - | - | - | - | - | - | - | 90.6 | poor |
Yu et al. (2020) | Yu, Cai | 2020-04-27 | China | 95 | Hospital | NA | 44.2 | 8.4 | - | - | - | - | - | - | - | - | - | - | - | 91.6 | poor |
Ziehr et al. (2020) | Ziehr | 2020-04-29 | USA | 66 | Hospital | 58 (23-87) | 35.0 | - | - | - | - | - | - | - | 33.3 | 63.6 | - | - | - | 3.0 | poor |
Yi Zheng et al. (2020) | Zheng, Xiong | 2020-04-30 | China | 73 | Hospital | 43^ (NA) | 45.2 | - | - | - | - | - | - | - | 11.0 | 89.0 | - | - | - | 0.0 | poor |
Kalan et al. (2020) | Kalan | 2020-05-01 | Iran | 193 | Hospital | 52.6^ (37-67) | 36.3 | 7.3 | - | - | - | - | - | - | - | 85.0 | - | - | - | 7.8 | poor |
Kolin et al. (2020) | Kolin | 2020-05-05 | UK | 1,474 | Community and Hospital | 58 (49-67) | 46.6 | 14.5 | - | - | - | 40.2 | - | - | - | 44.6 | - | - | - | 0.8 | fair |
Borobia et al. (2020) | Borobia | 2020-05-06 | Spain | 2,226 | Hospital | 61 (46-78) | 52.0 | 7.1 | - | - | - | - | - | - | - | - | - | - | - | 93.0 | poor |
Giacomelli et al. (2020) | Giacomelli | 2020-05-06 | Italy | 233 | Hospital | 61 (50-72) | 31.9 | - | - | - | - | - | - | - | 30.0 | 70.0 | - | - | - | 0.0 | poor |
Shah et al. (2020) | Shah | 2020-05-06 | USA | 316 | Hospital | 63 (43-72) | 48.1 | 16.5 | - | - | - | 17.7 | - | - | - | 42.1 | - | - | - | 23.7 | poor |
Williamson et al. (2020) | The OpenSAFELY Collaborative | 2020-05-07 | UK | 17,425,445 | Community and Hospital | NA | 50.1 | 17.0 | - | - | - | 32.9 | - | - | - | 45.9 | - | - | - | 4.2 | fair |
Allenbach et al. (2020) | Allenbach | 2020-05-08 | France | 152 | Hospital | 77 (60-83) | 31.1 | - | - | - | - | - | - | - | 6.6 | - | - | - | - | 93.4 | poor |
Robilotti et al. (2020) | Robilotti | 2020-05-08 | USA | 423 | Hospital | NA | 50.0 | 2.1 | - | - | - | 37.6 | - | - | - | 58.6 | - | - | - | 1.6 | fair |
Lubetzky et al. (2020) | Lubetzky | 2020-05-08 | USA | 54 | Hospital | 57 (29-83) | 62.0 | - | - | - | - | - | - | - | 22.2 | - | - | - | - | 77.8 | poor |
Yin et al. (2020) | Yin, Yang | 2020-05-10 | China | 106 | Hospital | 73 (61-85) | 39.6 | - | - | - | - | - | - | - | 17.0 | - | - | - | - | 83.0 | poor |
Rica et al. (2020) | de la Rica | 2020-05-11 | Spain | 48 | Hospital | 66^ (33-88) | 33.0 | - | - | - | - | - | - | - | 20.8 | - | - | - | - | 79.2 | poor |
Cho et al. (2020) | Cho | 2020-05-11 | UK | 1,331 | Community and Hospital | NA | 49.2 | 19.0 | - | - | - | 27.0 | - | - | - | 54.0 | - | - | - | 0.0 | fair |
Yanover et al. (2020) | Yanover | 2020-05-13 | Israel | 4,353 | Community and Hospital | 35 (22-54) | 44.5 | 11.8 | - | - | - | 3.0 | - | - | - | 85.2 | - | - | - | 0.0 | fair |
Hamer et al. (2020) | Hamer | 2020-05-13 | UK | 387,109 | Hospital | 56.2 (48-64) | 55.1 | 9.7 | - | - | - | 34.8 | - | - | - | 55.5 | - | - | - | 0.0 | fair |
Targher et al. (2020) | Targher | 2020-05-13 | China | 339 | Hospital | 48.4^ (NA) | 52.8 | 8.3 | - | - | - | - | - | - | - | - | - | - | - | 91.7 | poor |
Carrillo-Vega et al. (2020) | Carillo-Vega | 2020-05-14 | Mexico | 10,544 | Community and Hospital | 46.5^ (30-62) | 42.3 | 8.9 | - | - | - | - | - | - | - | - | - | - | - | 91.1 | poor |
Regina et al. (2020) | Regina | 2020-05-14 | Switzerland | 200 | Hospital | 70 (55-81) | 40.0 | 4.5 | - | - | - | - | - | - | - | - | - | - | - | 95.5 | poor |
Almazeedi et al. (2020) | Almazeedi | 2020-05-15 | Kuwait | 1,096 | Hospital | 41 (25-57) | 19.0 | 4.0 | - | - | - | - | - | - | - | - | - | - | 96.0 | 0.0 | poor |
Lusignan et al. (2020) | de Lusignan | 2020-05-15 | UK | 3,802 | Community | 58 (34-73) | 57.6 | 10.9 | - | - | - | 46.1 | - | - | - | 29.6 | - | - | - | 13.4 | fair |
Palaiodimos et al. (2020) | Palaiodimos | 2020-05-15 | USA | 200 | Hospital | 64 (50-73.5) | 51.0 | - | - | - | - | - | - | - | 32.5 | 67.5 | - | - | - | 0.0 | poor |
Mejia-Vilet et al. (2020) | Mejia-Vilet | 2020-05-16 | Mexico | 329 | Hospital | 49 (41-60) | 36.0 | - | - | - | - | - | - | - | 7.0 | - | - | - | - | 93.0 | poor |
C. Chen et al. (2020) | Chen, Jiang | 2020-05-16 | China | 135 | Hospital | NA | 42.2 | - | - | - | - | - | - | - | 9.6 | - | - | - | - | 90.4 | poor |
Jiong Li et al. (2020) | Li, Chen | 2020-05-16 | China | 1,008 | Hospital | 55 (44-65) | 43.6 | 5.7 | - | - | - | - | - | - | - | - | - | - | - | 94.3 | poor |
Valenti et al. (2020) | Valenti | 2020-05-18 | Italy | 789 | Community | 40.7^ (NA) | 35.0 | 25.9 | - | - | - | - | - | - | - | - | - | - | - | 74.1 | poor |
Feuth et al. (2020) | Feuth | 2020-05-18 | Finland | 28 | Hospital | 56 (47-72) | 46.0 | 10.7 | - | - | - | 28.6 | - | - | - | 60.7 | - | - | - | 0.0 | fair |
Ge et al. (2020) | Ge | 2020-05-18 | China | 51 | Hospital | 70 (58-79) | 27.5 | 13.7 | - | - | - | - | - | - | - | - | - | - | - | 86.3 | poor |
Parrotta et al. (2020) | Parrotta | 2020-05-18 | USA | 76 | Community and Hospital | 44.9 (13-71) | 61.8 | 2.6 | - | - | - | 26.3 | - | - | - | 68.4 | - | - | - | 2.6 | fair |
Shekhar et al. (2020) | Shekhar | 2020-05-18 | USA | 50 | Hospital | 55.5 (20-85) | 54.0 | 48.0 | - | - | - | - | - | - | - | - | - | - | - | 52.0 | poor |
Rimland et al. (2020) | Rimland | 2020-05-19 | USA | 11 | Hospital | 59 (48-65) | 18.2 | 9.1 | 9.1 | - | - | - | - | - | - | - | - | - | - | 81.8 | poor |
Basse et al. (2020) | Basse | 2020-05-19 | France | 141 | Hospital | 62 (52-72) | 72.0 | 17.7 | - | - | - | - | - | - | - | - | - | - | - | 82.3 | poor |
Freites et al. (2020) | Freites | 2020-05-19 | Spain | 123 | Hospital | 59.88^ (44-74) | 69.9 | 3.3 | - | - | - | - | - | - | - | - | - | - | - | 96.8 | poor |
Alshami et al. (2020) | Alshami | 2020-05-19 | Saudi Arabia | 128 | Quarantine Centre | 39.6^ (24-55) | 53.9 | 15.6 | - | - | - | 2.3 | - | - | - | - | - | - | - | 82.0 | poor |
Q. Shi et al. (2020) | Shi, Zhao | 2020-05-20 | China | 101 | Hospital | 71 (59-80) | 40.6 | - | - | - | - | - | - | - | 5.0 | - | - | - | - | 95.0 | poor |
Al-Hindawi et al. (2020) | Al-Hindawi | 2020-05-20 | UK | 31 | Hospital | 61 (NA) | 12.9 | 3.2 | - | - | - | 71.0 | - | - | - | 25.8 | - | - | - | 0.0 | fair |
M. A. Wu et al. (2020) | Wu | 2020-05-21 | Italy | 174 | Hospital | 61.2^ (50-71) | 30.5 | - | - | - | - | - | - | - | 33.3 | - | - | - | - | 66.7 | poor |
L. Kim et al. (2020) | Kim, Garg | 2020-05-22 | USA | 2,491 | Hospital | 62 (50-75) | 46.8 | 6.0 | - | - | - | 25.8 | - | - | - | - | - | - | 68.1 | 0.1 | poor |
Docherty et al. (2020) | Docherty | 2020-05-22 | Multiple | 20,133 | Hospital | 72.9 (58-82) | 40.0 | 4.2 | - | - | - | 21.7 | - | - | - | 44.5 | - | - | - | 29.6 | poor |
Petrilli et al. (2020) | Petrilli | 2020-05-22 | USA | 5,279 | Community and Hospital | 54 (38-66) | 51.5 | 5.5 | - | - | - | 17.1 | - | - | - | 61.9 | - | - | - | 15.6 | fair |
Klang et al. (n.d.) | Klang | 2020-05-23 | USA | 3,406 | Hospital | NA | 61.8 | - | - | - | - | - | - | - | 23.3 | - | - | - | - | 76.7 | poor |
Vaquero et al. (2020) | Vaquero-Roncero | 2020-05-24 | Spain | 146 | Hospital | 66^ (59-72) | 32.2 | - | - | - | - | - | - | - | 6.8 | - | - | - | - | 93.2 | poor |
Ip et al. (2020) | Ip | 2020-05-25 | USA | 2,512 | Hospital | 64 (52-76) | 37.6 | 3.1 | - | - | - | 17.8 | - | - | - | 64.5 | - | - | - | 14.6 | fair |
Heili-Frades (n.d.) | Heili-Frades | 2020-05-25 | Spain | 4,712 | Hospital | 62 (47-77) | 50.5 | 4.9 | - | - | - | 17.4 | - | - | - | - | - | - | 66.5 | 11.2 | poor |
Berumen et al. (2020) | Berumen | 2020-05-26 | Mexico | 102,875 | Hospital | NA | 49.1 | - | - | - | - | - | - | - | 9.6 | - | - | - | 90.4 | 0.0 | poor |
Garibaldi et al. (2020) | Garibaldi | 2020-05-26 | USA | 832 | Hospital | 63 (49-75) | 47.0 | 5.5 | - | - | - | 22.6 | - | - | - | - | - | - | - | 71.9 | poor |
Soto-Mota et al. (2020) | Soto-Mota | 2020-05-27 | Mexico | 400 | Hospital | NA | 30.0 | - | - | - | - | - | - | - | 12.0 | - | - | - | - | 88.0 | poor |
Jingwen Li et al. (n.d.) | Li, Long | 2020-05-28 | China | 145 | Not Stated | 49^ (13-80) | 61.0 | - | - | - | - | - | - | - | 5.5 | - | - | - | - | 94.5 | poor |
Louis et al. (2020) | Louis | 2020-05-28 | USA | 22 | Hospital | 66.5^ (55-77) | 36.4 | - | - | - | - | - | - | - | 45.5 | - | - | - | - | 54.5 | poor |
Kuderer et al. (2020) | Kuderer | 2020-05-28 | Multiple | 928 | Community and Hospital | 66 (57-76) | 50.0 | 4.6 | - | - | - | 35.1 | - | - | - | 50.5 | - | - | - | 9.7 | fair |
M. Gianfrancesco et al. (2020) | Gianfrancesco | 2020-05-29 | Multiple | 600 | Community and Hospital | 56 (45-67) | 71.0 | - | - | - | - | - | - | - | 21.5 | 64.8 | - | - | - | 13.7 | poor |
Chaudhry et al. (2020) | Chaudhry | 2020-05-29 | USA | 40 | Community and Hospital | 52 (45.5-61) | 60.0 | - | - | - | - | - | - | - | 15.0 | - | - | - | - | 85.0 | poor |
Niedzwiedz et al. (2020) | Niedzwiedz | 2020-05-29 | UK | 392,116 | Community and Hospital | NA | 54.9 | 9.8 | - | - | - | 34.8 | - | - | - | 55.4 | - | - | - | 0.0 | fair |
Valle et al. (2020) | del Valle | 2020-05-30 | USA | 1,484 | Hospital | 62 (52-72) | 40.6 | 5.5 | - | - | - | 23.3 | - | - | - | - | - | - | - | 71.2 | poor |
Bello-Chavolla, Bahena-López, et al. (2020) | Bello-Chavolla | 2020-05-31 | Mexico | 177,133 | Community and Hospital | 42.6 (26-59) | 48.9 | - | - | - | - | - | - | - | 9.3 | - | - | - | - | 90.7 | poor |
Batty et al. (2020) | Batty | 2020-06-01 | UK | 908 | Hospital | 57.27^ (48-66) | 44.3 | 11.2 | - | - | - | - | - | - | - | - | - | - | - | 88.8 | poor |
Israel, Feldhamer, et al. (2020) | Israel | 2020-06-01 | Israel | 24,906 | Community and Hospital | 40 (27-59) | 48.7 | 16.8 | - | - | - | 12.7 | - | - | - | 70.5 | - | - | - | 0.0 | fair |
Hao et al. (2020) | Hao | 2020-06-01 | China | 788 | Hospital | 46 (35-56) | 48.4 | 6.9 | - | - | - | - | - | - | - | - | - | - | - | 93.2 | poor |
Lassale et al. (2020) | Lassale | 2020-06-01 | UK | 900 | Hospital | 57.2^ (48-66) | 44.4 | 11.4 | - | - | - | 41.9 | - | - | - | 46.7 | - | - | - | 0.0 | fair |
Eugen-Olsen et al. (2020) | Eugen-Olsen | 2020-06-02 | Denmark | 407 | Hospital | 64 (47-77) | 57.7 | 20.6 | - | - | - | 36.9 | - | - | - | 39.6 | - | - | - | 3.0 | fair |
Martinez-Portilla et al. (2020) | Martinez-Portilla | 2020-06-02 | Mexico | 224 | Community and Hospital | 29 (26-33) | 100.0 | - | - | - | - | - | - | - | 3.1 | - | - | - | - | 96.9 | poor |
Raisi-Estabragh et al. (n.d.) | Raisi-Estabragh | 2020-06-02 | UK | 4,510 | Hospital | NA | 48.8 | - | - | - | - | - | - | - | 51.8 | - | - | - | - | 48.2 | poor |
H. Luo et al. (2020) | Luo | 2020-06-02 | China | 625 | Hospital | 46 (NA) | 47.7 | 3.0 | - | - | - | - | - | - | - | - | - | - | - | 97.0 | poor |
Boulware et al. (2020) | Boulware | 2020-06-03 | Multiple | 821 | Community | 40 (33-50) | 51.6 | 3.3 | - | - | - | - | - | - | - | - | - | - | - | 96.7 | poor |
Ikitimur et al. (n.d.) | Ikitimur | 2020-06-03 | Turkey | 81 | Hospital | 55^ (38-72) | 44.0 | - | - | - | - | - | - | - | 28.4 | - | - | - | - | 71.6 | poor |
Sierpiński et al. (2020) | Sierpinski | 2020-06-03 | Poland | 1,942 | Community | 50 (NA) | 60.0 | 6.3 | - | - | - | - | - | - | - | - | - | - | 49.7 | 44.0 | poor |
B. Wang et al. (2020) | Wang, Oekelen | 2020-06-05 | USA | 58 | Community and Hospital | 67 (NA) | 48.0 | - | - | - | - | - | - | - | 36.2 | - | - | - | - | 63.8 | poor |
Perrone et al. (2020) | Perrone | 2020-06-05 | Italy | 1,189 | Hospital | NA | 21.2 | - | - | - | - | - | - | - | 21.9 | - | - | - | - | 78.1 | poor |
Sharma et al. (2020) | Sharma | 2020-06-05 | India | 501 | Hospital | 35.1^ (18-51) | 36.0 | - | - | - | - | - | - | - | 4.2 | - | - | - | - | 95.8 | poor |
Magagnoli et al. (2020) | Magagnoli | 2020-06-05 | USA | 807 | Hospital | 70 (60-75) | 4.3 | - | - | - | - | - | - | - | 15.9 | - | - | - | - | 84.1 | poor |
Ramlall et al. (2020) | Ramlall | 2020-06-06 | USA | 11,116 | Community and Hospital | 52 (34.7-69.5) | 55.2 | - | - | - | - | - | - | - | 26.8 | 73.2 | - | - | - | 0.0 | poor |
Giannouchos et al. (2020) | Giannouchos | 2020-06-07 | Mexico | 236,439 | Community and Hospital | 42.5^ (25-59) | 49.1 | 9.1 | - | - | - | - | - | - | - | - | - | - | 90.9 | 0.0 | poor |
Romão et al. (2020) | Romao | 2020-06-08 | Portugal | 34 | Community | 41^ (26-66) | 67.7 | - | - | - | - | - | - | - | 26.5 | - | - | - | - | 73.5 | poor |
Cen et al. (2020) | Cen | 2020-06-08 | China | 1,007 | Hospital | 61 (49-68) | 51.0 | - | - | - | - | - | - | - | 8.7 | - | - | - | - | 91.3 | poor |
Houlihan et al. (2020) | Houlihan | 2020-06-09 | UK | 200 | Community | 34 (29-44) | 61.0 | 11.0 | - | - | - | 16.5 | - | - | - | 66.5 | - | - | - | 6.0 | fair |
Lan et al. (2020) | Lan | 2020-06-09 | USA | 104 | Community | 49^ (34-63) | 47.1 | - | - | - | - | - | - | - | 24.0 | - | - | - | - | 76.0 | poor |
Russell et al. (2020) | Russell | 2020-06-09 | UK | 156 | Community and Hospital | 65.18^ (50-79) | 42.3 | 7.1 | - | - | - | 25.0 | - | - | - | 37.8 | - | - | - | 30.1 | poor |
Veras et al. (2020) | Veras | 2020-06-09 | Brazil | 32 | Hospital | 58.9^ (40-77) | 47.0 | - | - | - | - | - | - | - | 25.0 | - | - | - | - | 75.0 | poor |
Rossi et al. (2020) | Rossi | 2020-06-09 | France | 246 | Hospital | 68^ (53-83) | 39.0 | - | - | - | - | - | - | - | 25.2 | - | - | - | - | 74.8 | poor |
Martin-Jimenez et al. (2020) | Martin-Jiminez | 2020-06-09 | Spain | 339 | Hospital | 81.6 (72-87) | 39.5 | - | - | - | - | - | - | - | 30.7 | - | - | - | - | 69.3 | poor |
Rajter et al. (2020) | Rajter | 2020-06-10 | USA | 280 | Hospital | 59.6^ (41-77) | 45.5 | 5.7 | - | - | - | 10.7 | - | - | - | 74.6 | - | - | - | 8.9 | fair |
Yaya Zhou et al. (2020) | Zhou, He | 2020-06-10 | China | 238 | Hospital | 55.5 (35-67) | 57.0 | 2.9 | - | - | - | - | - | - | - | - | - | - | - | 97.1 | poor |
Woolford et al. (2020) | Woolford | 2020-06-11 | UK | 4,510 | Community and Hospital | 70.5 (NA) | 51.2 | 13.0 | - | - | - | 38.1 | - | - | - | 48.1 | - | - | - | 0.8 | fair |
Hultcrantz et al. (2020) | Hultcrantz | 2020-06-11 | USA | 127 | Community and Hospital | 68 (41-91) | 46.0 | - | - | - | - | - | - | - | 26.8 | 72.4 | - | - | - | 0.8 | poor |
Hernández-Garduño (2020) | Hernandez, Garduno | 2020-06-11 | Mexico | 32,583 | Community and Hospital | 45 (34-56) | 48.7 | - | - | - | - | - | - | - | 11.0 | - | - | - | 88.8 | 0.1 | poor |
Sterlin et al. (2020) | Sterlin | 2020-06-11 | France | 135 | Hospital | 61 (50-72) | 41.0 | 3.7 | - | - | - | 38.5 | - | - | - | 57.8 | - | - | - | 0.0 | fair |
Maraschini et al. (2020) | Maraschini | 2020-06-12 | Italy | 146 | Hospital | 32.5^ (27-38) | 100.0 | - | - | - | - | 9.6 | - | - | - | 80.8 | - | - | - | 9.6 | poor |
A.-L. Wang et al. (2020) | Wang, Zhong | 2020-06-12 | USA | 7,592 | Community and Hospital | NA | 45.1 | 3.6 | - | - | - | 17.1 | - | - | - | 51.9 | - | - | - | 27.4 | poor |
McQueenie et al. (2020) | McQueenie | 2020-06-12 | UK | 428,199 | Community and Hospital | NA | 54.9 | - | - | - | - | - | - | - | 44.4 | 55.0 | - | - | - | 0.6 | poor |
Miyara et al. (2020) | Miyara | 2020-06-12 | France | 479 | Community and Hospital | NA | 44.7 | 6.7 | 0.4 | - | - | 31.6 | - | - | - | 59.5 | - | - | - | 1.9 | fair |
Apea et al. (2021) | Apea | 2020-06-12 | UK | 1,737 | Hospital | 63.4^ (NA) | 30.4 | - | - | - | - | - | - | - | 10.0 | - | - | - | - | 90.0 | poor |
Garassino et al. (2020) | Garassino | 2020-06-12 | Multiple | 200 | Community and Hospital | 68 (61.8-75) | 30.0 | 24.0 | - | - | - | 55.5 | - | - | - | 18.5 | - | - | - | 2.0 | fair |
Zeng et al. (2020) | Zeng | 2020-06-16 | China | 1,031 | Hospital | 60.3^ (46-74) | 47.8 | - | - | - | - | - | - | - | 10.2 | - | - | - | - | 89.8 | poor |
Suleyman et al. (2020) | Suleyman | 2020-06-16 | USA | 463 | Hospital | 57.5^ (40-74) | 55.9 | - | - | - | - | - | - | - | 34.6 | - | - | - | - | 65.4 | poor |
L. Chen et al. (2020) | Chen, Yu | 2020-06-16 | China | 1,859 | Hospital | 59 (45-68) | 50.0 | 2.4 | - | - | - | 3.6 | - | - | - | 94.0 | - | - | - | 0.0 | fair |
Kibler et al. (2020) | Kibler | 2020-06-16 | France | 702 | Community and Hospital | 82^ (75-88) | 56.0 | 3.7 | - | - | - | - | - | - | - | - | - | - | - | 96.3 | poor |
Olivares et al. (2020) | Olivares | 2020-06-16 | Chile | 21 | Hospital | 61^ (26-85) | 76.2 | - | - | - | - | - | - | - | 9.5 | - | - | - | - | 90.5 | poor |
Elezkurtaj et al. (2020) | Elezkurtaj | 2020-06-17 | Germany | 26 | Hospital | 70 (61.8-78.3) | 34.6 | - | - | - | - | - | - | - | 19.2 | - | - | - | - | 80.8 | poor |
Zuo, Estes, et al. (2020) | Zuo, Estes | 2020-06-17 | China | 172 | Hospital | 61^ (25-95) | 44.0 | - | - | - | - | - | - | - | 26.2 | - | - | - | - | 73.8 | poor |
Killerby (2020) | Killerby | 2020-06-17 | USA | 531 | Community and Hospital | 51.6 (38-62) | 57.1 | - | - | - | - | - | - | - | 17.1 | 71.4 | - | - | - | 11.5 | poor |
Gu et al. (2020) | Gu | 2020-06-18 | USA | 5,698 | Community and Hospital | 47^ (26-67) | 62.0 | 7.0 | - | - | - | 24.7 | - | - | - | 50.8 | - | - | - | 17.5 | fair |
Wei et al. (2020) | Wei | 2020-06-18 | USA | 147 | Hospital | 52^ (34-70) | 41.0 | 14.3 | - | - | - | - | - | - | - | - | - | - | - | 85.7 | poor |
Crovetto et al. (2020) | Crovetto | 2020-06-19 | Spain | 874 | Community and Hospital | 33.7^ (28-38) | 100.0 | 1.1 | - | - | - | - | - | - | - | - | - | - | 13.2 | 85.7 | poor |
Govind et al. (2020) | Govind | 2020-06-20 | UK | 6,309 | Community and Hospital | 46.5^ (31-61) | 38.3 | 66.3 | - | - | - | 26.8 | - | - | - | 5.5 | - | - | - | 1.5 | fair |
Sisó-Almirall et al. (2020) | Siso-Almirall | 2020-06-20 | Spain | 322 | Community and Hospital | 56.7^ (38-74) | 50.0 | - | - | - | - | - | - | - | 25.2 | - | - | - | - | 74.8 | poor |
Salton et al. (2020) | Salton | 2020-06-20 | Italy | 173 | Hospital | 64.4^ (NA) | 34.9 | - | - | - | - | - | - | - | 29.5 | - | - | - | - | 70.5 | poor |
Duan et al. (2020) | Duan | 2020-06-22 | China | 616 | Hospital | 64 (53-70) | 57.5 | 3.7 | - | - | - | - | - | - | - | - | - | - | - | 96.3 | poor |
Lenka et al. (2020) | Lenka | 2020-06-22 | USA | 32 | Hospital | 62.2^ (51-73) | 37.5 | - | - | - | - | - | - | - | 50.0 | - | - | - | - | 50.0 | poor |
Fisman et al. (2020) | Fisman | 2020-06-23 | Canada | 21,922 | Community and Hospital | NA | 57.0 | - | - | - | - | - | - | - | 2.3 | - | - | - | - | 97.7 | poor |
Madariaga et al. (2020) | Madariaga | 2020-06-23 | USA | 103 | Community and Hospital | 41.8^ (27-55) | 48.5 | - | - | - | - | - | - | - | 25.2 | 74.8 | - | - | - | 0.0 | poor |
C. Jin et al. (2020) | Jin, Gu | 2020-06-25 | China | 6 | Hospital | 60.5^ (51-75) | 33.3 | 33.3 | - | - | - | - | - | - | - | - | - | - | - | 66.7 | poor |
Mendy et al. (2020) | Mendy | 2020-06-27 | USA | 689 | Community and Hospital | 49.5 (35.2-67.5) | 47.0 | - | - | - | - | - | - | - | 24.7 | - | - | - | - | 75.3 | poor |
Sigel et al. (n.d.) | Sigel | 2020-06-28 | USA | 493 | Hospital | 60 (55-67) | 24.1 | - | - | - | - | - | - | - | 28.6 | - | - | - | - | 71.4 | poor |
Souza et al. (2020) | de Souza | 2020-06-28 | Brazil | 8,443 | Hospital | NA | 53.0 | - | - | - | - | - | - | - | 1.7 | - | - | - | 96.3 | 2.0 | poor |
Nguyen et al. (2020) | Nguyen | 2020-06-29 | USA | 689 | Community and Hospital | 55 (40-68) | 57.0 | - | - | - | - | - | - | - | 24.8 | - | - | - | - | 75.2 | poor |
Melo et al. (2020) | de Melo | 2020-06-29 | Brazil | 181 | Hospital | 55.3^ (34-76) | 60.8 | 9.9 | - | - | - | 12.2 | - | - | - | 38.1 | - | - | - | 39.8 | poor |
Auvinen et al. (2020) | Auvinen | 2020-06-29 | Finland | 61 | Hospital | 53 (41-67) | 36.0 | 18.0 | - | - | - | 27.9 | - | - | - | 54.1 | - | - | - | 0.0 | fair |
Magleby et al. (n.d.) | Magleby | 2020-06-30 | USA | 678 | Hospital | 68 (50-81) | 38.9 | - | - | - | - | - | - | - | 28.6 | - | - | - | - | 71.4 | poor |
Hewitt et al. (2020) | Hewitt | 2020-06-30 | Multiple | 1,564 | Hospital | 74 (61-83) | 42.3 | 7.7 | - | - | - | 38.6 | - | - | - | 52.0 | - | - | - | 1.7 | fair |
Mohamud et al. (2020) | Mohamud | 2020-07-02 | USA | 6 | Hospital | 65.8^ (55-78) | 16.7 | - | - | - | - | - | - | - | 16.7 | - | - | - | - | 83.3 | poor |
Trubiano et al. (2020) | Trubiano | 2020-07-02 | Australia | 2,935 | Community and Hospital | 39 (29-53) | 63.5 | - | - | - | - | - | - | - | 8.8 | - | - | - | - | 91.2 | poor |
Patel et al. (2020) | Patel | 2020-07-03 | USA | 129 | Hospital | 60.8^ (47-74) | 45.0 | 37.2 | - | - | - | - | - | - | - | - | - | - | 55.8 | 7.0 | poor |
Merzon et al. (2020) | Merzon | 2020-07-03 | Israel | 7,807 | Community and Hospital | 46.2^ (NA) | 58.6 | - | - | - | - | - | - | - | 16.2 | - | - | - | - | 83.8 | poor |
Bello-Chavolla, Antonio-Villa, et al. (2020) | Bello-Chavolla, Antonio-Villa | 2020-07-04 | Mexico | 60,121 | Community and Hospital | 45.5^ (29-61) | 47.0 | - | - | - | - | - | - | - | 10.5 | - | - | - | - | 89.5 | poor |
Zacharioudakis et al. (2020) | Zacharioudakis | 2020-07-04 | USA | 314 | Hospital | 64 (54-72) | 34.7 | - | - | - | - | - | - | - | 22.8 | - | - | - | - | 77.2 | poor |
Antonio-Villa et al. (2020) | Antonio-Villa | 2020-07-04 | Mexico | 34,263 | Community and Hospital | 40^ (29-50) | 62.9 | 9.7 | - | - | - | - | - | - | - | - | - | - | - | 90.3 | poor |
Kimmig et al. (2020) | Kimmig | 2020-07-06 | USA | 111 | Hospital | 63^ (48-78) | 44.1 | 7.2 | - | - | - | 36.0 | - | - | - | 56.8 | - | - | - | 0.0 | fair |
Senkal (2020) | Senkal | 2020-07-07 | Turkey | 611 | Hospital | 57^ (18-98) | 40.6 | 11.3 | - | - | - | - | - | - | - | - | - | - | - | 88.7 | poor |
Xie et al. (2020) | Xie | 2020-07-07 | China | 619 | Hospital | NA | 52.0 | - | - | - | - | - | - | - | 8.2 | - | - | - | - | 91.8 | poor |
Elmunzer et al. (2020) | Elmunzer | 2020-07-09 | Multiple | 1,992 | Hospital | 60^ (43-76) | 43.0 | 6.3 | - | - | - | 28.6 | - | - | - | 59.0 | - | - | - | 6.1 | fair |
Alizadehsani et al. (2020) | Alizadehsani | 2020-07-09 | Iran | 319 | Hospital | 45.48^ (26-63) | 55.5 | - | - | - | - | - | - | - | 0.3 | - | - | - | - | 99.7 | poor |
Maucourant et al. (2020) | Maucourant | 2020-07-10 | Sweden | 27 | Hospital | 57 (18-78) | 22.2 | 11.1 | - | - | - | 25.9 | - | - | - | 40.7 | - | - | - | 22.2 | poor |
Fan et al. (2020) | Fan | 2020-07-11 | UK | 1,425 | Community and Hospital | NA | 46.7 | 12.2 | - | - | - | 40.1 | - | - | - | 46.9 | - | - | - | 0.8 | fair |
Z. Shi et al. (2020) | Shi, Resurreccion | 2020-07-11 | UK | 1,521 | Community and Hospital | 61.5^ (57-66.8) | 45.9 | - | - | - | - | - | - | - | 54.9 | - | - | - | - | 45.1 | poor |
Riley et al. (2020) | Riley | 2020-07-11 | UK | 120,620 | Community and Hospital | NA | 54.0 | 2.2 | - | - | - | - | - | - | - | - | - | - | 16.5 | 81.3 | poor |
Hippisley-Cox et al. (2020) | Hippisley-Cox | 2020-07-13 | UK | 8,275,949 | Community and Hospital | 48.5^ (30-66) | 50.3 | 17.2 | - | - | - | 21.4 | - | - | - | 57.3 | - | - | - | 4.0 | fair |
Jin‐jin Zhang et al. (2020) | Zhang, Cao | 2020-07-14 | China | 289 | Hospital | 57 (22-88) | 46.6 | 3.5 | - | - | - | 6.2 | - | - | - | - | - | - | - | 90.3 | poor |
Eiros et al. (2020) | Eiros | 2020-07-14 | Spain | 139 | Community and Hospital | 52 (41-57) | 72.0 | 4.3 | - | - | - | 50.4 | - | - | - | - | - | - | - | 45.3 | poor |
Marcos et al. (2020) | Marcos | 2020-07-14 | Spain | 918 | Hospital | 72.8^ (58-87) | 42.2 | 6.1 | - | - | - | - | - | - | 15.3 | - | - | - | - | 78.7 | poor |
Hoertel, Rico, Vernet, Beeker, et al. (2020) | Hoertel, Sanchez, Rico | 2020-07-14 | France | 7,345 | Hospital | NA | 49.3 | 8.5 | - | - | - | - | - | - | - | - | - | - | - | 91.5 | poor |
H. Shi et al. (2020) | Shi, Zuo | 2020-07-15 | USA | 172 | Hospital | 61.48^ (25-96) | 44.0 | - | - | - | - | - | - | - | 26.2 | - | - | - | - | 73.8 | poor |
Hussein et al. (2020) | Hussein | 2020-07-15 | USA | 502 | Hospital | 60.9^ (45-76) | 52.0 | 9.0 | - | - | - | 22.1 | - | - | - | - | - | - | 68.9 | 0.0 | poor |
Bian et al. (2020) | Bian | 2020-07-15 | China | 28 | Hospital | 56^ (42-67) | 42.9 | 7.1 | - | - | - | - | - | - | - | - | - | - | - | 92.9 | poor |
Z. Zhan et al. (2020) | Zhan | 2020-07-16 | China | 75 | Hospital | 57 (25-75) | 48.0 | - | - | - | - | - | - | - | 12.0 | - | - | - | - | 88.0 | poor |
Omrani et al. (2020) | Omrani | 2020-07-16 | Qatar | 1,409 | Community and Hospital | 39 (30-50) | 17.2 | - | - | - | - | - | - | - | 9.2 | - | - | - | - | 90.8 | poor |
Gupta et al. (2020) | Gupta | 2020-07-16 | USA | 496 | Hospital | 70 (60-78) | 46.0 | - | - | - | - | - | - | - | 7.3 | - | - | - | 31.7 | 61.1 | poor |
Soares et al. (2020) | Soares | 2020-07-16 | Brazil | 10,713 | Community and Hospital | NA | 55.0 | 2.0 | - | - | - | - | - | - | - | - | - | - | 98.0 | 0.0 | poor |
Abolghasemi et al. (n.d.) | Abolghasemi | 2020-07-17 | Iran | 24 | Hospital | 49^ (29-64) | 37.5 | - | - | - | - | - | - | - | 4.2 | - | - | - | - | 95.8 | poor |
Merkely et al. (2020) | Merkely | 2020-07-17 | Hungary | 10,474 | Community | 48.7^ (30-66) | 53.6 | 28.0 | - | - | - | 20.5 | - | - | - | 51.4 | - | - | - | 0.2 | good |
Fox et al. (n.d.) | Fox | 2020-07-17 | UK | 55 | Community and Hospital | 63 (23-88) | 31.0 | 1.8 | - | - | - | 10.9 | - | - | - | 56.4 | - | - | - | 30.9 | poor |
Pandolfi et al. (2020) | Pandolfi | 2020-07-17 | Italy | 33 | Hospital | 62 (52-65) | 21.1 | 3.0 | - | - | - | 24.2 | - | - | - | 72.7 | - | - | - | 0.0 | fair |
Girardeau et al. (2020) | Girardeau | 2020-07-17 | France | 10 | Community | 30 (29-33) | 50.0 | 40.0 | 10.0 | - | - | 10.0 | - | - | - | - | - | - | - | 40.0 | poor |
Kurashima et al. (2020) | Kurashima | 2020-07-17 | Japan | 53 | Hospital | 62.9^ (49-76) | 35.8 | - | - | - | - | - | - | - | 50.9 | - | - | - | - | 49.1 | poor |
McGrail & Edwards (2020) | Edwards | 2020-07-19 | USA | 209 | Hospital | 62.5 (NA) | 38.8 | - | - | - | - | - | - | - | 18.7 | - | - | - | - | 81.3 | poor |
Martinez-Resendez et al. (2020) | Martinez-Resendez | 2020-07-20 | Mexico | 8 | Hospital | 57 (48-69) | 25.0 | - | - | - | - | - | - | - | 12.5 | - | - | - | - | 87.5 | poor |
Hoertel, Rico, Vernet, Jannot, et al. (2020) | Hoertel | 2020-07-20 | France | 12,612 | Hospital | 58.7^ (39-77) | 49.6 | - | - | - | - | - | - | - | 9.3 | - | - | - | - | 90.7 | poor |
Z.-H. Wang et al. (2020) | Wang, Shu | 2020-07-20 | China | 59 | Hospital | 67.4^ (56-78) | 35.6 | - | - | - | - | - | - | - | 15.3 | - | - | - | - | 84.8 | poor |
Bernaola et al. (2020) | Bernaola | 2020-07-21 | Spain | 1,645 | Hospital | NA | 38.5 | 2.5 | - | - | - | 10.9 | - | - | - | 86.6 | - | - | - | 0.0 | fair |
Schneeweiss et al. (2020) | Schneeweiss | 2020-07-22 | USA | 24,313 | Community and Hospital | 67^ (53-80) | 53.0 | - | - | - | - | - | - | - | 2.9 | - | - | - | - | 97.1 | poor |
Concha-Mejia & Rincon-Sanchez (2020) | Mejia | 2020-07-24 | Colombia | 72 | Community and Hospital | 46 (28-64) | 47.0 | 8.3 | - | - | - | 11.1 | - | - | - | - | - | - | - | 80.6 | poor |
Izquierdo et al. (2020) | Izquierdo | 2020-07-24 | Spain | 71,192 | Community and Hospital | 42^ (18-66) | 59.0 | 10.0 | - | - | - | - | - | - | - | - | - | - | 90.0 | 0.0 | poor |
Santos et al. (2020) | Santos | 2020-07-25 | USA | 23 | Community and Hospital | NA | - | - | - | - | - | - | - | - | 8.7 | - | - | - | - | 91.3 | poor |
Reiter et al. (2020) | Reiter | 2020-07-26 | Austria | 235 | Community | 44.2^ (32-55) | 70.0 | 22.6 | - | - | - | 22.6 | - | - | - | 54.5 | - | - | - | 0.4 | fair |
Motta et al. (2020) | Motta | 2020-07-26 | USA | 374 | Hospital | 64.7^ (46-82) | 41.4 | - | - | - | - | - | - | - | 33.2 | 66.8 | - | - | - | 0.0 | poor |
Altamimi et al. (2020) | Altamimi | 2020-07-27 | Qatar | 68 | Hospital | 49^ (40-58) | 2.0 | 16.2 | - | - | - | - | - | - | - | - | - | - | 83.8 | 0.0 | poor |
Thompson et al. (2020) | Thompson | 2020-07-27 | UK | 470 | Hospital | 71 (57-82) | 46.0 | 14.0 | - | - | - | 27.2 | - | - | - | 58.7 | - | - | - | 0.0 | fair |
Zobairy et al. (2020) | Zobairy | 2020-07-28 | Iran | 203 | Community and Hospital | 49.2^ (32-65) | 44.8 | 5.9 | - | - | - | - | - | - | - | - | - | - | 94.1 | 0.0 | poor |
K. Zhou et al. (2020) | Zhou, Sun | 2020-07-29 | China | 144 | Hospital | 47 (38-56) | 46.5 | 9.0 | - | - | - | - | - | - | - | - | - | - | 91.0 | 0.0 | poor |
Kumar et al. (2020) | Kumar | 2020-07-29 | India | 91 | Hospital | 47^ (41-52) | 21.0 | 44.0 | - | - | - | - | - | - | - | - | - | - | - | 56.0 | poor |
Qu et al. (2020) | Qu | 2020-07-29 | China | 246 | Hospital | 53.6^ (38-68) | 53.3 | 42.3 | - | - | - | - | - | - | - | - | - | - | - | 57.7 | poor |
Higuchi et al. (2020) | Higuchi | 2020-07-30 | Japan | 57 | Hospital | 52 (35-70) | 43.9 | 12.3 | - | - | - | 29.8 | - | - | - | 57.9 | - | - | - | 0.0 | fair |
Zhao et al. (2020) | Zhao, Chen | 2020-07-30 | USA | 641 | Hospital | 60 (NA) | 40.1 | 21.7 | - | - | - | - | - | - | - | - | - | - | - | 78.3 | poor |
Fond et al. (2020) | Fond | 2020-07-30 | France | 1,092 | Hospital | 62.5 (51-76) | 45.7 | 11.4 | - | - | - | - | - | - | - | - | - | - | 88.6 | 0.0 | poor |
Jun et al. (2020) | Jun | 2020-08-01 | USA | 3,086 | Hospital | 66 (56-77) | 40.9 | 3.7 | - | - | - | 21.3 | - | - | - | 52.8 | - | - | - | 22.2 | poor |
Morshed et al. (2020) | Morshed | 2020-08-02 | Bangladesh | 103 | Community | 37 (31-53) | 28.2 | 31.1 | - | - | - | - | - | - | - | - | - | - | 68.9 | 0.0 | poor |
Iversen et al. (2020) | Iversen | 2020-08-03 | Denmark | 28,792 | Community and Hospital | 44.4^ (31-57) | 78.9 | 16.0 | - | - | - | 6.5 | - | - | - | 76.8 | - | - | - | 0.7 | fair |
Ebinger et al. (2020) | Ebinger | 2020-08-04 | USA | 6,062 | Community | 41.5^ (29-53) | 67.8 | 1.7 | 1.4 | - | - | - | - | - | - | - | - | - | - | 96.9 | poor |
Hadi et al. (2020) | Hadi | 2020-08-05 | USA | 370 | Community and Hospital | 48.2^ (34-62) | 29.5 | - | - | - | - | - | - | - | 15.1 | 84.9 | - | - | - | 0.0 | poor |
Tao et al. (2020) | Tao | 2020-08-06 | China | 70 | Community | 33.2^ (12-53) | 48.6 | - | - | - | - | - | - | - | 15.7 | - | - | - | 84.3 | 0.0 | poor |
Klang et al. (2020) | Klang, Soffer | 2020-08-09 | USA | 1,320 | Hospital | NA | 41.5 | - | - | - | - | - | - | - | 24.7 | - | - | - | - | 75.3 | poor |
J. Zhou et al. (2021) | Zhou, Ma | 2020-08-10 | China | 429 | Hospital | 58.3^ (42-74) | 50.6 | - | - | - | - | - | - | - | 8.4 | - | - | - | 91.6 | 0.0 | poor |
Altibi et al. (2020) | Altibi | 2020-08-11 | USA | 706 | Hospital | 66.7^ (51-81) | 43.0 | 4.0 | - | - | - | 37.3 | - | - | - | 58.8 | - | - | - | 0.0 | fair |
Izzi-Engbeaya et al. (2020) | Izzi-Engbeaya | 2020-08-11 | UK | 889 | Hospital | 65.8^ (48-83) | 40.0 | - | - | - | - | - | - | - | 21.3 | 33.2 | - | - | - | 45.6 | poor |
Rizzo et al. (2020) | Rizzo | 2020-08-11 | USA | 76,819 | Hospital | 54 (38-67) | 55.2 | 6.7 | - | - | - | 20.8 | - | - | - | 50.4 | - | - | - | 22.1 | poor |
Jehi et al. (2020) | Jehi | 2020-08-11 | USA | 4,536 | Community and Hospital | NA | - | 7.3 | - | - | - | 28.5 | - | - | - | 49.9 | - | - | - | 14.4 | fair |
Holman et al. (2020) | Holman | 2020-08-13 | UK | 10,989 | Community and Hospital | NA | 38.8 | 5.5 | - | - | - | 42.6 | - | - | - | 49.0 | - | - | - | 2.8 | fair |
Ouyang et al. (2020) | Ouyang | 2020-08-14 | China | 217 | Hospital | 46.5^ (30-62) | 53.5 | 16.6 | - | - | - | - | - | - | - | - | - | - | - | 83.4 | poor |
Valenzuela et al. (2020) | Valenzuela | 2020-08-14 | Chile | 29 | Hospital | 56.9^ (43-70) | 6.9 | 17.2 | - | - | - | - | - | - | - | - | - | - | 82.8 | 0.0 | poor |
Monteiro et al. (2020) | Monteiro | 2020-08-14 | USA | 112 | Hospital | 61 (45-74) | 34.0 | 6.2 | - | - | - | 17.9 | - | - | - | 68.8 | - | - | - | 7.1 | fair |
Philipose et al. (2020) | Philipose | 2020-08-14 | UK | 466 | Hospital | 67 (6-97) | 41.8 | 6.0 | - | - | - | 73.2 | - | - | - | 16.5 | - | - | - | 4.3 | fair |
Weerahandi et al. (2020) | Weerahandi | 2020-08-14 | USA | 394 | Community | 63 (55-70) | 37.0 | 5.3 | - | - | - | 25.9 | - | - | - | 55.8 | - | - | - | 12.9 | fair |
Parra-Bracamonte et al. (2020) | Parra-Bracamonte | 2020-08-14 | Mexico | 331,298 | Community and Hospital | 44 (33-56) | 46.2 | - | - | - | - | - | - | - | 7.4 | - | - | - | - | 92.6 | poor |
Peters et al. (2020) | Peters | 2020-08-15 | Netherlands | 1,893 | Hospital | 66.8^ (52-81) | 39.4 | 4.9 | - | - | - | - | - | - | - | - | - | - | - | 95.1 | poor |
Islam et al. (2020) | Islam | 2020-08-18 | Bangladesh | 1,016 | Community and Hospital | 37 (28-49) | 35.9 | 18.2 | - | - | - | - | - | - | - | - | - | - | - | 77.8 | poor |
Chand et al. (2020) | Chand | 2020-08-19 | USA | 300 | Hospital | 58.2^ (45-70) | 39.3 | 22.3 | - | - | - | - | - | - | - | - | - | - | - | 77.7 | poor |
Aksu et al. (2020) | Aksu | 2020-08-19 | Turkey | 123 | Community and Hospital | 49.7^ (36-63) | 33.3 | 11.4 | - | - | - | - | - | - | - | - | - | - | 88.6 | 0.0 | poor |
Alkurt et al. (2020) | Alkurt | 2020-08-20 | Turkey | 932 | Community and Hospital | 34.8^ (25-44) | 64.4 | 24.5 | - | - | - | - | - | - | - | - | - | - | - | 75.5 | poor |
Ward et al. (2020) | Ward | 2020-08-21 | UK | 99,908 | Community | NA | 56.1 | 10.6 | - | - | - | - | - | - | - | - | - | - | 88.4 | 1.0 | poor |
Salerno et al. (2020) | Salerno | 2020-08-22 | USA | 15,920 | Hospital | 49 (30-65) | 57.0 | - | - | - | - | - | - | - | 36.8 | 55.9 | - | - | - | 7.3 | poor |
M. Rashid et al. (2020) | Rashid | 2020-08-22 | UK | 517 | Hospital | 72.8^ (59-86) | 31.9 | 9.9 | - | - | - | 29.0 | - | - | - | 29.4 | - | - | - | 31.7 | poor |
Pan et al. (2020) | Pan | 2020-08-22 | USA | 12,084 | Community and Hospital | 45.5^ (27-63) | 54.3 | - | - | - | - | - | - | - | 17.5 | - | - | - | - | 82.5 | poor |
Fillmore et al. (2020) | Fillmore | 2020-08-24 | USA | 22,914 | Community and Hospital | NA | - | 37.5 | - | - | - | 40.7 | - | - | - | 15.5 | - | - | - | 6.4 | fair |
Wei Zhou et al. (2020) | Zhou, Qin | 2020-08-25 | China | 51 | Hospital | 57.37^ (42-72) | 29.4 | - | - | - | - | - | - | - | 78.4 | 21.6 | - | - | - | 0.0 | poor |
Ibrahim et al. (2020) | Ibrahim | 2020-08-27 | USA | 38 | Hospital | 63^ (51-75) | 47.0 | 10.5 | - | - | - | - | - | - | - | - | - | - | - | 89.5 | poor |
Oliveira et al. (2020) | Oliveira | 2020-08-31 | USA | 131 | Hospital | 61 (49.5-71.5) | 64.9 | - | - | - | - | - | - | - | 17.6 | 26.7 | - | - | - | 55.7 | poor |
Yoo et al. (2020) | Yoo | 2020-08-31 | USA | 4,840 | Hospital | 66.4 (54.9-77.8) | 43.5 | 4.4 | - | - | - | 21.4 | - | - | - | 53.3 | - | - | - | 20.9 | poor |
T. Zhan et al. (2020) | Zhan, Liu | 2020-08-31 | China | 405 | Hospital | 56^ (17-95) | 54.1 | - | - | - | - | - | - | - | 11.4 | 88.6 | - | - | - | 0.0 | poor |
Mohamed-Hussein et al. (2020) | Hussein, Galal | 2020-09-01 | Egypt | 444 | Community | 33.1^ (21-45) | 56.8 | 13.1 | - | - | - | 9.0 | - | - | - | 77.9 | - | - | - | 0.0 | fair |
Villar-Garcia et al. (2020) | Vilar-Garcia | 2020-09-01 | Spain | 7,699,568 | Community and Hospital | 43 (24-59) | 50.9 | 17.1 | - | - | - | - | - | - | - | - | - | - | - | 82.9 | poor |
Ibarra-Nava et al. (2020) | Ibarra-Nava | 2020-09-01 | Mexico | 416,546 | Community and Hospital | NA | 46.9 | 7.4 | - | - | - | - | - | - | - | - | - | - | - | 92.6 | poor |
Rubio-Rivas et al. (2020) | Rubio-Rivas | 2020-09-01 | Spain | 186 | Hospital | 64.3^ (51-77) | 30.6 | 4.3 | - | - | - | 20.4 | - | - | - | 75.3 | - | - | - | 0.0 | fair |
Mamtani et al. (2020) | Mamtani | 2020-09-02 | USA | 403 | Hospital | 55^ (41-68) | 32.3 | 9.7 | - | - | - | 12.7 | - | - | - | 68.5 | - | - | - | 9.2 | fair |
Ren, Guo, Blighe, et al. (2020) | Ren | 2020-09-02 | China | 432 | Hospital | NA | 57.9 | 10.0 | - | - | - | - | - | - | - | 90.0 | - | - | - | 0.0 | poor |
Mutambudzi et al. (2020) | Mutambudzi | 2020-09-03 | UK | 120,075 | Community and Hospital | NA | 54.2 | 11.7 | - | - | - | 26.4 | - | - | - | 61.9 | - | - | - | 0.0 | fair |
Yan et al. (2020) | Yan | 2020-09-07 | China | 578 | Hospital | 49.2^ (35-63) | 49.3 | 9.2 | - | - | - | - | - | - | - | - | - | - | - | 90.8 | poor |
Mancilla-Galindo et al. (2020) | Mancilla-Galindo | 2020-09-08 | Mexico | 183,779 | Community and Hospital | 45^ (28-61) | 46.0 | 7.6 | - | - | - | - | - | - | - | - | - | - | - | 92.4 | poor |
Ullah et al. (2020) | Ullah | 2020-09-08 | UK | 212 | Community and Hospital | 66.7 (54.2-80.5) | 44.8 | 11.3 | - | - | - | 48.1 | - | - | - | 37.7 | - | - | - | 2.8 | fair |
Hamadah et al. (2020) | Hamadah | 2020-09-10 | Kuwait | 1,123 | Hospital | 40 (1-93) | 18.7 | 3.9 | - | - | - | - | - | - | - | - | - | - | 96.1 | 0.0 | poor |
Sami et al. (2020) | Sami | 2020-09-14 | Iran | 490 | Community and Hospital | 56.6^ (41-71) | 39.0 | 14.1 | - | - | - | - | - | - | - | - | - | - | - | 85.9 | poor |
Pongpirul et al. (2020) | Pongpirul | 2020-09-16 | Thailand | 193 | Community and Hospital | 37 (29-53) | 41.5 | - | - | - | - | - | - | - | 15.0 | 66.3 | - | - | - | 18.6 | poor |
Burrell et al. (2020) | Burrell | 2020-09-16 | Australia | 204 | Hospital | 63.5 (53-72) | 31.4 | - | - | - | - | - | - | - | 13.2 | - | - | - | 82.8 | 3.9 | poor |
Nicholson et al. (2020) | Nicholson | 2020-09-17 | USA | 1,042 | Hospital | 64 (53-75) | 43.2 | 8.3 | - | - | - | 22.2 | - | - | - | 37.1 | - | - | - | 32.4 | poor |
Ariza et al. (2020) | Ariza | 2020-09-18 | Colombia | 351 | Community and Hospital | 30.5 (NA) | 54.0 | 6.8 | - | - | - | - | - | - | - | - | - | - | 93.2 | 0.0 | poor |
Carrat et al. (2020) | Carrat | 2020-09-18 | France | 14,628 | Community | NA | 60.3 | 12.0 | - | - | - | 40.8 | - | - | - | 45.6 | - | - | - | 1.6 | good |
Favara et al. (2020a) | Favara | 2020-09-20 | UK | 434 | Community | 40 (19-66) | 82.0 | 8.5 | - | - | - | - | - | - | - | - | - | - | 91.5 | 0.0 | poor |
Favara et al. (2020b) | Favara | 2020-09-20 | UK | 434 | Community | 40 (19-66) | 82.0 | 8.5 | - | - | - | - | - | - | - | - | - | - | 91.5 | 0.0 | poor |
Invernizzi et al. (2020) | Invernizzi | 2020-09-20 | Italy | 54 | Hospital | 49.9^ (34-65) | 29.7 | - | - | - | - | - | - | - | 24.1 | - | - | - | - | 75.9 | poor |
Zhu et al. (2020) | Zhu | 2020-09-21 | China | 432 | Community and Hospital | 49 (35-60) | 47.9 | 14.4 | - | - | - | - | - | - | - | - | - | - | - | 85.7 | poor |
O’Reilly et al. (2020) | O'Reilly | 2020-09-21 | Australia | 1,334 | Hospital | NA | - | - | - | - | - | - | - | - | 28.5 | - | - | - | - | 71.5 | poor |
Meini et al. (n.d.) | Meini | 2020-09-23 | Italy | 461 | Hospital | NA | 51.2 | 10.4 | - | - | - | 25.8 | - | - | - | 63.8 | - | - | - | 0.0 | fair |
Silva Neto et al. (2020) | da Silva Neto | 2020-09-23 | Brazil | 91 | Community and Hospital | 49^ (29-68) | 49.4 | - | - | - | - | - | - | - | 19.8 | - | - | - | 80.2 | 0.0 | poor |
Ioannou et al. (2020) | Ioannou | 2020-09-23 | USA | 88,747 | Community and Hospital | NA | 9.0 | 20.6 | - | - | - | 37.5 | - | - | - | 29.3 | - | - | - | 12.6 | fair |
Torres-Macho et al. (2020) | Torres-Macho | 2020-09-23 | Spain | 1,968 | Hospital | NA | 44.0 | - | - | - | - | - | - | - | 23.4 | - | - | - | - | 76.6 | poor |
F. Li et al. (2020) | Li, Cai | 2020-09-28 | China | 98 | Hospital | 68.5 (63-75) | 58.2 | - | - | - | - | - | - | - | 11.2 | - | - | - | 88.8 | 0.0 | poor |
J. G. Wang et al. (2020) | Wang | 2020-09-29 | USA | 1,078 | Hospital | NA | 38.2 | 3.7 | - | - | - | 24.9 | - | - | - | 49.0 | - | - | - | 22.4 | poor |
Lopez-Medrano et al. (2020) | Lopez-Medrano | 2020-09-30 | Spain | 261 | Hospital | NA | 43.7 | - | - | - | - | - | - | - | 37.2 | - | - | - | 62.8 | 0.0 | poor |
Collard et al. (2020) | Collard | 2020-10-01 | Netherlands | 1,604 | Hospital | 65.7^ (50-80) | 39.5 | 4.9 | - | - | - | - | - | - | - | - | - | - | - | 95.1 | poor |
Makaronidis et al. (2020) | Makaronidis | 2020-10-01 | UK | 567 | Community | 39.4^ (27-51) | 69.1 | 9.3 | - | - | - | - | - | - | - | - | - | - | 90.7 | 0.0 | poor |
Yadaw et al. (2020) | Yadaw | 2020-10-01 | USA | 5,051 | Community and Hospital | NA | - | 3.6 | - | - | - | 15.9 | - | - | - | 51.4 | - | - | - | 29.1 | poor |
Talavera et al. (2020) | Talavera | 2020-10-01 | Spain | 576 | Hospital | 67.2^ (52-81) | 43.4 | - | - | - | - | - | - | - | 20.5 | - | - | - | - | 79.5 | poor |
Jakob et al. (2020) | Jakob | 2020-10-01 | Multiple | 2,155 | Community and Hospital | NA | 40.3 | 6.6 | - | - | - | 7.3 | - | - | - | 34.3 | - | - | - | 51.7 | poor |
Incerti et al. (2020) | Incerti | 2020-10-02 | USA | 13,658 | Hospital | 62 (49-75) | 48.1 | 6.3 | - | - | - | 22.6 | - | - | - | 45.4 | - | - | - | 25.6 | poor |
J. Luo et al. (2020) | Luo, Rizvi | 2020-10-03 | USA | 102 | Hospital | 68 (61-75) | 52.0 | - | - | - | - | - | - | - | 26.5 | - | - | - | 73.5 | 0.0 | poor |
Alharthy et al. (2020) | Alharthy | 2020-10-03 | Saudi Arabia | 352 | Hospital | 50.6^ (37-63) | 12.8 | 49.4 | - | - | - | - | - | - | - | - | - | - | 50.6 | 0.0 | poor |
Robinson et al. (2021) | Robinson | 2020-10-05 | USA | 3,248 | Hospital | 51^ (34-68) | 72.0 | 4.0 | - | - | - | 17.6 | - | - | - | 61.8 | - | - | - | 16.6 | fair |
Adrish et al. (2020) | Adrish | 2020-10-05 | USA | 1,173 | Hospital | NA | 38.6 | 14.0 | - | - | - | 14.7 | - | - | - | 71.4 | - | - | - | 0.0 | fair |
Erber et al. (2020) | Erber | 2020-10-06 | Germany | 4,554 | Community | 38.5^ (NA) | 70.4 | - | - | - | - | - | - | - | 18.0 | - | - | - | 82.0 | 0.0 | poor |
Chaudhary et al. (2020) | Chaudhary | 2020-10-06 | Nepal | 220 | Hospital | 31.5 (25-37) | 17.7 | 11.4 | - | - | - | 7.7 | - | - | - | 80.0 | - | - | - | 0.9 | fair |
Raines et al. (2021) | Raines | 2020-10-07 | USA | 453 | Community and Hospital | 60.8^ (46-74) | 10.7 | - | - | - | - | - | - | - | 53.0 | 41.9 | - | - | - | 5.1 | poor |
Roederer et al. (2021) | Roederer | 2020-10-09 | France | 818 | Community | NA | 20.4 | 36.9 | - | - | - | 8.8 | - | - | - | 53.9 | - | - | - | 0.4 | fair |
Zinellu et al. (2021) | Zinellu | 2020-10-11 | Italy | 105 | Hospital | 72 (59.5-80) | 33.3 | 30.5 | - | - | - | 10.5 | - | - | - | 59.0 | - | - | - | 0.0 | fair |
Ramachandran et al. (2020) | Ramachandran | 2020-10-12 | USA | 188 | Hospital | NA | - | 18.6 | - | - | - | - | - | - | - | - | - | - | - | 81.4 | poor |
Lamure et al. (2020) | Lamure | 2020-10-12 | France | 89 | Hospital | 67 (19-92) | 34.0 | 5.6 | - | - | - | 32.6 | - | - | - | 48.3 | - | - | - | 13.5 | fair |
Ghinai et al. (2020) | Ghinai | 2020-10-12 | USA | 1,435 | Homeless Shelters | NA | 27.6 | 36.6 | - | - | - | 17.5 | - | - | - | 33.2 | - | - | - | 12.8 | fair |
Best et al. (2020) | Best | 2020-10-12 | USA | 3,471 | Hospital | 63.5^ (47-79) | 51.2 | - | - | - | - | - | - | - | 28.6 | - | - | - | 71.4 | 0.0 | poor |
Savarraj et al. (n.d.) | Savarraj | 2020-10-18 | USA | 48 | Hospital | 50^ (33-67) | 48.0 | 10.4 | - | - | - | - | - | - | - | - | - | - | - | 89.6 | poor |
Israel, Schäffer, et al. (2020) | Israel, Schaffer | 2020-10-18 | Israel | 26,959 | Hospital | NA | 50.6 | 6.8 | - | - | - | 15.2 | - | - | - | 77.0 | - | - | - | 1.1 | fair |
El-Solh et al. (2020) | El-Solh | 2020-10-20 | USA | 7,816 | Hospital | 69 (60-74) | 5.5 | - | - | - | - | - | - | - | 45.3 | - | - | - | 54.7 | 0.0 | poor |
Perico et al. (2020) | Perico | 2020-10-22 | Italy | 423 | Community | 44.3^ (34-54) | 36.4 | 21.7 | - | - | - | 18.0 | - | - | - | 60.3 | - | - | - | 0.0 | fair |
Wenqian Zhou et al. (2020) | Zhou, Song | 2020-10-22 | China | 124 | Hospital | 67 (30-86) | 48.0 | 19.1 | - | - | - | - | - | - | - | - | - | - | - | 80.9 | poor |
Chudasama et al. (2020) | Chudasama | 2020-10-23 | UK | 1,706 | Community and Hospital | 68 (48-85) | 42.5 | 13.8 | - | - | - | 41.0 | - | - | - | 45.3 | - | - | - | 0.0 | fair |
Salama et al. (2021) | Salama | 2020-10-23 | Multiple | 377 | Hospital | 55.9^ (41-70) | 40.8 | 5.8 | - | - | - | 17.0 | - | - | - | 77.2 | - | - | - | 0.0 | fair |
Z. Wang et al. (2020) | Wang, Zheutlin | 2020-10-26 | USA | 3,273 | Hospital | 65 (53-77) | 42.7 | 3.5 | - | - | - | 20.7 | - | - | - | 53.2 | - | - | - | 22.6 | poor |
Yiwu Zhou et al. (2020) | Zhou, He, Yang | 2020-10-27 | China | 1,087 | Hospital | NA | 51.7 | - | - | - | - | - | - | - | 85.0 | 15.0 | - | - | - | 0.0 | poor |
Hoertel, Sánchez, et al. (2020) | Hoertel, Sanchez, Vernet | 2020-10-27 | France | 12,210 | Hospital | NA | 50.1 | 9.0 | - | - | - | - | - | - | - | - | - | - | - | 91.0 | poor |
Arleo et al. (2020) | Arleo | 2020-10-27 | USA | 70 | Community and Hospital | 56.6^ (48-65) | 80.0 | 1.4 | - | - | - | 28.6 | - | - | - | 70.0 | - | - | - | 0.0 | fair |
Bermejo-Martin et al. (2020) | Bermejo-Martin | 2020-10-27 | Spain | 250 | Community and Hospital | NA | 64.0 | 6.0 | - | - | - | - | - | - | - | - | - | - | - | 94.0 | poor |
Joubert et al. (2020) | Joubert | 2020-10-29 | France | 74 | Community and Hospital | NA | - | 5.4 | - | - | - | - | - | - | - | - | - | - | - | 94.6 | poor |
Kortela et al. (2020) | Kortela | 2020-11-01 | Finland | 3,008 | Community and Hospital | 51 (36-69) | 59.6 | 11.0 | - | - | - | 14.0 | - | - | - | 29.2 | - | - | - | 45.8 | poor |
M. A. Gianfrancesco et al. (2020) | Gianfrancesco, Leykina | 2020-11-03 | USA | 1,324 | Community and Hospital | NA | 75.9 | - | - | - | - | - | - | - | 26.7 | 68.2 | - | - | - | 5.1 | poor |
Colaneri et al. (2021) | Colaneri | 2020-11-03 | Italy | 1,447 | Community | 45 (33.2-53.4) | 69.6 | 17.1 | - | - | - | 9.5 | - | - | - | 49.8 | - | - | - | 23.6 | poor |
Gallichotte et al. (2020) | Gallichotte | 2020-11-05 | USA | 239 | Community | 41^ (16-76) | - | 20.1 | 5.9 | - | - | 16.7 | - | - | - | 57.3 | - | - | - | 0.0 | fair |
Lin et al. (2020) | Lin | 2020-11-05 | USA | 2,821 | Hospital | 62.7^ (NA) | 45.0 | 2.9 | - | - | - | 12.5 | - | - | - | 3.3 | - | - | - | 81.3 | poor |
(kim_easy?)–use_2020 | Kim, Han | 2020-11-09 | South Korea | 4,787 | Hospital | 55 (38-68) | 60.1 | 5.5 | - | - | - | 2.8 | - | - | - | 91.7 | - | - | - | 0.0 | fair |
Galal et al. (2020) | Galal | 2020-11-12 | Egypt | 430 | Community | 37.4^ (24-50) | 63.7 | 6.0 | - | - | - | 7.7 | - | - | - | 86.3 | - | - | - | 0.0 | fair |
Riou et al. (2021) | Riou | 2020-11-12 | France | 124 | Hospital | 62 (54-72) | 40.0 | - | - | - | - | - | - | - | 41.1 | - | - | - | - | 58.9 | poor |
Sourij et al. (2020) | Sourij | 2020-11-16 | Austria | 238 | Hospital | 71.1^ (58-83) | 36.1 | 1.7 | - | - | - | 16.0 | - | - | - | 82.4 | - | - | - | 0.0 | fair |
Clavario et al. (2020) | Clavario | 2020-11-16 | Italy | 110 | Community | 61.7 (53.5-69.2) | 40.9 | 40.9 | - | - | - | - | - | - | - | - | - | - | - | 59.1 | poor |
Saeed et al. (2020) | Saeed | 2020-11-16 | United Arab Emirates | 173 | Hospital | NA | 34.1 | 6.4 | - | - | - | - | - | - | - | - | - | - | - | 93.6 | poor |
Mansour et al. (2020) | Mansour | 2020-11-16 | Iran | 353 | Hospital | 61.7^ (45-78) | 42.5 | 7.1 | - | - | - | - | - | - | - | - | - | - | - | 92.9 | poor |
Cadegiani et al. (2020) | Cadegiani | 2020-11-18 | Brazil | 130 | Community | 42^ (NA) | 0.0 | 7.7 | - | - | - | - | - | - | - | - | - | - | - | 92.3 | poor |
Ilic et al. (2021) | Ilic | 2020-11-19 | Serbia | 107 | Community and Hospital | 39.1^ (27-50) | - | 29.9 | - | - | - | - | - | - | - | - | - | - | - | 70.1 | poor |
Benaim et al. (2020) | Benaim | 2020-11-19 | Israel | 693 | Hospital | 59.8 (NA) | 47.9 | - | - | - | - | - | - | - | 5.1 | - | - | - | - | 95.0 | poor |
F. K. Ho et al. (2020) | Ho | 2020-11-19 | UK | 235,928 | Community and Hospital | NA | - | - | - | - | - | - | - | - | 45.4 | - | - | - | 54.6 | 0.0 | poor |
Singh et al. (2020) | Singh | 2020-11-20 | UK | 930 | Hospital | 71.4^ (54-87) | 44.8 | - | - | - | - | - | - | - | 19.0 | - | - | - | 81.0 | 0.0 | poor |
Márquez-Salinas et al. (2020) | Marquez-Salinas | 2020-11-24 | Mexico | 1,068 | Hospital | 53 (44-63) | 36.8 | - | - | - | - | - | - | - | 15.0 | - | - | - | - | 85.0 | poor |
Díez-Manglano et al. (2020) | Diez-Manglanas | 2020-11-24 | Spain | 4,393 | Hospital | 53^ (NA) | 40.8 | 6.6 | - | - | - | - | - | - | - | - | - | - | - | 93.4 | poor |
Bellan et al. (2020) | Bellan | 2020-11-26 | Italy | 1,697 | Hospital | 71 (58-80) | 41.0 | 3.2 | - | - | - | - | - | - | - | - | - | - | 15.2 | 81.6 | poor |
Woolcott & Castilla-Bancayán (2021a) | Woolcott | 2020-11-26 | Mexico | 1,636,050 | Community and Hospital | 42 (34-54) | 51.9 | - | - | - | - | - | - | - | 8.8 | - | - | - | - | 91.2 | poor |
Woolcott & Castilla-Bancayán (2021b) | Woolcott | 2020-11-26 | Mexico | 1,636,050 | Community and Hospital | 42 (34-54) | 51.9 | - | - | - | - | - | - | - | 8.8 | - | - | - | - | 91.2 | poor |
K. Yao et al. (2021) | Yao, Hasegawa | 2020-11-26 | Japan | 101 | Hospital | 60^ (17-97) | 39.6 | - | - | - | - | - | - | - | 28.7 | - | - | - | 71.3 | 0.0 | poor |
H. Chen et al. (2020) | Chen, Varathraja | 2020-11-29 | USA | 10,123 | Community and Hospital | 40 (28-54) | 53.6 | 4.4 | - | - | - | 9.7 | - | - | - | 45.9 | - | - | - | 40.0 | poor |
Serling-Boyd et al. (2020) | Serling-Boyd | 2020-11-30 | USA | 831 | Hospital | NA | 76.0 | 3.0 | - | - | - | 23.2 | - | - | - | 50.1 | - | - | - | 23.7 | poor |
Simons et al. (2020) | Simons | 2020-11-30 | UK | 446 | Hospital | 64.9 (52.4-76.2) | 35.9 | 9.4 | - | - | - | 38.6 | - | - | - | 52.0 | - | - | - | 0.0 | fair |
Dupraz et al. (2020) | Dupraz | 2020-11-30 | Switzerland | 219 | Community | NA | 54.8 | 11.0 | - | - | - | - | - | - | - | - | - | - | - | 89.0 | poor |
Barasa et al. (2020) | Barasa | 2020-11-30 | USA | 394 | Hospital | NA | 47.7 | 14.7 | - | - | - | 36.0 | - | - | - | 41.6 | - | - | - | 7.6 | fair |
Ren, Guo, Tu, et al. (2020) | Ren, Guo | 2020-11-30 | China | 481 | Hospital | NA | 45.7 | 7.7 | - | - | - | 0.6 | - | - | - | 91.7 | - | - | - | 0.0 | fair |
J. Li et al. (2020) | Li, Long, Zhang | 2020-12-03 | China | 954 | Hospital | NA | - | - | - | - | - | - | - | - | 5.9 | 94.1 | - | - | - | 0.0 | poor |
Martini et al. (2020) | Martini | 2020-12-04 | Italy | 146 | Hospital | NA | 49.0 | - | - | - | - | - | - | - | 46.6 | 53.4 | - | - | - | 0.0 | poor |
O’Gallagher et al. (2020) | O'Gallagher | 2020-12-04 | UK | 1,721 | Hospital | 71 (56-83) | 43.4 | 6.6 | - | - | - | 18.5 | - | - | - | 74.9 | - | - | - | 0.0 | fair |
Alguwaihes et al. (2020) | Alguwaihes | 2020-12-05 | Saudi Arabia | 439 | Hospital | 55 (19-101) | 31.7 | 2.1 | - | - | - | - | - | - | - | - | - | - | 97.9 | 0.0 | poor |
Zuo, Warnock, et al. (2020) | Zuo, Warnock | 2020-12-05 | USA | 118 | Hospital | 61^ (44-78) | 46.0 | - | - | - | - | - | - | - | 23.7 | - | - | - | - | 76.3 | poor |
Xiaomeng Zhang et al. (2020) | Zhang, Li | 2020-12-06 | UK | 1,746 | Community and Hospital | 68.8^ (59-78) | 47.1 | 10.1 | - | - | - | 35.1 | - | - | - | 44.2 | - | - | - | 10.5 | fair |
Dai et al. (2020) | Dai | 2020-12-09 | China | 1,574 | Hospital | 57.3^ (41-73) | 48.2 | - | - | - | - | - | - | - | 9.2 | 90.8 | - | - | - | 0.0 | poor |
Vila-Córcoles et al. (2020) | Vila-Corcoles | 2020-12-10 | Spain | 79,083 | Community | NA | 52.4 | - | - | - | - | - | - | - | 16.1 | - | - | - | - | 83.9 | poor |
Bisso et al. (2020) | Bisso | 2020-12-11 | Argentina | 168 | Hospital | 67 (58-75) | 34.0 | 10.7 | - | - | - | - | - | - | - | - | - | - | - | 89.3 | poor |
C. T. Rentsch et al. (2020) | Rentsch, Beckman | 2020-12-11 | USA | 4,297 | Hospital | 68 (58-75) | 6.6 | 36.8 | - | - | - | 39.3 | - | - | - | 1.9 | - | - | - | 22.1 | poor |
Thiabaud et al. (2020) | Thiabaud | 2020-12-11 | Switzerland | 3,582 | Hospital | 68 (54-79) | 40.5 | - | - | - | - | - | - | - | 6.6 | - | - | - | 50.5 | 42.9 | poor |
Vila-Corcoles et al. (2020) | Vila-Corcoles, Satue-Gracia | 2020-12-11 | Spain | 282 | Community and Hospital | 65.9^ (53-78) | 50.3 | 8.9 | - | - | - | - | - | - | - | - | - | - | - | 91.1 | poor |
Lévy et al. (2020) | Levy | 2020-12-12 | France | 61 | Hospital | 60 (50-69) | 20.0 | 8.2 | - | - | - | - | - | - | - | - | - | - | - | 91.8 | poor |
Kantele et al. (2020) | Kantele | 2020-12-13 | Finland | 1,095 | Community and Hospital | 38 (31-48) | 82.7 | 16.0 | 0.2 | - | - | 25.3 | - | - | - | 55.3 | - | - | - | 0.0 | fair |
Iftime et al. (2020) | Iftimie | 2020-12-14 | Spain | 468 | Hospital | NA | 44.9 | - | - | - | - | - | - | - | 7.9 | - | - | - | - | 92.1 | poor |
K. S. Ho et al. (2020) | Ho, Narasimhan | 2020-12-15 | USA | 9,991 | Community and Hospital | 58^ (39-76) | 45.9 | 4.1 | - | - | - | 18.1 | - | - | - | 77.9 | - | - | - | 0.0 | fair |
Caliskan & Saylan (2020) | Caliskan | 2020-12-16 | Turkey | 565 | Hospital | 48 (38-58) | - | 20.9 | - | - | - | 14.0 | - | - | - | 65.1 | - | - | - | 0.0 | fair |
Muñoz et al. (2020) | Munoz | 2020-12-16 | Spain | 314 | Community | 45 (40-53) | 52.5 | 6.7 | - | - | - | - | - | - | - | - | - | - | - | 93.3 | poor |
Crooks et al. (2020) | Crooks | 2020-12-16 | UK | 2,964 | Hospital | NA | 52.6 | 11.7 | 5.1 | - | - | - | - | - | - | - | - | - | - | 83.2 | poor |
Nunez-Gil et al. (2020) | Nunez-Gil | 2020-12-17 | Multiple | 2,798 | Hospital | 67 (53-78) | 40.0 | 6.2 | - | - | - | - | - | - | - | - | - | - | - | 93.8 | poor |
Núñez-Gil et al. (2021) | Nunez-Gil | 2020-12-17 | Multiple | 2,798 | Hospital | 67 (53-78) | 40.0 | 6.2 | - | - | - | - | - | - | - | - | - | - | - | 93.8 | poor |
Gori et al. (2020) | Gori | 2020-12-17 | Italy | 1,352 | Hospital | 68 (58-77) | 28.4 | 3.6 | - | - | - | 18.4 | - | - | - | 66.6 | - | - | - | 11.4 | fair |
Rowlands et al. (2020) | Rowlands | 2020-12-18 | UK | 580 | Community | 63.8^ (56-70) | 52.2 | 10.2 | - | - | - | 38.1 | - | - | - | 51.7 | - | - | - | 0.0 | fair |
Richard et al. (2020) | Richard | 2020-12-18 | Switzerland | 8,344 | Community | 46.9^ (NA) | 53.5 | 15.2 | - | - | - | 17.1 | - | - | - | 66.2 | - | - | - | 1.5 | good |
Schubl et al. (2020) | Schuble* | 2020-12-19 | USA | 1,557 | Community | NA | 68.9 | 2.4 | - | - | - | - | - | - | - | - | - | - | - | 97.6 | poor |
Ugur Chousein et al. (2020) | Chousein | 2020-12-21 | Turkey | 114 | Hospital | 51.1^ (36-66) | 32.5 | 16.7 | - | - | - | 20.2 | - | - | - | 63.2 | - | - | - | 0.0 | fair |
Modrák et al. (2020) | Modrak | 2020-12-22 | Czechia | 213 | Hospital | 69 (58-80) | 51.0 | - | - | - | - | - | - | - | 13.1 | - | - | - | - | 86.8 | poor |
Kara Polat et al. (2020) | Polat | 2020-12-22 | Turkey | 1,322 | Community | NA | 47.6 | 35.6 | - | - | - | 15.6 | - | - | - | 48.8 | - | - | - | 0.0 | fair |
Kjetland et al. (2020) | Kjetland | 2020-12-24 | Norway | 7,839 | Community and Hospital | 45.3^ (33-56) | 77.0 | - | - | - | - | - | - | - | 41.0 | - | - | - | - | 59.0 | poor |
Lewnard et al. (2021) | Lewnard | 2021-01-02 | USA | 1,115 | Community | NA | 52.6 | 4.4 | - | - | - | 14.2 | - | - | - | 81.3 | - | - | - | 0.1 | fair |
Nezhadmoghadam & Tamez-Peña (2021) | Nezhadmoghadam | 2021-01-04 | Mexico | 33,325 | Hospital | NA | - | 10.2 | - | - | - | - | - | - | - | - | - | - | - | 89.8 | poor |
Covid-19 in pregnancy et al. (2021) | Vousden | 2021-01-05 | UK | 1,148 | Community and Hospital | NA | 100.0 | 8.6 | - | - | - | - | - | - | - | - | - | - | - | 91.4 | poor |
Boyd & Martin-Loeches (2021) | Boyd | 2021-01-07 | Ireland | 38 | Hospital | NA | 26.3 | - | - | - | - | - | - | - | 5.3 | - | - | - | - | 94.7 | poor |
Paleiron et al. (2021) | Paleiron | 2021-01-09 | France | 1,688 | Community | 28 (23-35) | 13.0 | 42.1 | 12.9 | - | - | 19.9 | - | - | - | 25.1 | - | - | - | 0.0 | fair |
Ader et al. (2021) | Ader | 2021-01-09 | Multiple | 583 | Hospital | 63 (54-71) | 28.3 | 3.1 | - | - | - | - | - | - | - | - | - | - | - | 96.9 | poor |
Giannini et al. (2021) | Giannini | 2021-01-10 | Italy | 91 | Hospital | 74^ (61-87) | 45.0 | 23.1 | - | - | - | - | - | - | - | - | - | - | - | 76.9 | poor |
Shade et al. (2021) | Shade | 2021-01-10 | USA | 3,779 | Community and Hospital | NA | 47.2 | 3.3 | - | - | - | 15.7 | - | - | - | - | - | - | - | 80.9 | poor |
Park et al. (2021) | Park | 2021-01-11 | South Korea | 2,269 | Hospital | 55.5^ (35-75) | 64.1 | 4.1 | - | - | - | - | - | - | - | - | - | - | - | 95.9 | poor |
Ferrari et al. (2021) | Ferrari | 2021-01-12 | Brazil | 198 | Community | 61 (19-91) | 65.0 | - | - | - | - | - | - | - | 20.7 | 79.3 | - | - | - | 0.0 | poor |
Y. Zhang et al. (2021) | Zhang, Yang | 2021-01-12 | UK | 1,485 | Community and Hospital | 68.2^ (59-77) | 47.2 | 48.5 | - | - | - | 39.2 | - | - | - | 11.3 | - | - | - | 1.0 | fair |
Ebrahimian et al. (2021) | Ebrahimian | 2021-01-13 | USA | 226 | Hospital | NA | - | - | - | - | - | - | - | - | 10.6 | - | - | - | 89.4 | 0.0 | poor |
Vahidy et al. (2021) | Vahidy | 2021-01-13 | USA | 96,473 | Hospital | 51.2^ (32-69) | 59.6 | - | - | - | - | - | - | - | 26.2 | 73.8 | - | - | - | 0.0 | poor |
Mendes et al. (2021) | Mendes | 2021-01-14 | Switzerland | 265 | Hospital | 85.9^ (79-92) | 57.0 | 5.7 | - | - | - | - | - | - | - | - | - | - | - | 94.3 | poor |
Saurabh et al. (2021) | Saurabh | 2021-01-14 | India | 911 | Community | 43.1^ (23-62) | 35.2 | 7.0 | - | - | - | 0.6 | - | - | - | 79.1 | - | - | - | 0.0 | fair |
Ayoubkhani et al. (2021) | Ayoubkhani | 2021-01-15 | UK | 47,780 | Hospital | NA | 45.1 | 8.4 | - | - | - | 40.9 | - | - | - | 42.5 | - | - | - | 8.2 | fair |
Thakur et al. (2021) | Thakar | 2021-01-18 | India | 250 | Hospital | NA | 42.4 | - | - | - | - | - | - | - | 49.2 | - | - | - | 50.8 | 0.0 | poor |
Zhong et al. (2020) | Zhong | 2021-01-18 | China | 91 | Hospital | 47.3^ (30-64) | 49.5 | - | - | - | - | - | - | - | 18.7 | - | - | - | - | 81.3 | poor |
Cummins et al. (2021) | Cummins | 2021-01-20 | UK | 1,781 | Community and Hospital | NA | 44.8 | 10.2 | - | - | - | - | - | - | - | - | - | - | - | 89.8 | poor |
Sun et al. (2021) | Sun | 2021-01-21 | USA | 323 | Community and Hospital | NA | 57.6 | - | - | - | - | - | - | - | 39.3 | - | - | - | 60.7 | 0.0 | poor |
Lowe et al. (2021) | Lowe | 2021-01-25 | USA | 7,102 | Hospital | 50.3^ (NA) | 61.2 | 2.4 | - | - | - | 12.8 | - | - | - | 84.8 | - | - | - | 0.0 | fair |
Caglar & Kacer (2021) | Caglar | 2021-01-25 | Turkey | 120 | Hospital | 57 (47-67) | 51.7 | - | - | - | - | - | - | - | 37.5 | - | - | - | 62.5 | 0.0 | poor |
De Santi et al. (2021) | De, Santi | 2021-01-25 | Italy | 341 | Community | 47 (20-82) | 51.6 | 25.8 | - | - | - | - | - | - | - | - | - | - | - | 74.2 | poor |
Quan et al. (2021) | Quan | 2021-01-27 | USA | 2,038 | Hospital | 64^ (47-80) | 50.4 | - | - | - | - | - | - | - | 39.7 | - | - | - | - | 60.3 | poor |
Strangfeld et al. (2021) | Strangfeld | 2021-01-27 | Multiple | 3,729 | Community and Hospital | 57^ (41-72) | 68.0 | - | - | - | - | - | - | - | 20.8 | 64.0 | - | - | - | 15.2 | poor |
Tardif et al. (2021) | Tardif | 2021-01-27 | Canada | 4,488 | Community and Hospital | NA | 53.9 | 9.6 | - | - | - | 33.6 | - | - | - | 56.8 | - | - | - | 0.0 | fair |
Jafari et al. (2021) | Jafari | 2021-01-28 | USA | 1,979 | Hospital | 66 (57-74) | 32.0 | 12.1 | - | - | - | - | - | - | - | - | - | - | - | 87.9 | poor |
Prats-Uribe, Tobed, et al. (2021) | Prats-Uribe | 2021-01-30 | Spain | 696 | Hospital | 63^ (52-73) | 30.9 | - | - | - | - | - | - | - | 16.1 | 74.6 | - | - | - | 9.3 | poor |
Nuño et al. (2021) | Nuno | 2021-02-01 | USA | 4,730 | Hospital | 61 (46-73) | 43.6 | 10.1 | - | - | - | - | - | - | - | - | - | - | - | 89.8 | poor |
Abajo et al. (2021) | de Abajo | 2021-02-03 | Spain | 625 | Hospital | NA | 39.4 | 4.6 | - | - | - | 29.3 | - | - | - | 39.2 | - | - | - | 26.9 | poor |
Mora et al. (2021) | Mora | 2021-02-03 | USA | 1,058 | Community | 39.7^ (27-52) | 52.5 | 4.5 | - | - | - | 14.6 | - | - | - | 80.8 | - | - | - | 0.1 | fair |
Molenaar et al. (2021) | Molenaar | 2021-02-03 | USA | 696 | Community and Hospital | 33.1^ (NA) | 100.0 | 4.5 | - | - | - | - | - | - | - | - | - | - | - | 95.5 | poor |
Leister et al. (2021) | Leister | 2021-02-03 | Austria | 3,301 | Community and Hospital | 43.6^ (33-54) | 68.0 | 23.3 | - | - | - | - | - | - | - | - | - | - | - | 76.7 | poor |
Didikoglu et al. (2021) | Didikoglu | 2021-02-04 | UK | 384,816 | Community and Hospital | 68.3^ (60-76) | 54.9 | 9.8 | - | - | - | 35.2 | - | - | - | 55.0 | - | - | - | 0.0 | fair |
Estiri et al. (2021) | Estiri | 2021-02-04 | USA | 16,709 | Hospital | NA | 57.2 | - | - | - | - | - | - | - | 8.6 | - | - | - | - | 91.4 | poor |
Tavakol et al. (2021) | Tavakol | 2021-02-04 | Iran | 206 | Community and Hospital | 40.9^ (29-52) | 57.8 | - | - | - | - | - | - | - | 12.6 | - | - | - | 87.4 | 0.0 | poor |
Cai et al. (2021) | Cai, Yang | 2021-02-05 | China | 455 | Hospital | NA | 52.6 | 7.5 | - | - | - | - | - | - | - | - | - | - | - | 92.5 | poor |
Lohia et al. (2021) | Lohia | 2021-02-05 | USA | 1,871 | Hospital | 64.1^ (48-80) | 48.4 | - | - | - | - | - | - | - | 37.6 | - | - | - | - | 62.4 | poor |
Vila-Corcoles et al. (2021) | Vila-Corcoles, Satue-Gracia, Vila-Rovira | 2021-02-05 | Spain | 79,083 | Community | 65.8^ (54-77) | 52.4 | 16.1 | - | - | - | - | - | - | - | - | - | - | - | 83.9 | poor |
Gégout petit et al. (2021) | Gegout Petit | 2021-02-12 | France | 2,006 | Community | NA | 55.0 | 16.8 | - | - | - | - | - | - | - | - | - | - | 78.9 | 4.2 | poor |
Q. Zhang et al. (2021) | Zhang, Wang | 2021-02-13 | China | 172 | Hospital | 47.9^ (29-66) | 46.5 | 7.0 | - | - | - | 1.2 | - | - | 91.9 | - | - | - | - | 0.0 | poor |
Dambha-Miller et al. (2021) | Dambha, Miller | 2021-02-19 | UK | 5,451 | Community and Hospital | 59^ (37-80) | 100.0 | 8.9 | - | - | - | 49.8 | - | - | - | 39.0 | - | - | - | 2.3 | fair |
Badr et al. (2021a) | Ibrahim, Badr | 2021-02-19 | Saudi Arabia | 159 | Hospital | NA | 30.0 | - | - | - | - | - | - | - | 38.4 | - | - | - | - | 61.6 | poor |
Badr et al. (2021b) | Ibrahim, Badr | 2021-02-19 | Saudi Arabia | 159 | Hospital | NA | 30.0 | - | - | - | - | - | - | - | 38.4 | - | - | - | - | 61.6 | poor |
Hoertel et al. (2021) | Hoertel, A | 2021-02-20 | France | 545 | Community and Hospital | NA | 46.0 | 21.7 | - | - | - | - | - | - | - | - | - | - | - | 78.3 | poor |
Lombardi et al. (2021) | Lombardi | 2021-02-22 | Italy | 4,055 | Community | 44.8^ (NA) | 69.6 | 20.8 | - | - | - | 13.6 | - | - | - | 61.5 | - | - | - | 4.1 | fair |
Gharebaghi et al. (2021) | Gharebaghi | 2021-02-24 | Iran | 215 | Hospital | 50.9^ (33-68) | 42.3 | 20.5 | - | - | - | - | - | - | - | - | - | - | - | 79.5 | poor |
Shields et al. (2021) | Shields | 2021-02-26 | UK | 1,507 | Community | 37 (29-47) | 75.4 | 10.4 | - | - | - | 16.6 | - | - | - | 73.0 | - | - | - | 0.0 | fair |
Voruz et al. (2021) | Voruz | 2021-02-26 | Switzerland | 45 | Community and Hospital | NA | 42.0 | - | - | - | - | - | - | - | 6.7 | - | - | - | 93.3 | 0.0 | poor |
The OpenSAFELY Collaborative et al. (2021) | Williamson, Tazare | 2021-03-01 | UK | 11,972,947 | Community | NA | 52.1 | 18.8 | - | - | - | 32.7 | - | - | - | 46.3 | - | - | - | 2.1 | good |
González, Vielot, et al. (2021) | Gonzalez, Vielot | 2021-03-01 | Nicaragua | 1,351 | Community | NA | 59.0 | - | - | - | - | - | - | - | 7.6 | 50.3 | - | - | - | 42.1 | poor |
Lucar et al. (2021) | Lucar | 2021-03-01 | USA | 100 | Hospital | 59 (44-70) | 53.0 | - | - | - | - | - | - | - | 22.0 | - | - | - | - | 78.0 | poor |
Drozd et al. (2021) | Drozd | 2021-03-01 | UK | 493,295 | Community | NA | 54.5 | 10.6 | - | - | - | 34.7 | - | - | - | 54.8 | - | - | - | 0.0 | fair |
Printza et al. (2021) | Printza | 2021-03-02 | Greece | 150 | Hospital | 51.6^ (34-68) | 38.0 | 14.0 | - | - | - | - | - | - | - | - | - | - | - | 86.0 | poor |
Dashti et al. (2021) | Dashti | 2021-03-02 | USA | 12,347 | Hospital | 47 (32-62) | 53.3 | 4.6 | - | - | - | 15.9 | - | - | - | 57.1 | - | - | - | 22.4 | poor |
Nielsen et al. (2021) | Nielsen | 2021-03-03 | Denmark | 840 | Community | NA | 84.0 | 4.6 | - | - | - | 31.4 | - | - | - | 63.9 | - | - | - | 0.0 | fair |
Peng et al. (2021) | Peng, Lei | 2021-03-03 | China | 622 | Hospital | NA | 48.9 | 10.0 | - | - | - | - | - | - | - | - | - | - | - | 90.0 | poor |
Dayem Ullah et al. (2021) | Dayem, Ullah | 2021-03-04 | UK | 15,440 | Community | 57.2 (44.9-69.4) | 56.2 | 21.2 | - | - | - | 33.8 | - | - | - | 42.2 | - | - | - | 2.8 | fair |
Velasco-Rodríguez et al. (2021) | Velasco, Rodriguez | 2021-03-04 | Spain | 2,070 | Hospital | 67 (54-79) | 42.7 | 4.1 | - | - | - | - | - | - | - | - | - | - | - | 0.7 | poor |
Action to beat coronavirus/Action pour battre le coronavirus (Ab-C) Study Investigators & Jha (2021) | Jha | 2021-03-05 | Canada | 8,967 | Community | NA | 57.0 | - | - | - | - | - | - | - | 46.7 | 51.9 | - | - | - | 1.3 | poor |
Guzmán et al. (2021) | Macias, Guzman | 2021-03-08 | Mexico | 196 | Hospital | 58.1^ (42-73) | 62.0 | - | - | - | - | - | - | - | 36.2 | - | - | - | - | 63.8 | poor |
García-Abellán et al. (2021) | Garcia, Abellan | 2021-03-08 | Spain | 146 | Hospital | 64 (54-76) | 39.7 | 8.2 | - | - | - | - | - | - | - | - | - | - | - | 91.8 | poor |
Martin-Vicente et al. (2021) | Martin, Vicente | 2021-03-08 | Spain | 92 | Hospital | 66 (50-71.5) | 34.8 | 5.4 | - | - | - | - | - | - | - | - | - | - | - | 94.6 | poor |
Rogier et al. (2021) | Rogier | 2021-03-08 | France | 374 | Hospital | NA | 48.4 | 9.6 | - | - | - | - | - | - | - | - | - | - | - | 90.4 | poor |
Greenbaum et al. (2021) | Greenbaum | 2021-03-10 | USA | 44 | Hospital | 60 (37-84) | 43.2 | 4.5 | - | - | - | 20.5 | - | - | - | 75.0 | - | - | - | 0.0 | fair |
Grint et al. (2021) | Grint | 2021-03-10 | UK | 184,786 | Community and Hospital | 38 (24-52) | 53.1 | 10.5 | - | - | - | 27.0 | - | - | - | 47.3 | - | - | - | 15.2 | good |
Kline et al. (2021) | Kline | 2021-03-10 | USA | 19,850 | Hospital | NA | 52.5 | 17.9 | - | - | - | - | - | - | - | - | - | - | - | 82.1 | poor |
Hausfater et al. (2021) | Hausfater | 2021-03-12 | France | 1,062 | Community | 33 (28-42) | 71.4 | 17.8 | - | - | - | - | - | - | - | - | - | - | 48.5 | 33.7 | poor |
Daugherty et al. (2021) | Daugherty | 2021-03-12 | USA | 266,586 | Community and Hospital | 41.7^ (27-55) | 52.4 | 3.0 | - | - | - | - | - | - | - | - | - | - | - | 97.0 | poor |
Vanegas-Cedillo et al. (2021) | Vanegas, Cedillo | 2021-03-14 | Mexico | 551 | Community and Hospital | NA | 35.6 | 4.9 | - | - | - | - | - | - | - | - | - | - | - | 95.1 | poor |
Amanat et al. (2021) | Amanat | 2021-03-16 | Iran | 873 | Hospital | 60.7^ (42-78) | 36.3 | 15.7 | - | - | - | - | - | - | - | - | - | - | - | 84.3 | poor |
Yamei Zheng et al. (2021) | Zheng, Gao, Wu | 2021-03-19 | China | 70 | Hospital | 51.2^ (37-64) | 41.4 | 7.1 | - | - | - | - | - | - | - | - | - | - | - | 92.9 | poor |
Melotti et al. (2021) | Melotti | 2021-03-20 | Italy | 2,244 | Community | NA | 51.0 | 14.5 | - | - | - | 15.1 | - | - | - | 70.5 | - | - | - | 0.0 | fair |
HPG23 Covid-19 Study Group et al. (2021) | Raimondi | 2021-03-20 | Italy | 431 | Hospital | 67.6^ (54-80) | 27.6 | 4.2 | - | - | - | 22.0 | - | - | - | 47.8 | - | - | - | 26.0 | poor |
Martinez-Lacalzada, Viteri-Noël, et al. (2020) | Martinez-Lacalzada | 2021-03-21 | Spain | 10,433 | Hospital | NA | 56.5 | 5.2 | - | - | - | 23.8 | - | - | - | 66.1 | - | - | - | 5.0 | fair |
Martinez-Lacalzada, Adrián Viteri-Noël, et al. (2020) | Martinez-Lacalzada | 2021-03-21 | Spain | 10,433 | Hospital | NA | 56.5 | 5.2 | - | - | - | 23.8 | - | - | - | 66.1 | - | - | - | 5.0 | fair |
Q. Wang et al. (2021) | Wang, Codd | 2021-03-22 | UK | 6,775 | Community and Hospital | NA | 52.0 | 11.0 | - | - | - | 35.6 | - | - | - | 53.0 | - | - | - | 0.3 | fair |
Rachmawati et al. (2021a) | Rachmawati | 2021-03-23 | Indonesia | 490 | Hospital | NA | 53.1 | 17.1 | - | - | - | 13.1 | - | - | - | 69.8 | - | - | - | 0.0 | fair |
Rachmawati et al. (2021b) | Rachmawati | 2021-03-23 | Indonesia | 490 | Hospital | NA | 53.1 | 17.1 | - | - | - | 13.1 | - | - | - | 69.8 | - | - | - | 0.0 | fair |
Fernandez-Fuertes et al. (2021) | Fernandez, Fuertes | 2021-03-24 | Spain | 710 | Community | 52 (43-57) | 19.3 | 100.0 | - | - | - | - | - | - | - | - | - | - | - | 0.0 | poor |
Menges et al. (2021) | Menges | 2021-03-24 | Switzerland | 431 | Community | 47 (33-58) | 50.0 | 14.2 | - | - | - | 28.3 | - | - | - | 56.8 | - | - | - | 0.7 | fair |
Dev et al. (2021) | Dev | 2021-03-24 | India | 506 | Community | 32^ (23-41) | 44.0 | 16.0 | - | - | - | - | - | - | - | - | - | - | - | 84.0 | poor |
PHOSP-COVID Collaborative Group et al. (2021) | P-HOSP-COVID Collaborative | 2021-03-25 | UK | 1,077 | Community and Hospital | 58^ (45-71) | 35.7 | 1.5 | - | - | - | 34.4 | - | - | - | 46.9 | - | - | - | 17.3 | fair |
Asem et al. (2021) | Asem | 2021-03-25 | Egypt | 8,162 | Quarantine Centre | NA | 45.5 | 16.6 | - | - | - | - | - | - | - | - | - | - | - | 83.4 | poor |
S. F. Lee et al. (2021) | Lee, Niksic | 2021-03-25 | UK | 89 | Community | 74 (68-78) | 47.0 | 13.5 | - | - | - | 48.3 | - | - | - | 37.1 | - | - | - | 1.1 | fair |
Avouac et al. (2021) | Avouac | 2021-03-25 | France | 1,090 | Hospital | NA | 67.0 | 9.7 | - | - | - | - | - | - | - | - | - | - | 90.3 | 0.0 | poor |
(schaad_point?)–care_2021 | Schaad | 2021-03-26 | Switzerland | 134 | Community and Hospital | 35 (29-46) | 63.0 | 29.1 | - | - | - | - | - | - | - | - | - | - | - | 70.9 | poor |
Mok et al. (2021) | Mok | 2021-03-26 | USA | 211 | Hospital | 70.4^ (57-83) | 43.6 | - | - | - | - | - | - | - | 37.0 | - | - | - | - | 63.0 | poor |
Faverio et al. (2021) | Faverio | 2021-03-30 | Italy | 312 | Community and Hospital | NA | 26.6 | 4.8 | - | - | - | 20.8 | - | - | - | 58.0 | - | - | - | 16.4 | fair |
Bell et al. (2021) | Bell | 2021-03-31 | USA | 303 | Community | 43.6 (27-60) | 70.0 | - | - | 13.2 | - | - | - | - | - | - | - | - | - | 86.8 | poor |
Gil et al. (2021) | Gil | 2021-03-31 | Brazil | 186 | Hospital | NA | 93.0 | 24.7 | - | - | - | - | - | - | - | - | - | - | 75.3 | 0.0 | poor |
Galluzzi et al. (2021) | Galluzzi | 2021-04-01 | Italy | 376 | Community and Hospital | 60.8^ (48-73) | 37.0 | 2.1 | - | - | - | 17.3 | - | - | - | 77.7 | - | - | - | 2.9 | fair |
Wagner et al. (2021) | Wagner | 2021-04-04 | Germany | 4,203 | Community | 52 (35-64) | 51.7 | 20.3 | - | - | - | 24.5 | - | - | - | 54.7 | - | - | - | 0.6 | good |
Mady et al. (2021) | Mady | 2021-04-07 | Saudi Arabia | 415 | Hospital | NA | 31.8 | - | - | - | - | - | - | - | 34.0 | - | - | - | - | 66.0 | poor |
Rubina et al. (2021) | Rubina | 2021-04-07 | Russia | 52 | Hospital | NA | 46.0 | 3.8 | - | - | - | - | - | - | - | - | - | - | - | 17.3 | poor |
Scully et al. (2021) | Scully | 2021-04-07 | USA | 2,608 | Hospital | NA | 48.7 | 6.0 | - | - | - | 20.7 | - | - | - | 62.9 | - | - | - | 10.3 | fair |
Manohar et al. (2021) | Manohar | 2021-04-07 | USA | 11,930 | Community and Hospital | 57.3^ (NA) | 50.7 | 2.0 | - | - | - | 11.6 | - | - | - | 11.8 | - | - | - | 74.6 | poor |
Durstenfeld et al. (2021) | Durstenfeld | 2021-04-07 | USA | 21,528 | Hospital | NA | 45.9 | 6.5 | - | - | - | - | - | - | - | - | - | - | - | 93.5 | poor |
R. A. Rashid et al. (2021) | Rashid, Zgair | 2021-04-07 | Iraq | 276 | Community | 29 (23-37) | 71.7 | 11.6 | - | - | - | - | - | - | - | - | - | - | - | 0.0 | poor |
J. Wang et al. (2021) | Wang, Su | 2021-04-08 | China | 185 | Hospital | 41 (32-57) | 48.6 | - | - | - | - | - | - | - | 10.8 | - | - | - | - | 89.2 | poor |
Thomas et al. (2021) | Rhys, Thomas | 2021-04-09 | UK | 2,820 | Community | NA | - | - | - | 16.5 | - | - | - | - | - | - | - | - | - | 83.5 | poor |
S. Li, Jun, et al. (2021) | Li, Jun | 2021-04-11 | USA | 2,627 | Hospital | NA | - | 5.2 | - | - | - | 25.7 | - | - | - | 46.6 | - | - | - | 22.5 | poor |
Atergeleh et al. (2021) | Atergeleh | 2021-04-13 | Iran | 4,394 | Community | 61^ (NA) | 59.0 | - | - | - | - | - | - | - | 9.0 | 91.0 | - | - | - | 0.0 | poor |
Boscolo-Rizzo et al. (2021) | Boscolo-Rizzo | 2021-04-13 | Italy | 304 | Community and Hospital | NA | 60.9 | 16.8 | - | - | - | 24.3 | - | - | - | 58.9 | - | - | - | 0.0 | fair |
Chalkias et al. (2021) | Chalkias | 2021-04-15 | Multiple | 81 | Hospital | NA | 65.0 | - | - | - | - | - | - | - | 30.9 | 69.1 | - | - | - | 0.0 | poor |
Byttebier et al. (2021) | Byttebier | 2021-04-15 | Belgium | 959 | Hospital | 73 (0-98) | 45.5 | - | - | - | - | - | - | - | 14.9 | - | - | - | - | 85.1 | poor |
Husain et al. (2021) | Husain | 2021-04-19 | USA | 2,892 | Community and Hospital | NA | 40.7 | 4.2 | - | - | - | 16.8 | - | - | - | 68.3 | - | - | - | 10.8 | fair |
Reese et al. (2021) | Reese | 2021-04-20 | USA | 24,788 | Community and Hospital | NA | 60.0 | - | - | - | - | - | - | - | 11.7 | 88.3 | - | - | - | 0.0 | poor |
Desgranges et al. (2021) | Desgranges | 2021-04-20 | Switzerland | 507 | Community | NA | 62.7 | 14.4 | - | - | - | - | - | - | - | - | - | - | - | 85.6 | poor |
S. Li, Sarangarajan, et al. (2021) | Li, Sarangarajan | 2021-04-22 | USA | 6,218 | Hospital | NA | 46.1 | 4.3 | - | - | - | 19.0 | - | - | - | 54.2 | - | - | - | 22.4 | poor |
Tarifi et al. (2021) | Tarifi | 2021-04-22 | Jordan | 97 | Hospital | NA | 47.4 | - | - | - | - | - | - | - | 41.2 | 58.8 | - | - | - | 0.0 | poor |
Zell et al. (2021) | Zell | 2021-04-23 | USA | 995 | Community | NA | 20.8 | 7.7 | 6.6 | - | - | 28.0 | - | - | - | 63.4 | - | - | - | 0.8 | fair |
S. C. Lee et al. (2021) | Lee, Son | 2021-04-23 | South Korea | 4,167 | Community | NA | 65.3 | 6.7 | - | - | - | 14.8 | - | - | - | 78.4 | - | - | - | 0.0 | fair |
Joubert et al. (2021) | Joubert, Andry | 2021-04-26 | Reunion | 1,013 | Community | NA | 60.0 | 16.0 | - | - | - | - | - | - | - | - | - | - | - | 84.0 | poor |
Halabi et al. (2021) | El, Halabi | 2021-04-26 | USA | 5,859 | Community and Hospital | 60.5^ (43-78) | 44.0 | - | - | - | - | - | - | - | 21.9 | 53.6 | - | - | - | 24.5 | poor |
Shiri et al. (2021) | Shiri | 2021-04-28 | Iran | 78 | Hospital | NA | 46.2 | 2.8 | - | - | - | - | - | - | - | - | - | - | - | 97.2 | poor |
Gerhards et al. (2021) | Gerhards | 2021-04-28 | Germany | 61 | Community | 46.4^ (18-76) | 59.0 | 6.6 | - | - | - | - | - | - | - | - | - | - | - | 93.4 | poor |
Radon et al. (2021) | Radon | 2021-04-29 | Germany | 4,433 | Community | NA | 52.0 | 16.4 | - | - | - | 27.8 | - | - | - | 50.0 | - | - | - | 5.7 | good |
González, Zepeda, et al. (2021) | Gonzalez, Zepeda | 2021-04-29 | Nicaragua | 157 | Community | NA | 39.5 | 11.5 | - | - | - | - | - | - | - | - | - | - | - | 88.5 | poor |
Ahmadi et al. (2021) | Ahmadi | 2021-05-01 | UK | 468,569 | Community | 56.5^ (48-64) | 54.6 | 10.2 | - | - | - | 30.8 | - | - | - | 35.3 | - | - | - | 23.6 | poor |
Ravindra et al. (2021) | Ravindra | 2021-05-05 | India | 1,035 | Hospital | 46.7^ (29-63) | 36.8 | 0.2 | - | - | - | - | - | - | - | - | - | - | - | 0.0 | poor |
Mann et al. (2021) | Mann | 2021-05-06 | USA | 1,769 | Hospital | 64.4^ (47-80) | 47.0 | - | - | - | - | - | - | - | 36.5 | 56.7 | - | - | - | 6.8 | poor |
Noh et al. (2021) | Noh | 2021-05-07 | South Korea | 265 | Hospital | 46 (30-60) | 52.1 | 10.2 | - | - | - | - | - | - | - | - | - | - | - | 89.8 | poor |
Bhaskaran et al. (2021) | Bhaskaran | 2021-05-08 | UK | 17,456,515 | Community | NA | 50.1 | 17.0 | - | - | - | 32.9 | - | - | - | 50.1 | - | - | - | 0.0 | fair |
Chetboun et al. (2021) | Chetboun | 2021-05-09 | Multiple | 1,461 | Hospital | 64 (56-73) | 26.8 | 5.7 | - | - | - | - | - | - | - | - | - | - | - | 94.3 | poor |
Fogh et al. (2021) | Fogh | 2021-05-10 | Denmark | 3,236 | Community | NA | - | - | - | - | - | - | - | - | 26.2 | - | - | - | - | 73.8 | poor |
Madakkatel et al. (2021) | Madakkatel | 2021-05-11 | UK | 421,111 | Community and Hospital | NA | 55.1 | 9.9 | - | - | - | 34.3 | - | - | - | 55.3 | - | - | - | 0.6 | fair |
Bertuzzi et al. (2021) | Bertuzzi | 2021-05-11 | Italy | 557 | Hospital | 65^ (NA) | 32.7 | 9.0 | - | - | - | - | - | - | - | - | - | - | - | 0.0 | poor |
Röthlin Eriksen et al. (2021) | Rothlin, Eriksen | 2021-05-12 | Denmark | 819 | Community | NA | 43.8 | - | - | - | - | - | - | - | 71.7 | - | - | - | - | 28.3 | poor |
Gornyk et al. (2021a) | Gornyk | 2021-05-13 | Germany | 13,045 | Community | 50.9^ (33-68) | 55.2 | 19.4 | - | - | - | 30.9 | - | - | - | 49.6 | - | - | - | 0.1 | good |
Gornyk et al. (2021b) | Gornyk | 2021-05-13 | Germany | 13,045 | Community | 50.9^ (33-68) | 55.2 | 19.4 | - | - | - | 30.9 | - | - | - | 49.6 | - | - | - | 0.1 | good |
Campbell et al. (2021) | Campbell | 2021-05-14 | Canada | 2,128 | Community | 48 (37-57) | 38.0 | 15.6 | - | - | - | 6.1 | - | - | - | 78.4 | - | - | - | 0.0 | fair |
Marimuthu et al. (2021) | Marimuthu | 2021-05-17 | India | 854 | Hospital | 45.3^ (28-62) | 47.4 | - | - | - | - | - | - | - | 1.2 | - | - | - | - | 98.8 | poor |
Bruce et al. (2021) | Bruce | 2021-05-17 | Multiple | 1,584 | Hospital | 74 (61.5-83) | 42.7 | 7.1 | - | - | - | 38.2 | - | - | - | 52.0 | - | - | - | 2.7 | fair |
Bark et al. (2021) | Bark | 2021-05-18 | Canada | 157 | Community | 39^ (18-73) | 66.0 | - | - | 17.2 | - | - | - | - | - | - | - | - | - | 82.8 | poor |
Jha et al. (2021) | Jha, Shrestha | 2021-05-18 | Nepal | 198 | Hospital | 40.8 (29.8-51.3) | 26.3 | 11.6 | - | - | - | 12.6 | - | - | - | 75.8 | - | - | - | 0.0 | fair |
Lekoubou et al. (2021) | Lekoubou | 2021-05-18 | USA | 8,815 | Hospital | 51^ (33-69) | 57.0 | 2.9 | - | - | - | 6.6 | - | - | - | 18.1 | - | - | - | 72.3 | poor |
Kahlert et al. (2021) | Kahlert | 2021-05-18 | Switzerland | 4,664 | Community | 38.3 (29.7-49.5) | 78.3 | 17.6 | - | - | - | 20.4 | - | - | - | 62.0 | - | - | - | 0.0 | fair |
Hirschtick et al. (2021) | Hirschtick | 2021-05-19 | USA | 593 | Community | 51.5^ (35-67) | 56.0 | 6.2 | - | - | - | - | - | - | - | - | - | - | - | 93.8 | poor |
Y. Li et al. (2021) | Li, Tong | 2021-05-19 | USA | 18,148 | Community | 47 (37-56) | 67.1 | 12.3 | - | - | - | - | - | - | - | - | - | - | - | 0.1 | poor |
AlSafar et al. (2021) | Alsafar | 2021-05-19 | United Arab Emirates | 464 | Community and Hospital | 47^ (32-62) | 40.0 | 10.8 | - | - | - | - | - | - | - | - | - | - | 89.2 | 0.0 | poor |
Wallis et al. (2021) | Wallis | 2021-05-21 | UK | 101 | Hospital | 53 (45-63) | 46.5 | - | - | - | - | - | - | - | 34.7 | - | - | - | - | 65.3 | poor |
Ayhan et al. (2021) | Ayhan | 2021-05-21 | Turkey | 92 | Hospital | 67 (55-73) | 44.6 | 17.4 | - | - | - | - | - | - | - | - | - | - | 43.5 | 39.1 | poor |
Nanda et al. (2021) | Nanda | 2021-05-24 | USA | 1,169 | Hospital | 28.6 (NA) | 50.7 | 12.8 | - | - | - | 14.9 | - | - | - | 72.3 | - | - | - | 0.0 | fair |
Prats-Uribe, Xie, et al. (2021) | Prats-Uribe, Xie | 2021-05-25 | UK | 1,591 | Community and Hospital | NA | 47.5 | 12.1 | - | - | - | 39.5 | - | - | - | 48.5 | - | - | - | 0.0 | fair |
Egede et al. (2021) | Egede | 2021-05-26 | USA | 30,976 | Community and Hospital | 52.8^ (33-71) | 60.0 | 13.9 | - | - | - | 32.3 | - | - | - | - | - | - | 53.8 | 0.0 | poor |
Kleynhans et al. (2021) | Kleynhans | 2021-05-29 | South Africa | 350 | Community | NA | 65.0 | 10.3 | - | - | - | - | - | - | - | - | - | - | - | 35.4 | poor |
Puebla Neira et al. (2021) | Puebla, Neira | 2021-06-01 | USA | 10,216 | Community and Hospital | 45.8^ (27-63) | 64.9 | 3.9 | - | - | - | 9.0 | - | - | - | 87.1 | - | - | - | 0.0 | fair |
Lassen et al. (2021) | Hojbjerg, Lassen | 2021-06-01 | Denmark | 171 | Hospital | NA | 55.0 | 5.8 | - | - | - | 53.8 | - | - | - | 38.6 | - | - | - | 1.8 | fair |
S. Chen et al. (2021) | Chen, Zheng | 2021-06-06 | China | 1,030 | Hospital | 55 (44-65) | 44.1 | - | - | - | - | - | - | - | 10.5 | 89.5 | - | - | - | 0.0 | poor |
Fisher et al. (2021) | Fisher | 2021-06-09 | UK | 146 | Hospital | NA | 24.0 | - | - | - | - | - | - | - | 41.1 | - | - | - | - | 58.9 | poor |
Ghani et al. (2021) | Ghani | 2021-06-09 | UK | 2,366 | Hospital | NA | - | - | - | - | - | - | - | - | 33.1 | - | - | - | - | 66.9 | poor |
Andrade Barreto et al. (2021) | Andrade, Barreto | 2021-06-09 | Brazil | 602 | Community | 51.8^ (37-66) | 59.0 | - | - | - | - | - | - | - | 25.6 | - | - | - | - | 74.4 | poor |
Aabakke et al. (2021) | Aabakke | 2021-06-10 | Denmark | 420 | Community | 29 (27-33) | 100.0 | 2.4 | - | - | - | - | - | - | - | - | - | - | - | 51.0 | poor |
Yozgat et al. (2021) | Yozgat | 2021-06-10 | Turkey | 382 | Hospital | NA | 37.4 | 29.6 | - | - | - | - | - | - | - | - | - | - | - | 0.0 | poor |
Sandri et al. (2021) | Sandri | 2021-06-10 | Italy | 3,985 | Community | NA | 66.8 | 23.9 | - | - | - | - | - | - | - | - | - | - | - | 76.1 | poor |
Jose et al. (2021) | Jose | 2021-06-10 | USA | 69,264 | Community and Hospital | NA | 62.1 | 8.8 | - | 1.5 | 0.7 | 25.8 | 0.9 | 1.3 | - | 60.3 | 0.3 | 0.3 | - | 0.0 | fair |
Herzberg et al. (2021) | Herzberg | 2021-06-13 | Germany | 52 | Community | 39.7^ (27-52) | 75.0 | - | - | - | - | - | - | - | 19.2 | - | - | - | - | 80.8 | poor |
Han et al. (2021) | Han, Peng | 2021-06-15 | China | 160 | Hospital | 62.3^ (51-73) | 42.8 | - | - | - | - | - | - | - | 16.9 | - | - | - | - | 83.1 | poor |
Abdulamir et al. (2021) | Abdulamir | 2021-06-17 | Iraq | 150 | Hospital | 49.3^ (33-65) | 46.7 | 27.3 | - | - | - | - | - | - | - | - | - | - | - | 0.0 | poor |
L. Chauhan et al. (2021) | Chauhan | 2021-06-18 | USA | 376 | Hospital | 58.9^ (42-75) | 43.1 | 6.1 | - | - | - | - | - | - | - | - | - | - | - | 93.9 | poor |
Barchuk et al. (2021) | Barchuk | 2021-06-21 | Russia | 962 | Community | NA | 62.8 | 20.3 | - | - | - | 27.8 | - | - | - | 48.5 | - | - | - | 3.4 | good |
Patone et al. (2021) | Patone | 2021-06-22 | UK | 429,926 | Community and Hospital | 37.7^ (19-55) | 52.7 | 11.2 | - | - | - | 17.6 | - | - | - | 56.3 | - | - | - | 15.0 | fair |
Mollan et al. (2021) | Mollan | 2021-06-25 | USA | 204 | Community | 40 (27-52) | 51.0 | - | - | 14.7 | - | - | 16.7 | - | - | - | 68.1 | - | - | 0.5 | fair |
Sonnweber et al. (2021) | Sonnweber | 2021-06-25 | Austria | 108 | Hospital | 57^ (43-71) | 45.4 | 3.7 | - | - | - | 42.6 | - | - | - | - | - | - | - | 53.7 | poor |
Nassar et al. (2021) | Nassar | 2021-06-25 | Egypt | 160 | Hospital | 60^ (46-74) | 32.5 | 10.6 | - | - | - | - | - | - | - | - | - | - | - | 89.4 | poor |
Ali et al. (2021) | Ali, Hasan | 2021-06-25 | Bangladesh | 326 | Hospital | NA | 39.9 | 20.9 | - | - | - | - | - | - | - | - | - | - | 79.1 | 0.0 | poor |
Demichev et al. (2021) | Demichev | 2021-06-26 | Multiple | 50 | Hospital | 62 (54-73) | 30.0 | 2.0 | - | - | - | 16.0 | - | - | - | 82.0 | - | - | - | 0.0 | fair |
Mostafa et al. (2021) | Mostafa | 2021-06-28 | Egypt | 4,040 | Community | NA | 61.5 | 11.9 | - | - | - | 2.0 | - | - | - | 86.2 | - | - | - | 0.0 | fair |
Tehrani et al. (2021a) | Tehrani | 2021-06-30 | USA | 8,222 | Hospital | NA | 44.0 | - | - | - | - | - | - | - | 6.3 | - | - | - | - | 93.7 | poor |
Tehrani et al. (2021b) | Tehrani | 2021-06-30 | USA | 8,222 | Hospital | NA | 44.0 | - | - | - | - | - | - | - | 6.3 | - | - | - | - | 93.7 | poor |
Amer et al. (2021) | Amer | 2021-07-01 | Multiple | 860 | Hospital | NA | 34.0 | 4.9 | 0.1 | - | - | 20.1 | - | - | - | - | - | - | - | 74.9 | poor |
X. Wu et al. (2021) | Wu, Liu | 2021-07-01 | China | 83 | Hospital | 60 (52-66) | 43.0 | - | - | - | - | - | - | - | - | 100.0 | - | - | - | 0.0 | poor |
N. K. Chauhan et al. (2021) | Chauhan, Shadrach | 2021-07-01 | India | 125 | Hospital | 49.9^ (32-67) | 25.6 | 20.0 | - | - | - | - | - | - | - | - | - | - | - | 80.0 | poor |
Mendez-Dominguez et al. (2021) | Mendez, Dominguez | 2021-07-02 | Mexico | 7,064 | Community | NA | 100.0 | 1.9 | - | - | - | - | - | - | - | - | - | - | - | 98.1 | poor |
The CONCOR-1 Study Group et al. (2021) | CONCOR-1 Study-group | 2021-07-03 | Canada | 921 | Hospital | 69 (58-79) | 41.9 | 2.7 | - | - | - | 31.7 | - | - | - | 52.4 | - | - | - | 13.1 | fair |
Gebhard et al. (2021) | Gebhard | 2021-07-06 | Switzerland | 2,799 | Hospital | 43.6^ (27-60) | 45.9 | - | - | - | - | - | - | - | 27.6 | - | - | - | - | 72.4 | poor |
Genecand et al. (2021) | Genecand | 2021-07-06 | Switzerland | 51,706 | Community | NA | 53.3 | 9.0 | - | - | - | - | - | - | - | - | - | - | - | 91.0 | poor |
Qureshi et al. (2021) | Qureshi | 2021-07-06 | USA | 85,645 | Hospital | NA | 54.4 | 15.8 | - | - | - | - | - | - | - | - | - | - | - | 84.2 | poor |
Y. I. Wan et al. (2021) | Wan, Apea | 2021-07-07 | UK | 5,533 | Hospital | NA | 46.8 | 13.3 | - | - | - | - | - | - | - | - | - | - | - | 86.7 | poor |
Gaitán-Duarte et al. (2021) | Gaitan, Duarte | 2021-07-10 | Colombia | 633 | Hospital | NA | 32.4 | 16.4 | - | - | - | - | - | - | - | - | - | - | - | 83.6 | poor |
Chuo et al. (2021) | Chuo | 2021-07-12 | USA | 138,792 | Community and Hospital | 44 (30-60) | 54.9 | 6.7 | - | - | - | - | - | - | - | - | - | - | - | 0.0 | poor |
Sholzberg et al. (2021) | Sholzberg | 2021-07-12 | Canada | 465 | Hospital | NA | 43.2 | 2.6 | - | - | - | - | - | - | - | - | - | - | - | 97.4 | poor |
Riyahi et al. (2021) | Riyahi | 2021-07-13 | USA | 413 | Hospital | 60^ (44-76) | 44.3 | - | - | - | - | - | - | - | 12.8 | - | - | - | - | 87.2 | poor |
International Severe Acute Respiratory and emerging Infections Consortium, Escher, et al. (2020) | Isaric, 11 | 2021-07-14 | Multiple | 442,643 | Hospital | 60 (NA) | 50.0 | 11.4 | - | - | - | - | - | - | - | - | - | - | - | 65.6 | poor |
International Severe Acute Respiratory and emerging Infections Consortium, Hall, et al. (2020) | Isaric, 11 | 2021-07-14 | Multiple | 442,643 | Hospital | 60 (NA) | 50.0 | 11.4 | - | - | - | - | - | - | - | - | - | - | - | 65.6 | poor |
Pritchard et al. (2020) | Isaric, 11 | 2021-07-14 | Multiple | 442,643 | Hospital | 60 (NA) | 50.0 | 11.4 | - | - | - | - | - | - | - | - | - | - | - | 65.6 | poor |
ISARIC Clinical Characterisation Group et al. (2020) | Isaric, 11 | 2021-07-14 | Multiple | 442,643 | Hospital | 60 (NA) | 50.0 | 11.4 | - | - | - | - | - | - | - | - | - | - | - | 65.6 | poor |
Aboueshia et al. (2021) | Aboueshia | 2021-07-15 | USA | 260 | Hospital | 58.6^ (18-93) | 52.3 | 21.5 | - | - | - | 8.8 | - | - | - | 60.4 | - | - | - | 9.2 | fair |
Matli et al. (2021) | Matli | 2021-07-16 | Lebanon | 242 | Hospital | NA | 31.0 | 21.9 | - | - | - | - | - | - | - | - | - | - | - | 78.1 | poor |
Alhamlan et al. (2021) | Alhamlan | 2021-07-16 | Saudi Arabia | 492 | Hospital | NA | 45.9 | 8.7 | - | - | - | - | - | - | - | - | - | - | - | 23.6 | poor |
Unadjusted smoking prevalence compared with overall estimates for national adult smoking prevalence split by country and study setting is presented in Figure 2. Lower than expected current smoking prevalence was generally observed, especially in studies with hospitalised samples. Former smoking prevalence was more similar to expected prevalence when reported; however, study-based prevalence was typically higher than national estimates. National smoking prevalence estimates used for comparison are presented in Supplementary table 3.
Figure 2. Weighted mean prevalence of current (left panel) and former (right panel) smoking in included studies, split by country. The circles represent individual studies, with colour corresponding to study setting (i.e. hospital, community and hospital, community) and size corresponding to relative study sample size. For comparison, national current and former smoking prevalence are indicated by the red lines. Countries with three or more eligible studies are shown.
Four studies provided data on access to SARS-CoV-2 diagnostic testing for those meeting local testing criteria by smoking status. In a cohort study of US military veterans aged 54-75 (C. Rentsch et al., 2020), current smokers were more likely to receive a test: 42.3% (1,603/3,789) of the sample were current smokers compared with 23.8% of all veterans aged 50+ years using any tobacco product between 2010-2015 (Odani, 2018). In the UK Biobank cohort (Niedzwiedz et al., 2020), a multivariable analysis showed former (RR = 1.29, 95% CI = 1.14-1.45, p < .001) and current (RR = 1.44, 95% CI = 1.20-1.71, p < .001) compared with never smokers to be more likely to receive a test. In an Australian rapid assessment screening clinic for COVID-19 (Trubiano et al., 2020), 9.4% (397/4,226) of the self-referred sample (subsequently assessed by a healthcare professional to decide on testing) were current smokers. Of these self-referrals, healthcare professionals decided that current compared with former or never smokers were less likely to require a test (RR = 0.93, 95% CI = 0.86-1.0, p = 0.045). In a further study using the UK Biobank cohort (Didikoglu et al., 2021), current (RR = 1.23, 95% CI = 1.19-1.26, p < 0.001) and former smokers (RR = 1.20, 95% CI = 1.18-1.23, p < 0.001) were more likely to receive a test compared with never smokers.
108 studies provided data on SARS-CoV-2 infection for people meeting local testing criteria by smoking status (see Table 2). Meta-analyses were performed for 6 ‘good’ and 33 ‘fair’ quality studies (see Figure 3 and 4). Current smokers were at reduced risk of testing positive for SARS-CoV-2 compared with never smokers (RR = 0.67, 95% Credible Interval (CrI) = 0.6-0.75, τ = 0.27). The six good quality studies each reported point estimates less than 1, although the CrI for two of the six studies crossed 1. The probability of current smokers being at reduced risk of infection compared with never smokers (RR ≤0.9) was >99%. Former compared with never smokers were at increased risk of testing positive, but data were inconclusive (RR = 0.99, 95% CrI = 0.94-1.05, τ = 0.12) and favoured there being no important association. The probability of former smokers being at increased risk of infection (RR ≥1.1) compared with never smokers was < 1%. Results were materially unchanged in sensitivity analyses.
SARS-CoV-2 negative | SARS-CoV-2 positive | ||||||||||||||||
Author | Total population tested | N (%) | Current smoker (%) | Former smoker (%) | Current/former smoker (%) | Never smoker (%) | Current vaper (%) | Current vaper and smoker (%) | Not stated (%) | N (%) | Current smoker (%) | Former smoker (%) | Current/former smoker (%) | Never smoker (%) | Current vaper (%) | Current vaper and smoker (%) | Not stated (%) |
Rentsch | 3,528 | 2974 (84.30%) | 1444 (48.55%) | 704 (23.67%) | - | 826 (27.77%) | - | - | - | 554 (15.70%) | 159 (28.70%) | 179 (32.31%) | - | 216 (38.99%) | - | - | - |
Fontanet | 661 | 490 (74.13%) | 64 (13.06%) | - | - | 426 (86.94%) | - | - | - | 171 (25.87%) | 5 (2.92%) | - | - | 166 (97.08%) | - | - | - |
Cho | 1,331 | 793 (59.58%) | 142 (17.91%) | 214 (26.99%) | - | 437 (55.11%) | - | - | - | 538 (40.42%) | 111 (20.63%) | 145 (26.95%) | - | 282 (52.42%) | - | - | - |
Shah | 243 | 212 (87.24%) | 52 (24.53%) | 47 (22.17%) | - | 113 (53.30%) | - | - | - | 29 (11.93%) | 0 (0.00%) | 9 (31.03%) | - | 20 (68.97%) | - | - | - |
Kolin | 1,474 | 805 (54.61%) | 141 (17.52%) | 307 (38.14%) | - | 354 (43.98%) | - | - | 3 (0.37%) | 669 (45.39%) | 72 (10.76%) | 285 (42.60%) | - | 303 (45.29%) | - | - | 9 (1.35%) |
de Lusignan | 3,291 | 2740 (83.26%) | 366 (13.36%) | 1450 (52.92%) | - | 924 (33.72%) | - | - | - | 551 (16.74%) | 47 (8.53%) | 303 (54.99%) | - | 201 (36.48%) | - | - | - |
Valenti | 789 | 689 (87.33%) | 197 (28.59%) | - | - | - | - | - | 492 (71.41%) | 40 (5.07%) | 7 (17.50%) | - | - | - | - | - | 33 (82.50%) |
Parrotta | 76 | 39 (51.32%) | 1 (2.56%) | 10 (25.64%) | - | 27 (69.23%) | - | - | 1 (2.56%) | 37 (48.68%) | 1 (2.70%) | 10 (27.03%) | - | 25 (67.57%) | - | - | 1 (2.70%) |
Berumen | 102,875 | 71353 (69.36%) | - | - | 7173 (10.05%) | 64180 (89.95%) | - | - | - | 31522 (30.64%) | - | - | 2748 (8.72%) | 28774 (91.28%) | - | - | - |
Israel | 24,906 | 20755 (83.33%) | 3783 (18.23%) | 2671 (12.87%) | - | 14301 (68.90%) | - | - | - | 4151 (16.67%) | 406 (9.78%) | 483 (11.64%) | - | 3262 (78.58%) | - | - | - |
del Valle | 1,108 | 143 (12.91%) | 27 (18.88%) | 53 (37.06%) | - | - | - | - | 63 (44.06%) | 965 (87.09%) | 55 (5.70%) | 293 (30.36%) | - | - | - | - | 617 (63.94%) |
Romao | 34 | 20 (58.82%) | - | - | 5 (25.00%) | - | - | - | 15 (75.00%) | 14 (41.18%) | - | - | 4 (28.57%) | - | - | - | 10 (71.43%) |
Ramlall | 11,116 | 4723 (42.49%) | - | - | - | - | - | - | - | 6393 (57.51%) | - | - | 1643.001 (25.70%) | 4749.999 (74.30%) | - | - | - |
Sharma | 501 | 267 (53.29%) | - | - | 1 (0.37%) | - | - | - | 266 (99.63%) | 234 (46.71%) | - | - | 20 (8.55%) | - | - | - | 214 (91.45%) |
Eugen-Olsen | 407 | 290 (71.25%) | 76 (26.21%) | 104 (35.86%) | - | 102 (35.17%) | - | - | - | 117 (28.75%) | 8 (6.84%) | 46 (39.32%) | - | 59 (50.43%) | - | - | - |
Raisi-Estabragh | 4,510 | 3184 (70.60%) | - | - | 1653 (51.92%) | - | - | - | 1531 (48.08%) | 1326 (29.40%) | - | - | 683 (51.51%) | - | - | - | 643 (48.49%) |
Houlihan | 177 | 97 (54.80%) | 14 (14.43%) | 14 (14.43%) | - | 69 (71.13%) | - | - | - | 80 (45.20%) | 7 (8.75%) | 19 (23.75%) | - | 54 (67.50%) | - | - | - |
McQueenie | 428,199 | 424355 (99.10%) | - | - | 189299 (44.61%) | 235056 (55.39%) | - | - | - | 1311 (0.31%) | - | - | 669 (51.03%) | 642 (48.97%) | - | - | - |
Woolford | 4,474 | 3161 (70.65%) | 441 (13.95%) | 1194 (37.77%) | - | 1526 (48.28%) | - | - | - | 1313 (29.35%) | 145 (11.04%) | 525 (39.98%) | - | 643 (48.97%) | - | - | - |
Lan | 104 | 83 (79.81%) | - | - | 24 (28.92%) | - | - | - | 59 (71.08%) | 21 (20.19%) | - | - | 1 (4.76%) | - | - | - | 20 (95.24%) |
Hernandez, Garduno | 32,583 | 20279 (62.24%) | - | - | 2399 (11.83%) | 17861 (88.08%) | - | - | - | 12304 (37.76%) | - | - | 1191 (9.68%) | 11083 (90.08%) | - | - | - |
Govind | 6,215 | 6207 (99.87%) | 4104 (66.12%) | 1669 (26.89%) | - | 342 (5.51%) | - | - | - | 102 (1.64%) | 78 (76.47%) | 20 (19.61%) | - | 2 (1.96%) | - | - | - |
Gu | 4,699 | 3815 (81.19%) | 360 (9.44%) | 1142 (29.93%) | - | 2313 (60.63%) | - | - | - | 884 (18.81%) | 40 (4.52%) | 264 (29.86%) | - | 580 (65.61%) | - | - | - |
Kibler | 702 | 680 (96.87%) | 25 (3.68%) | - | - | - | - | - | 655 (96.32%) | 22 (3.13%) | 1 (4.55%) | - | - | - | - | - | 21 (95.45%) |
Auvinen | 61 | 33 (54.10%) | 10 (30.30%) | 8 (24.24%) | - | 15 (45.45%) | - | - | - | 28 (45.90%) | 1 (3.57%) | 9 (32.14%) | - | 18 (64.29%) | - | - | - |
Antonio-Villa | 34,263 | 23338 (68.11%) | 2293 (9.83%) | - | - | - | - | - | 21045 (90.17%) | 10925 (31.89%) | 1023 (9.36%) | - | - | - | - | - | 9902 (90.64%) |
Merzon | 7,807 | 7025 (89.98%) | - | - | 1136 (16.17%) | - | - | - | 5889 (83.83%) | 782 (10.02%) | - | - | 127 (16.24%) | - | - | - | 655 (83.76%) |
Trubiano | 2,935 | 2827 (96.32%) | - | - | 256 (9.06%) | - | - | - | 2586 (91.48%) | 108 (3.68%) | - | - | 3 (2.78%) | - | - | - | 105 (97.22%) |
Shi, Resurreccion | 1,521 | 1265 (83.17%) | - | - | 681 (53.83%) | - | - | - | 584 (46.17%) | 256 (16.83%) | - | - | 154 (60.16%) | - | - | - | 102 (39.84%) |
Riley | 120,620 | 120461 (99.87%) | 2594 (2.15%) | - | - | 19914 (16.53%) | - | - | 97953 (81.32%) | 159 (0.13%) | 3 (1.89%) | - | - | 17 (10.69%) | - | - | 139 (87.42%) |
Alizadehsani | 319 | 196 (61.44%) | - | - | - | - | - | - | 196 (100.00%) | 123 (38.56%) | - | - | 1 (0.81%) | - | - | - | 122 (99.19%) |
Merkely | 10,474 | 10336 (98.68%) | 2904 (28.10%) | 2107 (20.39%) | - | 5310 (51.37%) | - | - | 15 (0.15%) | 70 (0.67%) | 16 (22.86%) | 15 (21.43%) | - | 38 (54.29%) | - | - | 1 (1.43%) |
Edwards | 209 | 118 (56.46%) | - | - | 31 (26.27%) | - | - | - | 87 (73.73%) | 91 (43.54%) | - | - | 8 (8.79%) | - | - | - | 83 (91.21%) |
Reiter | 235 | 175 (74.47%) | - | - | 93 (53.14%) | 82 (46.86%) | - | - | - | 60 (25.53%) | - | - | 13 (21.67%) | 47 (78.33%) | - | - | - |
Izquierdo | 71,192 | NA ( NA%) | - | - | - | - | - | - | - | 1006 (1.41%) | 111 (11.03%) | - | - | - | - | - | 895 (88.97%) |
Ward | 99,908 | 94416 (94.50%) | 10202 (10.81%) | - | - | - | - | - | 84214 (89.19%) | 5492 (5.50%) | 433 (7.88%) | - | - | - | - | - | 5059 (92.12%) |
Ebinger | 6,062 | 5850 (96.50%) | 99 (1.69%) | - | - | - | 83 (1.42%) | - | 5668 (96.89%) | 212 (3.50%) | 3 (1.42%) | - | - | - | 4 (1.89%) | - | 205 (96.70%) |
Salerno | 15,920 | 14753 (92.67%) | - | - | 5517 (37.40%) | 8278 (56.11%) | - | - | 958 (6.49%) | 1167 (7.33%) | - | - | 339 (29.05%) | 626 (53.64%) | - | - | 202 (17.31%) |
Iversen | 28,792 | 27629 (95.96%) | 4430 (16.03%) | 1799 (6.51%) | - | 21217 (76.79%) | - | - | 246 (0.89%) | 1163 (4.04%) | 177 (15.22%) | 78 (6.71%) | - | 898 (77.21%) | - | - | 10 (0.86%) |
Hippisley-Cox | 8,275,949 | NA ( NA%) | - | - | - | - | - | - | - | 19486 (0.24%) | 1354 (6.95%) | 5715 (29.33%) | - | 12036 (61.77%) | - | - | 381 (1.96%) |
Fillmore | 22,914 | 21120 (92.17%) | 8137 (38.53%) | 8416 (39.85%) | - | 3227 (15.28%) | - | - | 1340 (6.34%) | 1794 (7.83%) | 452 (25.20%) | 899 (50.11%) | - | 322 (17.95%) | - | - | 121 (6.74%) |
Alkurt | 119 | NA ( NA%) | - | - | - | - | - | - | - | 119 (100.00%) | 14 (11.76%) | - | - | - | - | - | 105 (88.24%) |
Petrilli | 10,620 | 5341 (50.29%) | 541 (10.13%) | 816 (15.28%) | - | 3454 (64.67%) | - | - | 530 (9.92%) | 5279 (49.71%) | 288 (5.46%) | 902 (17.09%) | - | 3268 (61.91%) | - | - | 821 (15.55%) |
Bello-Chavolla | 150,200 | 98567 (65.62%) | - | - | 9624 (9.76%) | - | - | - | 88943 (90.24%) | 51633 (34.38%) | - | - | 4366 (8.46%) | - | - | - | 47267 (91.54%) |
Ariza | 351 | 322 (91.74%) | 21 (6.52%) | - | - | - | - | - | 301 (93.48%) | 29 (8.26%) | 3 (10.34%) | - | - | - | - | - | 26 (89.66%) |
Carrat | 14,393 | 13426 (93.28%) | 1652 (12.30%) | 5620 (41.86%) | - | 6154 (45.84%) | - | - | - | 967 (6.72%) | 98 (10.13%) | 353 (36.50%) | - | 516 (53.36%) | - | - | - |
Meini | 461 | 243 (52.71%) | 39 (16.05%) | 66 (27.16%) | - | 138 (56.79%) | - | - | - | 218 (47.29%) | 9 (4.13%) | 53 (24.31%) | - | 156 (71.56%) | - | - | - |
Favara | 434 | 354 (81.57%) | 28 (7.91%) | - | - | - | - | - | 326 (92.09%) | 80 (18.43%) | 9 (11.25%) | - | - | - | - | - | 71 (88.75%) |
Erber | 4,554 | 4446 (97.63%) | - | - | 806 (18.13%) | - | - | - | 3640 (81.87%) | 108 (2.37%) | - | - | 11 (10.19%) | - | - | - | 97 (89.81%) |
Roederer | 815 | 390 (47.85%) | 175 (44.87%) | 32 (8.21%) | - | 183 (46.92%) | - | - | - | 425 (52.15%) | 127 (29.88%) | 40 (9.41%) | - | 258 (60.71%) | - | - | - |
Makaronidis | 567 | 127 (22.40%) | 16 (12.60%) | - | - | - | - | - | 111 (87.40%) | 440 (77.60%) | 37 (8.41%) | - | - | - | - | - | 403 (91.59%) |
Ioannou | 88,747 | 78616 (88.58%) | 17138 (21.80%) | 29245 (37.20%) | - | 22327 (28.40%) | - | - | 9906 (12.60%) | 10131 (11.42%) | 1135 (11.20%) | 4073 (40.20%) | - | 3647 (36.00%) | - | - | 1277 (12.60%) |
Perico | 423 | 260 (61.47%) | 69 (26.54%) | 35 (13.46%) | - | 156 (60.00%) | - | - | - | 163 (38.53%) | 23 (14.11%) | 41 (25.15%) | - | 99 (60.74%) | - | - | - |
Vila-Corcoles | 2,324 | 1944 (83.65%) | - | - | - | - | - | - | - | 380 (16.35%) | - | - | 27 (7.11%) | - | - | - | 353 (92.89%) |
O'Reilly | 1,334 | 1284 (96.25%) | - | - | 376 (29.28%) | - | - | - | 908 (70.72%) | 50 (3.75%) | - | - | 4 (8.00%) | - | - | - | 46 (92.00%) |
Ghinai | 1,435 | 1004 (69.97%) | 412 (41.04%) | 155 (15.44%) | - | 341 (33.96%) | - | - | 96 (9.56%) | 431 (30.03%) | 113 (26.22%) | 96 (22.27%) | - | 135 (31.32%) | - | - | 87 (20.19%) |
Kortela | 2,993 | 2419 (80.82%) | 300 (12.40%) | 340 (14.06%) | - | 636 (26.29%) | - | - | 1143 (47.25%) | 574 (19.18%) | 26 (4.53%) | 80 (13.94%) | - | 232 (40.42%) | - | - | 236 (41.11%) |
Gallichotte | 239 | 190 (79.50%) | 40 (21.05%) | 28 (14.74%) | - | 110 (57.89%) | 12 (6.32%) | - | - | 49 (20.50%) | 8 (16.33%) | 12 (24.49%) | - | 27 (55.10%) | 2 (4.08%) | - | - |
Saeed | 173 | 69 (39.88%) | 2 (2.90%) | - | - | - | - | - | 67 (97.10%) | 104 (60.12%) | 9 (8.65%) | - | - | - | - | - | 95 (91.35%) |
Woolcott | 1,636,050 | 878840 (53.72%) | - | - | 85816 (9.76%) | - | - | - | 793024 (90.24%) | 757210 (46.28%) | - | - | 57451 (7.59%) | - | - | - | 699759 (92.41%) |
Barasa | 394 | 277 (70.30%) | 49 (17.69%) | 105 (37.91%) | - | 110 (39.71%) | - | - | 13 (4.69%) | 117 (29.70%) | 9 (7.69%) | 37 (31.62%) | - | 54 (46.15%) | - | - | 17 (14.53%) |
Paleiron | 1,688 | 409 (24.23%) | 236 (57.70%) | 77 (18.83%) | - | 96 (23.47%) | - | - | - | 1279 (75.77%) | 579 (45.27%) | 309 (24.16%) | - | 391 (30.57%) | - | - | - |
Didikoglu | 43,428 | 35695 (82.19%) | 3919 (10.98%) | 13841 (38.78%) | - | 17939 (50.26%) | - | - | - | 7733 (17.81%) | 867 (11.21%) | 2966 (38.36%) | - | 3901 (50.45%) | - | - | - |
Kantele | 1,095 | 1059 (96.71%) | 176 (16.62%) | 272 (25.68%) | - | 611 (57.70%) | - | - | - | 36 (3.29%) | 3 (8.33%) | 11 (30.56%) | - | 21 (58.33%) | - | - | 1 (2.78%) |
Polat | 1,322 | NA ( NA%) | - | - | - | - | - | - | - | 23 (1.74%) | 4 (17.39%) | 2 (8.70%) | - | 17 (73.91%) | - | - | - |
Richard | 8,344 | 6798 (81.47%) | 1065 (15.67%) | 1171 (17.23%) | - | 4456 (65.55%) | - | - | 106 (1.56%) | 531 (6.36%) | 47 (8.85%) | 83 (15.63%) | - | 396 (74.58%) | - | - | 5 (0.94%) |
Schubl | 1,557 | 1392 (89.40%) | 33 (2.37%) | - | - | - | - | - | 1359 (97.63%) | 165 (10.60%) | 4 (2.42%) | - | - | - | - | - | 161 (97.58%) |
Nezhadmoghadam | 33,325 | 19958 (59.89%) | 2151 (10.78%) | - | - | - | - | - | 17807 (89.22%) | 13367 (40.11%) | 1251 (9.36%) | - | - | - | - | - | 12116 (90.64%) |
Mora | 1,058 | 857 (81.00%) | 40 (4.67%) | 118 (13.77%) | - | 698 (81.45%) | - | - | 1 (0.12%) | 201 (19.00%) | 8 (3.98%) | 36 (17.91%) | - | 157 (78.11%) | - | - | - |
Molenaar | 696 | 591 (84.91%) | 29 (4.91%) | - | - | - | - | - | 562 (95.09%) | 105 (15.09%) | 2 (1.90%) | - | - | - | - | - | 103 (98.10%) |
Vila-Corcoles, Satue-Gracia, Vila-Rovira | 4,113 | 3577 (86.97%) | 591 (16.52%) | - | - | - | - | - | 2986 (83.48%) | 536 (13.03%) | 41 (7.65%) | - | - | - | - | - | 495 (92.35%) |
Gegout Petit | 2,006 | 1964 (97.91%) | 334 (17.01%) | - | - | 1545 (78.67%) | - | - | 85 (4.33%) | 42 (2.09%) | 4 (9.52%) | - | - | 38 (90.48%) | - | - | - |
Leister | 3,301 | 3269 (99.03%) | 764 (23.37%) | - | - | - | - | - | 2505 (76.63%) | 32 (0.97%) | 5 (15.62%) | - | - | - | - | - | 27 (84.38%) |
Bell | 303 | NA ( NA%) | - | - | - | - | - | - | - | 303 (100.00%) | - | - | - | - | - | 40 (13.20%) | 263 (86.80%) |
Rhys, Thomas | 2,820 | 2621 (92.94%) | - | - | - | - | - | 422 (16.10%) | 2199 (83.90%) | 199 (7.06%) | - | - | - | - | - | 44 (22.11%) | 155 (77.89%) |
Radon | 4,433 | 4292 (96.82%) | 711 (16.57%) | 1194 (27.82%) | - | 2144 (49.95%) | - | - | 243 (5.66%) | 141 (3.18%) | 18 (12.77%) | 40 (28.37%) | - | 73 (51.77%) | - | - | 10 (7.09%) |
Hausfater | 1,062 | 999 (94.07%) | 246 (24.62%) | - | - | - | - | - | 753 (75.38%) | 61 (5.74%) | 4 (6.56%) | - | - | - | - | - | 57 (93.44%) |
Fernandez, Fuertes | 710 | 664 (93.52%) | 358 (53.92%) | - | - | - | - | - | 306 (46.08%) | 46 (6.48%) | 12 (26.09%) | - | - | - | - | - | 34 (73.91%) |
Shields | 1,507 | 1261 (83.68%) | 145 (11.50%) | 206 (16.34%) | - | 907 (71.93%) | - | - | - | 246 (16.32%) | 12 (4.88%) | 41 (16.67%) | - | 193 (78.46%) | - | - | - |
Gonzalez, Vielot | 782 | 540 (69.05%) | - | - | 75 (13.89%) | 465 (86.11%) | - | - | - | 242 (30.95%) | - | - | 28 (11.57%) | 214 (88.43%) | - | - | - |
Nielsen | 840 | 630 (75.00%) | 29 (4.60%) | 204 (32.38%) | - | 397 (63.02%) | - | - | - | 210 (25.00%) | 10 (4.76%) | 60 (28.57%) | - | 140 (66.67%) | - | - | - |
Jha | 8,967 | 8799 (98.13%) | - | - | 4120 (46.82%) | 4563 (51.86%) | - | - | 116 (1.32%) | 168 (1.87%) | - | - | 71 (42.26%) | 95 (56.55%) | - | - | 2 (1.19%) |
Joubert, Andry | 1,013 | 933 (92.10%) | 158 (16.93%) | - | - | - | - | - | 775 (83.07%) | 80 (7.90%) | 4 (5.00%) | - | - | - | - | - | 76 (95.00%) |
Daugherty | 266,586 | NA ( NA%) | - | - | - | - | - | - | - | 266586 (100.00%) | 8113 (3.04%) | - | - | - | - | - | 258473 (96.96%) |
Vanegas, Cedillo | 551 | NA ( NA%) | - | - | - | - | - | - | - | 551 (100.00%) | 27 (4.90%) | - | - | - | - | - | 524 (95.10%) |
Schaad | 134 | 103 (76.87%) | 32 (31.07%) | - | - | - | - | - | 71 (68.93%) | 31 (23.13%) | 7 (22.58%) | - | - | - | - | - | 24 (77.42%) |
Mok | 211 | NA ( NA%) | - | - | - | - | - | - | - | 211 (100.00%) | - | - | 78 (36.97%) | - | - | - | 133 (63.03%) |
Desgranges | 507 | 89 (17.55%) | 27 (30.34%) | - | - | - | - | - | 62 (69.66%) | 418 (82.45%) | 46 (11.00%) | - | - | - | - | - | 372 (89.00%) |
Gonzalez, Zepeda | 157 | 97 (61.78%) | 13 (13.40%) | - | - | - | - | - | 84 (86.60%) | 60 (38.22%) | 5 (8.33%) | - | - | - | - | - | 55 (91.67%) |
Fogh | 3,236 | 2632 (81.33%) | - | - | 727 (27.62%) | - | - | - | 1905 (72.38%) | 604 (18.67%) | - | - | 121 (20.03%) | - | - | - | 483 (79.97%) |
Rothlin, Eriksen | 819 | 764 (93.28%) | - | - | 554 (72.51%) | - | - | - | 210 (27.49%) | 55 (6.72%) | - | - | 33 (60.00%) | - | - | - | 22 (40.00%) |
Gornyk | 13,045 | 12791 (98.05%) | 2496 (19.51%) | 3947 (30.86%) | - | 6335 (49.53%) | - | - | 13 (0.10%) | 254 (1.95%) | 35 (13.78%) | 84 (33.07%) | - | 135 (53.15%) | - | - | - |
Campbell | 2,128 | 2075 (97.51%) | 326 (15.71%) | 127 (6.12%) | - | 1622 (78.17%) | - | - | - | 53 (2.49%) | 5 (9.43%) | 2 (3.77%) | - | 46 (86.79%) | - | - | - |
Kleynhans | 226 | 129 (57.08%) | 20 (15.50%) | - | - | - | - | - | 109 (84.50%) | 97 (42.92%) | 16 (16.49%) | - | - | - | - | - | 81 (83.51%) |
Rogier | 374 | 152 (40.64%) | 28 (18.42%) | - | - | - | - | - | 124 (81.58%) | 222 (59.36%) | 8 (3.60%) | - | - | - | - | - | 214 (96.40%) |
Mostafa | 4,040 | 3770 (93.32%) | 456 (12.10%) | 75 (1.99%) | - | 3239 (85.92%) | - | - | - | 270 (6.68%) | 23 (8.52%) | 4 (1.48%) | - | 243 (90.00%) | - | - | - |
Lombardi | 4,055 | 3746 (92.38%) | 808 (21.57%) | 503 (13.43%) | - | 2283 (60.95%) | - | - | - | 309 (7.62%) | 34 (11.00%) | 49 (15.86%) | - | 210 (67.96%) | - | - | - |
Li, Tong | 18,148 | 17248 (95.04%) | 2164 (12.55%) | - | - | - | - | - | 15069 (87.37%) | 900 (4.96%) | 74 (8.22%) | - | - | - | - | - | 826 (91.78%) |
Kahlert | 4,664 | 4525 (97.02%) | 806 (17.81%) | 924 (20.42%) | - | 2795 (61.77%) | - | - | - | 139 (2.98%) | 16 (11.51%) | 27 (19.42%) | - | 96 (69.06%) | - | - | - |
Egede | 30,976 | 28873 (93.21%) | 4148 (14.37%) | 9433 (32.67%) | - | 15292 (52.96%) | - | - | - | 2103 (6.79%) | 158 (7.51%) | 572 (27.20%) | - | 1373 (65.29%) | - | - | - |
De, Santi | 341 | 292 (85.63%) | 81 (27.74%) | - | - | - | - | - | 211 (72.26%) | 49 (14.37%) | 7 (14.29%) | - | - | - | - | - | 42 (85.71%) |
Dashti | 15,440 | 15214 (98.54%) | 3243 (21.32%) | 5110 (33.59%) | - | 6425 (42.23%) | - | - | 436 (2.87%) | 226 (1.46%) | 26 (11.50%) | 114 (50.44%) | - | 84 (37.17%) | - | - | 2 (0.88%) |
Chetboun | 1,447 | 1283 (88.67%) | 229 (17.85%) | 105 (8.18%) | - | 608 (47.39%) | - | - | 341 (26.58%) | 164 (11.33%) | 18 (10.98%) | 33 (20.12%) | - | 113 (68.90%) | - | - | - |
Barchuk | 962 | 868 (90.23%) | 183 (21.08%) | 241 (27.76%) | - | 412 (47.47%) | - | - | 32 (3.69%) | 94 (9.77%) | 12 (12.77%) | 26 (27.66%) | - | 55 (58.51%) | - | - | 1 (1.06%) |
Figure 3. Forest plot for risk of testing positive for SARS-CoV-2 in current vs. never smokers. * Indicates ‘good’ quality studies. The prior from the previous review version (v11) was RR = 0.71.
Figure 4. Forest plot for risk of testing positive for SARS-CoV-2 in former vs. never smokers. * Indicates ‘good’ quality studies. The prior from the previous review version (v11) was RR = 1.03.
55 studies examined hospitalisation for COVID-19 disease, stratified by smoking status (see Table 3). Meta-analyses were performed for 19 ‘fair’ quality studies (see Figure 5 and 6). Current (RR = 1.1, 95% CrI = 0.97-1.24, τ = 0.23) and former (RR = 1.27, CrI = 1.15-1.4, τ = 0.2) compared with never smokers were at increased risk of hospitalisation with COVID-19. However, data for current smokers were inconclusive and favoured there being no important association. The probability of current and former smokers being at increased risk of hospitalisation (RR ≥1.1) compared with never smokers was 50% and >99%, respectively. Results were materially unchanged in two sensitivity analyses.
Community | Hospitalised | ||||||||||||||
Author | Population with outcome | N (%) | Current smoker (%) | Former smoker (%) | Current/former smoker (%) | Never smoker (%) | Never/unknown smoker (%) | Not stated (%) | N (%) | Current smoker (%) | Former smoker (%) | Current/former smoker (%) | Never smoker (%) | Never/unknown smoker (%) | Not stated (%) |
Rentsch | 554 | 269 (48%) | 69 (25.65%) | 90 (33.46%) | - | 110 (40.89%) | - | - | 285 (51%) | 90 (31.58%) | 89 (31.23%) | - | 106 (37.19%) | - | - |
Chow (US CDC) | 6,637 | 5143 (77%) | 61 (1.19%) | 80 (1.56%) | - | - | - | 5002 (97.26%) | 1494 (22%) | 27 (1.81%) | 78 (5.22%) | - | - | - | 1389 (92.97%) |
Argenziano | 1,000 | 151 (15%) | 14 (9.27%) | 18 (11.92%) | - | 119 (78.81%) | - | - | 849 (84%) | 35 (4.12%) | 161 (18.96%) | - | 653 (76.91%) | - | - |
Lubetzky | 54 | 15 (27%) | - | - | 4 (26.67%) | - | - | 11 (73.33%) | 39 (72%) | - | - | 8 (20.51%) | - | - | 31 (79.49%) |
Carillo-Vega | 9,946 | 3922 (39%) | 408 (10.40%) | - | - | - | - | 3514 (89.60%) | 6024 (60%) | 486 (8.07%) | - | - | - | - | 5538 (91.93%) |
Yanover | 4,353 | 4180 (96%) | 484 (11.58%) | 118 (2.82%) | - | 3578 (85.60%) | - | - | 173 (3%) | 30 (17.34%) | 11 (6.36%) | - | 132 (76.30%) | - | - |
Hamer | 387,109 | 386349 (99%) | 37333 (9.66%) | 134542 (34.82%) | - | 214474 (55.51%) | - | - | 760 (0%) | 93 (12.24%) | 313 (41.18%) | - | 354 (46.58%) | - | - |
Heili-Frades | 4,712 | 1973 (41%) | 121 (6.13%) | 222 (11.25%) | - | - | 1630 (82.62%) | 1630 (82.62%) | 2739 (58%) | 112 (4.09%) | 598 (21.83%) | - | - | 2029 (74.08%) | - |
Freites | 123 | 69 (56%) | 1 (1.45%) | - | - | - | - | 68 (98.55%) | 54 (43%) | 3 (5.56%) | - | - | - | - | 51 (94.44%) |
Berumen | 31,522 | 18832 (59%) | - | - | 1546 (8.21%) | - | 17286 (91.79%) | - | 12690 (40%) | - | - | 1202 (9.47%) | - | 11488 (90.53%) | - |
Gianfrancesco | 600 | 323 (53%) | - | - | 61 (18.89%) | - | - | 262 (81.11%) | 277 (46%) | - | - | 68 (24.55%) | - | - | 209 (75.45%) |
Chaudhry | 40 | 19 (47%) | - | - | 0 (0.00%) | - | - | 19 (100.00%) | 21 (52%) | - | - | 6 (28.57%) | - | - | 15 (71.43%) |
Giannouchos | 89,756 | 58485 (65%) | 4679 (8.00%) | - | - | - | 53806 (92.00%) | - | 31271 (34%) | 2721 (8.70%) | - | - | - | 28550 (91.30%) | - |
Wang, Oekelen | 57 | 22 (38%) | - | - | 6 (27.27%) | - | - | 16 (72.73%) | 36 (63%) | - | - | 15 (41.67%) | - | - | 20 (55.56%) |
Miyara | 470 | 132 (28%) | 14 (10.61%) | 41 (31.06%) | - | 77 (58.33%) | - | - | 338 (71%) | 18 (5.33%) | 111 (32.84%) | - | 209 (61.83%) | - | - |
Suleyman | 463 | 108 (23%) | - | - | 23 (21.30%) | - | - | 85 (78.70%) | 355 (76%) | - | - | 137 (38.59%) | - | - | 218 (61.41%) |
Garassino | 196 | 48 (24%) | 10 (20.83%) | 27 (56.25%) | - | 11 (22.92%) | - | - | 152 (77%) | 38 (25.00%) | 84 (55.26%) | - | 26 (17.11%) | - | - |
Siso-Almirall | 260 | 119 (45%) | - | - | 31 (26.05%) | - | - | 88 (73.95%) | 141 (54%) | - | - | 50 (35.46%) | - | - | 91 (64.54%) |
Gu | 884 | 511 (57%) | 30 (5.87%) | 126 (24.66%) | - | 355 (69.47%) | - | - | 373 (42%) | 10 (2.68%) | 138 (37.00%) | - | 225 (60.32%) | - | - |
Killerby | 531 | 311 (58%) | - | - | 37 (11.90%) | 222 (71.38%) | - | 52 (16.72%) | 220 (41%) | - | - | 54 (24.55%) | 157 (71.36%) | - | 9 (4.09%) |
Nguyen | 689 | 333 (48%) | - | - | 57 (17.12%) | - | - | 276 (82.88%) | 356 (51%) | - | - | 114 (32.02%) | - | - | 242 (67.98%) |
Mendy | 689 | 473 (68%) | - | - | 84 (17.76%) | - | - | 389 (82.24%) | 216 (31%) | - | - | 86 (39.81%) | - | - | 130 (60.19%) |
Soares | 10,713 | 9561 (89%) | 132 (1.38%) | - | - | - | 9429 (98.62%) | - | 1152 (10%) | 77 (6.68%) | - | - | - | 1075 (93.32%) | - |
Zobairy | 203 | 65 (32%) | 1 (1.54%) | - | - | - | 64 (98.46%) | - | 138 (67%) | 11 (7.97%) | - | - | - | 127 (92.03%) | - |
Izquierdo | 1,006 | 743 (73%) | 52 (7.00%) | - | - | - | 691 (93.00%) | - | 263 (26%) | 16 (6.08%) | - | - | - | 247 (93.92%) | - |
Rizzo | 76,819 | 60039 (78%) | 3931 (6.55%) | 11379 (18.95%) | - | 30042 (50.04%) | - | 14687 (24.46%) | 16780 (21%) | 1254 (7.47%) | 4585 (27.32%) | - | 8693 (51.81%) | - | 2248 (13.40%) |
Pan | 12,084 | 8548 (70%) | - | - | 1263 (14.78%) | - | - | 7285 (85.22%) | 3536 (29%) | - | - | 874 (24.72%) | - | - | 2662 (75.28%) |
Petrilli | 5,279 | 2538 (48%) | 147 (5.79%) | 337 (13.28%) | - | 1678 (66.12%) | - | 376 (14.81%) | 2741 (51%) | 141 (5.14%) | 565 (20.61%) | - | 1590 (58.01%) | - | 445 (16.23%) |
Vilar-Garcia | 328,892 | 291254 (88%) | 64792 (22.25%) | - | - | - | - | 226462 (77.75%) | 37638 (11%) | 9526 (25.31%) | - | - | - | - | 28112 (74.69%) |
Ibarra-Nava | 416,546 | 302693 (72%) | 26773 (8.84%) | - | - | - | - | 275920 (91.16%) | 113853 (27%) | 8875 (7.80%) | - | - | - | - | 104978 (92.20%) |
da Silva Neto | 91 | 44 (48%) | - | - | 4 (9.09%) | - | 40 (90.91%) | - | 47 (51%) | - | - | 14 (29.79%) | - | 33 (70.21%) | - |
Israel, Schaffer | 26,676 | 13706 (51%) | 944 (6.89%) | 2166 (15.80%) | - | 10596 (77.31%) | - | - | 12970 (48%) | 880 (6.78%) | 1936 (14.93%) | - | 10154 (78.29%) | - | - |
Ioannou | 10,131 | 6624 (65%) | 716 (10.81%) | 2484 (37.50%) | - | 2542 (38.38%) | - | 882 (13.32%) | 3507 (34%) | 419 (11.95%) | 1593 (45.42%) | - | 1102 (31.42%) | - | 393 (11.21%) |
Zhang, Li | 1,596 | 576 (36%) | 63 (10.94%) | 190 (32.99%) | - | 318 (55.21%) | - | 5 (0.87%) | 1020 (63%) | 116 (11.37%) | 429 (42.06%) | - | 462 (45.29%) | - | 13 (1.27%) |
Parra-Bracamonte | 331,298 | 235840 (71%) | - | - | 16676 (7.07%) | - | - | 219164 (92.93%) | 95458 (28%) | - | - | 7517 (7.87%) | - | - | 87941 (92.13%) |
Jehi | 4,536 | 3578 (78%) | 247 (6.90%) | 943 (26.36%) | - | 1795 (50.17%) | - | 593 (16.57%) | 958 (21%) | 82 (8.56%) | 349 (36.43%) | - | 467 (48.75%) | - | 60 (6.26%) |
Arleo | 70 | 36 (51%) | 1 (2.78%) | 10 (27.78%) | - | 25 (69.44%) | - | - | 34 (48%) | 0 (0.00%) | 10 (29.41%) | - | 24 (70.59%) | - | - |
Kortela | 604 | 246 (40%) | 12 (4.88%) | 14 (5.69%) | - | 55 (22.36%) | - | 165 (67.07%) | 328 (54%) | 14 (4.27%) | 66 (20.12%) | - | 177 (53.96%) | - | 71 (21.65%) |
Didikoglu | 7,733 | 5239 (67%) | 554 (10.57%) | 1845 (35.22%) | - | 2841 (54.23%) | - | - | 2494 (32%) | 313 (12.55%) | 1121 (44.95%) | - | 1060 (42.50%) | - | - |
Ho, Narasimhan | 9,991 | 5082 (50%) | 189 (3.72%) | 744 (14.64%) | - | 4148 (81.62%) | - | - | 4909 (49%) | 217 (4.42%) | 1062 (21.63%) | - | 3630 (73.95%) | - | - |
Saurabh | 911 | 69 (7%) | 6 (8.70%) | 0 (0.00%) | - | 63 (91.30%) | - | - | 842 (92%) | 68 (8.08%) | 6 (0.71%) | - | 768 (91.21%) | - | - |
Munoz | 314 | 294 (93%) | 20 (6.80%) | - | - | - | - | 274 (93.20%) | 20 (6%) | 1 (5.00%) | - | - | - | - | 19 (95.00%) |
Cummins | 1,781 | 586 (32%) | 77 (13.14%) | - | - | - | - | 509 (86.86%) | 1195 (67%) | 104 (8.70%) | - | - | - | - | 1091 (91.30%) |
Fernandez, Fuertes | 46 | 41 (89%) | 12 (29.27%) | - | - | - | - | 29 (70.73%) | 5 (10%) | 0 (0.00%) | - | - | - | - | 5 (100.00%) |
Patone | 429,926 | 381887 (88%) | 45230 (11.84%) | 66378 (17.38%) | - | 213519 (55.91%) | - | 56760 (14.86%) | 48039 (11%) | 5488 (11.42%) | 12593 (26.21%) | - | 27255 (56.74%) | - | 2703 (5.63%) |
Wang, Codd | 6,775 | 5861 (86%) | 606 (10.34%) | 2001 (34.14%) | - | 3236 (55.21%) | - | 17 (0.29%) | 914 (13%) | 142 (15.54%) | 408 (44.64%) | - | 358 (39.17%) | - | 6 (0.66%) |
Manohar | 11,930 | 7035 (58%) | 185 (2.63%) | 951 (13.52%) | - | 534 (7.59%) | - | 2755 (39.16%) | 4895 (41%) | 54 (1.10%) | 431 (8.80%) | - | 873 (17.83%) | - | 3537 (72.26%) |
Puebla, Neira | 10,216 | 9066 (88%) | 369 (4.07%) | 723 (7.97%) | - | 7974 (87.95%) | - | - | 1150 (11%) | 29 (2.52%) | 194 (16.87%) | - | 927 (80.61%) | - | - |
Colaneri | 12,347 | 8946 (72%) | 353 (3.95%) | 1099 (12.28%) | - | 5133 (57.38%) | - | 2361 (26.39%) | 3401 (27%) | 210 (6.17%) | 171 (5.03%) | - | 1920 (56.45%) | - | 411 (12.08%) |
Figure 5. Forest plot for risk of hospitalisation in current vs. never smokers. The prior from the previous review version (v11) was RR = 1.1.
Figure 6. Forest plot for risk of hospitalisation in former vs. never smokers. The prior from the previous version (v11) was RR = 1.19.
91 studies reported disease severity in hospitalised patients stratified by smoking status (see Table 4). Severe (as opposed to non-severe) disease was broadly defined as requiring intensive treatment unit (ITU) admission, requiring oxygen as a hospital inpatient or in-hospital death. Meta-analyses were performed for 16 ‘fair’ quality studies (see Figure 7 and 8). Current (RR = 1.3, 95% CrI = 1.01-1.71, τ = 0.32) and former (RR = 1.69, 95% CrI = 1.3-2.22, τ = 0.43) compared with never smokers were at increased risk of greater disease severity. The probability of current and former smokers having increased risk of greater disease severity (RR ≥1.1) compared with never smokers was 92% and 100%, respectively. Results were materially unchanged in two sensitivity analyses.
Non severe disease | Severe disease | ||||||||||||||
Author | Population with severity | N (%) | Current smoker (%) | Former smoker (%) | Current/former smoker (%) | Never smoker (%) | Never/unknown smoker (%) | Not stated (%) | N (%) | Current smoker (%) | Former smoker (%) | Current/former smoker (%) | Never smoker (%) | Never/unknown smoker (%) | Not stated (%) |
Guan, Ni | 1,085 | 913 (84%) | 108 (11.83%) | 12 (1.31%) | - | 793 (86.86%) | - | - | 172 (15%) | 29 (16.86%) | 9 (5.23%) | - | 134 (77.91%) | - | - |
Zhang, Dong | 9 | 3 (33%) | 0 (0.00%) | 3 (100.00%) | - | 0 (0.00%) | - | - | 6 (66%) | 2 (33.33%) | 4 (66.67%) | - | 0 (0.00%) | - | - |
Wan | 9 | 8 (88%) | 8 (100.00%) | 0 (0.00%) | - | 0 (0.00%) | - | - | 1 (11%) | 1 (100.00%) | 0 (0.00%) | - | 0 (0.00%) | - | - |
Huang, Wang | 3 | 3 (100%) | 3 (100.00%) | 0 (0.00%) | - | 0 (0.00%) | - | - | 0 (0%) | 0 (NaN%) | 0 (NaN%) | - | 0 (NaN%) | - | - |
Rentsch | 285 | 168 (58%) | 47 (27.98%) | 53 (31.55%) | - | 68 (40.48%) | - | - | 117 (41%) | 43 (36.75%) | 36 (30.77%) | - | 38 (32.48%) | - | - |
Hu | 323 | 151 (46%) | - | - | 12 (7.95%) | - | 139 (92.05%) | - | 172 (53%) | - | - | 26 (15.12%) | - | 146 (84.88%) | - |
Wang, Pan | 125 | 100 (80%) | - | - | 9 (9.00%) | - | 91 (91.00%) | - | 25 (20%) | - | - | 7 (28.00%) | - | 18 (72.00%) | - |
Kim | 27 | 21 (77%) | 3 (14.29%) | - | - | - | 18 (85.71%) | - | 6 (22%) | 2 (33.33%) | 0 (0.00%) | - | - | 4 (66.67%) | - |
Shi, Yu | 474 | 425 (89%) | - | - | 34 (8.00%) | - | 391 (92.00%) | - | 49 (10%) | - | - | 6 (12.24%) | - | 43 (87.76%) | - |
Liao, Feng | 148 | 92 (62%) | - | - | 5 (5.43%) | - | - | 87 (94.57%) | 56 (37%) | 3 (5.36%) | - | - | - | - | 53 (94.64%) |
Shi, Ren | 134 | 88 (65%) | - | - | 8 (9.09%) | - | - | 80 (90.91%) | 46 (34%) | - | - | 6 (13.04%) | - | - | 40 (86.96%) |
Hadjadj | 50 | 15 (30%) | 1 (6.67%) | 2 (13.33%) | - | 12 (80.00%) | - | - | 35 (70%) | 0 (0.00%) | 7 (20.00%) | - | 28 (80.00%) | - | - |
Zheng, Xiong | 73 | 43 (58%) | - | - | 6 (13.95%) | 37 (86.05%) | - | - | 30 (41%) | - | - | 2 (6.67%) | 28 (93.33%) | - | - |
de la Rica | 48 | 26 (54%) | - | - | 6 (23.08%) | - | - | 20 (76.92%) | 20 (41%) | - | - | 4 (20.00%) | - | - | 16 (80.00%) |
Yin, Yang | 106 | 47 (44%) | - | - | 6 (12.77%) | - | - | 41 (87.23%) | 59 (55%) | - | - | 12 (20.34%) | - | - | 47 (79.66%) |
Allenbach | 147 | 100 (68%) | - | - | 9 (9.00%) | - | - | 91 (91.00%) | 47 (31%) | - | - | 0 (0.00%) | - | - | 47 (100.00%) |
Goyal | 393 | 263 (66%) | 14 (5.32%) | - | - | - | - | 249 (94.68%) | 130 (33%) | 6 (4.62%) | - | - | - | - | 124 (95.38%) |
Feng | 454 | 333 (73%) | 27 (8.11%) | - | - | - | - | 306 (91.89%) | 121 (26%) | 17 (14.05%) | - | - | - | - | 104 (85.95%) |
Yao | 108 | 83 (76%) | 1 (1.20%) | - | - | - | - | 82 (98.80%) | 25 (23%) | 3 (12.00%) | - | - | - | - | 22 (88.00%) |
Regina | 200 | 163 (81%) | 9 (5.52%) | - | - | - | - | 154 (94.48%) | 37 (18%) | 0 (0.00%) | - | - | - | - | 37 (100.00%) |
Feuth | 28 | 21 (75%) | 1 (4.76%) | 7 (33.33%) | - | 13 (61.90%) | - | - | 7 (25%) | 2 (28.57%) | 1 (14.29%) | - | 4 (57.14%) | - | - |
Mejia-Vilet | 329 | 214 (65%) | - | - | 13 (6.07%) | - | - | 201 (93.93%) | 115 (34%) | - | - | 10 (8.70%) | - | - | 105 (91.30%) |
Chen, Jiang | 135 | 54 (40%) | - | - | 4 (7.41%) | - | - | 50 (92.59%) | 81 (60%) | - | - | 9 (11.11%) | - | - | 72 (88.89%) |
Vaquero-Roncero | 146 | 75 (51%) | - | - | 4 (5.33%) | - | - | 71 (94.67%) | 71 (48%) | - | - | 6 (8.45%) | - | - | 65 (91.55%) |
Kim, Garg | 2,490 | 1692 (67%) | 112 (6.62%) | 395 (23.35%) | - | - | 1185 (70.04%) | - | 798 (32%) | 38 (4.76%) | 247 (30.95%) | - | - | 512 (64.16%) | - |
Wu | 174 | 92 (52%) | - | - | 47 (51.09%) | - | 45 (48.91%) | - | 82 (47%) | 11 (13.41%) | - | - | - | 71 (86.59%) | - |
Chaudhry | 40 | 34 (85%) | - | - | 5 (14.71%) | - | - | 29 (85.29%) | 6 (15%) | - | - | 1 (16.67%) | - | - | 5 (83.33%) |
Garibaldi | 832 | 532 (63%) | 25 (4.70%) | 107 (20.11%) | - | - | - | 400 (75.19%) | 300 (36%) | 21 (7.00%) | 81 (27.00%) | - | - | - | 198 (66.00%) |
Kuderer | 928 | 686 (73%) | 35 (5.10%) | 210 (30.61%) | - | 370 (53.94%) | - | 29 (4.23%) | 242 (26%) | 8 (3.31%) | 116 (47.93%) | - | 99 (40.91%) | 15 (6.20%) | 4 (1.65%) |
Romao | 14 | 14 (100%) | - | - | 4 (28.57%) | - | - | 10 (71.43%) | 0 (0%) | - | - | - | - | - | - |
Giannouchos | 89,756 | 78050 (86%) | 6322 (8.10%) | - | - | - | 71728 (91.90%) | - | 11706 (13%) | 1089 (9.30%) | - | - | - | 10617 (90.70%) | - |
Cen | 1,007 | 720 (71%) | - | - | 70 (9.72%) | - | - | 650 (90.28%) | 287 (28%) | - | - | 18 (6.27%) | - | - | 269 (93.73%) |
Maraschini | 132 | 89 (67%) | - | 11 (12.36%) | - | 78 (87.64%) | - | - | 43 (32%) | - | 3 (6.98%) | - | 40 (93.02%) | - | - |
Russell | 156 | 128 (82%) | 9 (7.03%) | 31 (24.22%) | - | 51 (39.84%) | - | 37 (28.91%) | 28 (17%) | 2 (7.14%) | 8 (28.57%) | - | 8 (28.57%) | - | 10 (35.71%) |
Siso-Almirall | 260 | 212 (81%) | - | - | 60 (28.30%) | - | - | 152 (71.70%) | 48 (18%) | - | - | 21 (43.75%) | - | - | 27 (56.25%) |
Gu | 645 | 511 (79%) | 30 (5.87%) | 126 (24.66%) | - | 355 (69.47%) | - | - | 134 (20%) | 3 (2.24%) | 61 (45.52%) | - | 70 (52.24%) | - | - |
Mendy | 689 | 598 (86%) | - | - | 133 (22.24%) | - | - | 465 (77.76%) | 91 (13%) | - | - | 37 (40.66%) | - | - | 54 (59.34%) |
Jin, Gu | 6 | 2 (33%) | - | - | 0 (0.00%) | - | - | 2 (100.00%) | 4 (66%) | - | - | 2 (50.00%) | - | - | 2 (50.00%) |
Senkal | 611 | 446 (73%) | 48 (10.76%) | - | - | - | - | 398 (89.24%) | 165 (27%) | 21 (12.73%) | - | - | - | - | 144 (87.27%) |
Patel | 129 | 89 (68%) | 26 (29.21%) | - | - | - | 58 (65.17%) | 5 (5.62%) | 40 (31%) | 22 (55.00%) | - | - | - | 14 (35.00%) | 4 (10.00%) |
Maucourant | 27 | 10 (37%) | 1 (10.00%) | 2 (20.00%) | - | 2 (20.00%) | - | 5 (50.00%) | 17 (62%) | 2 (11.76%) | 5 (29.41%) | - | 9 (52.94%) | - | 1 (5.88%) |
Xie | 619 | 469 (75%) | - | - | 32 (6.82%) | - | - | 437 (93.18%) | 150 (24%) | - | - | 19 (12.67%) | - | - | 131 (87.33%) |
Fox | 55 | 30 (54%) | 1 (3.33%) | 4 (13.33%) | - | 17 (56.67%) | - | 8 (26.67%) | 25 (45%) | 0 (0.00%) | 2 (8.00%) | - | 14 (56.00%) | - | 9 (36.00%) |
Zhang, Cao | 240 | 162 (67%) | 2 (1.23%) | 6 (3.70%) | - | - | - | 154 (95.06%) | 78 (32%) | 4 (5.13%) | 4 (5.13%) | - | - | - | 70 (89.74%) |
Kurashima | 53 | 10 (18%) | - | - | 3 (30.00%) | - | - | 7 (70.00%) | 43 (81%) | - | - | 24 (55.81%) | - | - | 19 (44.19%) |
Zhan | 75 | NA (NA%) | - | - | - | - | - | - | 75 (100%) | - | - | 9 (12.00%) | - | - | 66 (88.00%) |
Omrani | 858 | 806 (93%) | - | - | 121 (15.01%) | - | - | 685 (84.99%) | 52 (6%) | - | - | 9 (17.31%) | - | - | 43 (82.69%) |
Marcos | 918 | 555 (60%) | 38 (6.85%) | - | 69 (12.43%) | - | - | 448 (80.72%) | 363 (39%) | 18 (4.96%) | - | 71 (19.56%) | - | - | 292 (80.44%) |
Hoertel, Sanchez, Rico | 7,345 | 6014 (81%) | 433 (7.20%) | - | - | - | - | 5581 (92.80%) | 1331 (18%) | 190 (14.27%) | - | - | - | - | 1141 (85.73%) |
Qi | 267 | 217 (81%) | 22 (10.14%) | - | - | - | 195 (89.86%) | - | 50 (18%) | 31 (62.00%) | - | - | - | 19 (38.00%) | - |
Monteiro | 112 | 84 (75%) | 3 (3.57%) | 14 (16.67%) | - | 63 (75.00%) | - | 4 (4.76%) | 28 (25%) | 4 (14.29%) | 6 (21.43%) | - | 14 (50.00%) | - | 4 (14.29%) |
Morshed | 103 | 87 (84%) | 28 (32.18%) | - | - | - | 59 (67.82%) | - | 16 (15%) | 4 (25.00%) | - | - | - | 12 (75.00%) | - |
Zhou, Sun | 144 | 108 (75%) | 11 (10.19%) | - | - | - | - | 97 (89.81%) | 36 (25%) | 2 (5.56%) | - | - | - | - | 34 (94.44%) |
Zhao, Chen | 641 | 398 (62%) | 87 (21.86%) | - | - | - | - | 311 (78.14%) | 195 (30%) | 52 (26.67%) | - | - | - | - | 143 (73.33%) |
Qu | 246 | 226 (91%) | 90 (39.82%) | - | - | - | - | 136 (60.18%) | 20 (8%) | 14 (70.00%) | - | - | - | - | 6 (30.00%) |
Petrilli | 2,729 | 1739 (63%) | 97 (5.58%) | 325 (18.69%) | - | 1067 (61.36%) | - | 250 (14.38%) | 990 (36%) | 44 (4.44%) | 236 (23.84%) | - | 517 (52.22%) | - | 193 (19.49%) |
Ren | 432 | 314 (72%) | 26 (8.28%) | - | - | 288 (91.72%) | - | - | 118 (27%) | 17 (14.41%) | - | - | 101 (85.59%) | - | - |
Yan | 578 | 450 (77%) | 31 (6.89%) | - | - | - | - | 419 (93.11%) | 128 (22%) | 20 (15.62%) | - | - | - | - | 108 (84.38%) |
Nicholson | 1,042 | 550 (52%) | 37 (6.73%) | 106 (19.27%) | - | 211 (38.36%) | - | 196 (35.64%) | 401 (38%) | 41 (10.22%) | 92 (22.94%) | - | 155 (38.65%) | - | 113 (28.18%) |
Zhu | 432 | 285 (65%) | 46 (16.14%) | - | - | - | - | 239 (83.86%) | 147 (34%) | 16 (10.88%) | - | - | - | - | 147 (100.00%) |
Kalan | 193 | 122 (63%) | 9 (7.38%) | - | - | 102 (83.61%) | - | 11 (9.02%) | 71 (36%) | 5 (7.04%) | - | - | 62 (87.32%) | - | 4 (5.63%) |
Burrell | 204 | 85 (41%) | - | - | 7 (8.24%) | - | 75 (88.24%) | 3 (3.53%) | 119 (58%) | - | - | 20 (16.81%) | - | 94 (78.99%) | 5 (4.20%) |
Zhou, He, Yang | 1,087 | 990 (91%) | - | - | 849 (85.76%) | 141 (14.24%) | - | - | 97 (8%) | - | - | 75 (77.32%) | 22 (22.68%) | - | - |
Zhou, Qin | 51 | NA (NA%) | - | - | - | - | - | - | 51 (100%) | - | - | 40 (78.43%) | 11 (21.57%) | - | - |
Zhan, Liu | 405 | 257 (63%) | - | - | 21 (8.17%) | 236 (91.83%) | - | - | 148 (36%) | - | - | 25 (16.89%) | 123 (83.11%) | - | - |
Li, Long, Zhang | 954 | 838 (87%) | - | - | 34 (4.06%) | 804 (95.94%) | - | - | 116 (12%) | - | - | 22 (18.97%) | 94 (81.03%) | - | - |
Jakob | 2,155 | 1400 (64%) | - | - | 92 (6.57%) | 99 (7.07%) | - | 669 (47.79%) | 755 (35%) | 51 (6.75%) | 58 (7.68%) | - | 200 (26.49%) | - | 446 (59.07%) |
Aksu | 123 | 34 (27%) | 3 (8.82%) | - | - | - | 31 (91.18%) | - | 89 (72%) | 11 (12.36%) | - | - | - | 78 (87.64%) | - |
Hoertel, Sanchez, Vernet | 12,210 | 11018 (90%) | 921 (8.36%) | - | - | - | - | 10097 (91.64%) | 1192 (9%) | 181 (15.18%) | - | - | - | - | 1011 (84.82%) |
Vila-Corcoles, Satue-Gracia | 282 | 218 (77%) | - | - | 21 (9.63%) | - | - | 197 (90.37%) | 64 (22%) | - | - | 4 (6.25%) | - | - | 60 (93.75%) |
Boyd | 38 | 0 (0%) | - | - | - | - | - | - | 38 (100%) | - | - | 2 (5.26%) | - | - | 36 (94.74%) |
Caliskan | 565 | 474 (83%) | 96 (20.25%) | 45 (9.49%) | - | 333 (70.25%) | - | - | 91 (16%) | 22 (24.18%) | 34 (37.36%) | - | 35 (38.46%) | - | - |
Ebrahimian | 226 | 134 (59%) | - | - | 12 (8.96%) | - | 122 (91.04%) | - | 92 (40%) | - | - | 12 (13.04%) | - | 80 (86.96%) | - |
Ho, Narasimhan | 4,909 | 3859 (78%) | 169 (4.38%) | 833 (21.59%) | - | - | 2857 (74.03%) | - | 1050 (21%) | 48 (4.57%) | 229 (21.81%) | - | 773 (73.62%) | - | - |
Quan | 2,038 | 1452 (71%) | - | 549 (37.81%) | - | - | - | 903 (62.19%) | 586 (28%) | - | - | 261 (44.54%) | - | - | 325 (55.46%) |
Saurabh | 911 | 783 (85%) | 65 (8.30%) | 3 (0.38%) | - | 715 (91.32%) | - | - | 128 (14%) | 9 (7.03%) | 3 (2.34%) | - | 116 (90.62%) | - | - |
Chousein | 114 | 94 (82%) | 17 (18.09%) | 17 (18.09%) | - | 60 (63.83%) | - | - | 20 (17%) | 2 (10.00%) | 6 (30.00%) | - | 12 (60.00%) | - | - |
Tavakol | 206 | 182 (88%) | - | - | 24 (13.19%) | - | 158 (86.81%) | - | 24 (11%) | - | - | 2 (8.33%) | - | 22 (91.67%) | - |
Yao, Hasegawa | 101 | 78 (77%) | - | - | 17 (21.79%) | - | 71 (91.03%) | - | 23 (22%) | - | - | 12 (52.17%) | - | 11 (47.83%) | - |
Cummins | 1,195 | 1043 (87%) | 96 (9.20%) | - | - | - | - | 947 (90.80%) | 152 (12%) | 9 (5.92%) | - | - | - | - | 143 (94.08%) |
Nuno | 4,730 | 3536 (74%) | 333 (9.42%) | - | - | - | - | 3203 (90.58%) | 1194 (25%) | 147 (12.31%) | - | - | - | - | 1047 (87.69%) |
P-HOSP-COVID Collaborative | 1,077 | 604 (56%) | 11 (1.82%) | 205 (33.94%) | - | 277 (45.86%) | - | 111 (18.38%) | 473 (43%) | 5 (1.06%) | 165 (34.88%) | - | 228 (48.20%) | - | 75 (15.86%) |
Faverio | 312 | 71 (22%) | 1 (1.41%) | 8 (11.27%) | - | 47 (66.20%) | - | 15 (21.13%) | 241 (77%) | 14 (5.81%) | 57 (23.65%) | - | 134 (55.60%) | - | 36 (14.94%) |
Manohar | 4,895 | 3825 (78%) | 41 (1.07%) | 288 (7.53%) | - | 647 (16.92%) | - | 2849 (74.48%) | 1070 (21%) | 13 (1.21%) | 143 (13.36%) | - | 226 (21.12%) | - | 688 (64.30%) |
Jha, Shrestha | 198 | 165 (83%) | 17 (10.30%) | 19 (11.52%) | - | 129 (78.18%) | - | - | 33 (16%) | 6 (18.18%) | 6 (18.18%) | - | 21 (63.64%) | - | - |
Riou | 124 | 90 (72%) | - | - | 34 (37.78%) | - | - | 56 (62.22%) | 34 (27%) | - | - | 17 (50.00%) | - | - | 17 (50.00%) |
Rachmawati | 490 | 472 (96%) | 76 (16.10%) | 61 (12.92%) | - | 335 (70.97%) | - | - | 18 (3%) | 8 (44.44%) | 3 (16.67%) | - | 7 (38.89%) | - | - |
Peng, Lei | 622 | 254 (40%) | 19 (7.48%) | - | - | - | - | 235 (92.52%) | 368 (59%) | 43 (11.68%) | - | - | - | - | 325 (88.32%) |
Hojbjerg, Lassen | 171 | 127 (74%) | 10 (7.87%) | 58 (45.67%) | - | 56 (44.09%) | - | 3 (2.36%) | 44 (25%) | 0 (0.00%) | 34 (77.27%) | - | 10 (22.73%) | - | - |
Alsafar | 873 | 574 (65%) | 77 (13.41%) | - | - | - | - | 497 (86.59%) | 299 (34%) | 60 (20.07%) | - | - | - | - | 239 (79.93%) |
Ali, Hasan | 464 | 319 (68%) | 47 (14.73%) | - | - | - | 272 (85.27%) | - | 145 (31%) | 3 (2.07%) | - | - | - | 142 (97.93%) | - |
Figure 7. Forest plot for the risk of severe disease in current vs. never smokers. The prior from the previous review version (v11) was RR = 1.26.
Figure 8. Forest plot for the risk of severe disease in former vs. never smokers. The prior from the previous review version (v11) was RR = 1.8.
115 studies reported mortality from COVID-19 by smoking status (see Table 5), with 28 ‘fair’ quality studies included in meta-analyses (see Figure 9 and 10). Current (RR = 1.13, 95% CrI = 0.9-1.4, τ = 0.41) and former (RR = 1.59, 95% CrI = 1.34-1.89, τ = 0.37) compared with never smokers were at increased risk of in-hospital mortality from COVID-19. However, data for current smokers were inconclusive and favoured there being no important association. The probability of current and former smokers being at greater risk of in-hospital mortality (RR ≥1.1) compared with never smokers was 60% and >99%, respectively. Results were materially unchanged in two sensitivity analyses.
Recovered | Died | ||||||||||||||
Author | Population with mortality | N (%) | Current smoker (%) | Former smoker (%) | Current/former smoker (%) | Never smoker (%) | Never/unknown smoker (%) | Not stated (%) | N (%) | Current smoker (%) | Former smoker (%) | Current/former smoker (%) | Never smoker (%) | Never/unknown smoker (%) | Not stated (%) |
Chen | 274 | 161 (58%) | 5 (3.11%) | 5 (3.11%) | - | - | - | 151 (93.79%) | 113 (41%) | 7 (6.19%) | 2 (1.77%) | - | - | - | 104 (92.04%) |
Zhou, Yu | 191 | 137 (71%) | 6 (4.38%) | - | - | - | - | 131 (95.62%) | 54 (28%) | 5 (9.26%) | - | - | - | - | 49 (90.74%) |
Yang, Yu | 52 | 20 (38%) | 2 (10.00%) | - | - | - | 18 (90.00%) | - | 32 (61%) | - | - | - | - | 32 (100.00%) | - |
Borobia | 2,226 | 1766 (79%) | 113 (6.40%) | - | - | - | - | 1653 (93.60%) | 460 (20%) | 44 (9.57%) | - | - | - | - | 416 (90.43%) |
Giacomelli | 233 | 185 (79%) | - | - | 53 (28.65%) | 132 (71.35%) | - | - | 48 (20%) | - | - | 17 (35.42%) | 31 (64.58%) | - | 0 (0.00%) |
Yao | 108 | 96 (88%) | 1 (1.04%) | - | - | - | - | 95 (98.96%) | 12 (11%) | 3 (25.00%) | - | - | - | - | 9 (75.00%) |
Carillo-Vega | 9,946 | 8983 (90%) | 795 (8.85%) | - | - | - | - | 8188 (91.15%) | 963 (9%) | 99 (10.28%) | - | - | - | - | 864 (89.72%) |
Ge | 51 | 39 (76%) | 6 (15.38%) | - | - | - | - | 33 (84.62%) | 12 (23%) | 1 (8.33%) | - | - | - | - | 11 (91.67%) |
Chen, Jiang | 135 | NA (NA%) | - | - | - | - | - | - | 31 (22%) | - | - | 4 (12.90%) | - | - | 27 (87.10%) |
Heili-Frades | 4,712 | 4086 (86%) | 210 (5.14%) | 659 (16.13%) | - | - | 3217 (78.73%) | - | 626 (13%) | 23 (3.67%) | 161 (25.72%) | - | - | 442 (70.61%) | - |
Kim, Garg | 2,490 | 2070 (83%) | 128 (6.18%) | 481 (23.24%) | - | - | 1461 (70.58%) | - | 420 (16%) | 22 (5.24%) | 161 (38.33%) | - | - | 236 (56.19%) | - |
Al-Hindawi | 31 | 15 (48%) | 0 (0.00%) | 10 (66.67%) | - | 5 (33.33%) | - | - | 16 (51%) | 1 (6.25%) | 12 (75.00%) | - | 3 (18.75%) | - | - |
Louis | 22 | 16 (72%) | - | - | 7 (43.75%) | - | - | 9 (56.25%) | 6 (27%) | - | - | 3 (50.00%) | - | - | 3 (50.00%) |
Soto-Mota | 400 | 200 (50%) | - | - | 23 (11.50%) | - | - | 177 (88.50%) | 200 (50%) | - | - | 25 (12.50%) | - | - | 175 (87.50%) |
Garibaldi | 747 | 634 (84%) | 36 (5.68%) | 129 (20.35%) | - | - | - | 469 (73.97%) | 113 (15%) | 6 (5.31%) | 36 (31.86%) | - | - | - | 71 (62.83%) |
Docherty | 13,364 | 8199 (61%) | 370 (4.51%) | 1832 (22.34%) | - | 4179 (50.97%) | - | 1818 (22.17%) | 5165 (38%) | 214 (4.14%) | 1350 (26.14%) | - | 2105 (40.76%) | - | 1496 (28.96%) |
Kuderer | 928 | 807 (86%) | 38 (4.71%) | 262 (32.47%) | - | 425 (52.66%) | - | 31 (3.84%) | 121 (13%) | 5 (4.13%) | 64 (52.89%) | - | 44 (36.36%) | - | 2 (1.65%) |
Ramlall | 11,116 | 10498 (94%) | - | - | 2771 (26.40%) | 7727 (73.60%) | - | - | 618 (5%) | - | - | 208 (33.66%) | 410 (66.34%) | - | - |
Wang, Oekelen | 57 | 43 (75%) | - | - | 14 (32.56%) | - | - | 29 (67.44%) | 14 (24%) | - | - | 7 (50.00%) | - | - | 7 (50.00%) |
Martinez-Portilla | 224 | 217 (96%) | - | - | 7 (3.23%) | - | - | 210 (96.77%) | 7 (3%) | - | - | 0 (0.00%) | - | - | 7 (100.00%) |
Cen | 1,007 | 964 (95%) | - | - | 87 (9.02%) | - | - | 877 (90.98%) | 43 (4%) | - | - | 1 (2.33%) | - | - | 42 (97.67%) |
Klang | 3,406 | 2270 (66%) | - | - | 492 (21.67%) | - | - | 1778 (78.33%) | 1136 (33%) | - | - | 301 (26.50%) | - | - | 835 (73.50%) |
Wang, Zhong | 5,510 | 4874 (88%) | 247 (5.07%) | 1083 (22.22%) | - | 3544 (72.71%) | - | - | 636 (11%) | 28 (4.40%) | 214 (33.65%) | - | 394 (61.95%) | - | - |
Miyara | 338 | 211 (62%) | 13 (6.16%) | 58 (27.49%) | - | 141 (66.82%) | - | - | 46 (13%) | 1 (2.17%) | 23 (50.00%) | - | 21 (45.65%) | - | - |
Rajter | 255 | 209 (81%) | - | - | 28 (13.40%) | 181 (86.60%) | - | - | 53 (20%) | - | - | 18 (33.96%) | 28 (52.83%) | - | - |
Zeng | 1,031 | 866 (84%) | - | - | 69 (7.97%) | - | - | 797 (92.03%) | 165 (16%) | - | - | 36 (21.82%) | - | - | 129 (78.18%) |
Chen, Yu | 1,859 | 1651 (88%) | 32 (1.94%) | 54 (3.27%) | - | 1565 (94.79%) | - | - | 208 (11%) | 13 (6.25%) | 12 (5.77%) | - | 183 (87.98%) | - | - |
Garassino | 190 | 124 (65%) | - | - | 92 (74.19%) | 32 (25.81%) | - | - | 66 (34%) | - | 61 (92.42%) | - | 5 (7.58%) | - | - |
Gu | 884 | 864 (97%) | 40 (4.63%) | 250 (28.94%) | - | 219 (25.35%) | - | - | 20 (2%) | 0 (0.00%) | 14 (70.00%) | - | 6 (30.00%) | - | - |
Sigel | 88 | 70 (79%) | - | - | 37 (52.86%) | - | - | 33 (47.14%) | 18 (20%) | - | - | 11 (61.11%) | - | - | 7 (38.89%) |
Nguyen | 356 | 308 (86%) | - | - | 91 (29.55%) | - | - | 217 (70.45%) | 45 (12%) | - | - | 23 (51.11%) | - | - | 22 (48.89%) |
de Souza | 8,443 | 7826 (92%) | - | - | 95 (1.21%) | - | 7571 (96.74%) | 160 (2.04%) | 617 (7%) | - | - | 47 (7.62%) | - | 560 (90.76%) | 10 (1.62%) |
Mendy | 689 | 663 (96%) | - | - | 160 (24.13%) | - | - | 502 (75.72%) | 26 (3%) | - | - | 10 (38.46%) | - | - | 16 (61.54%) |
Shi, Resurreccion | 256 | 210 (82%) | - | - | 128 (60.95%) | - | - | 82 (39.05%) | 46 (17%) | - | - | 26 (56.52%) | - | - | 20 (43.48%) |
Xie | 619 | 591 (95%) | - | - | 43 (7.28%) | - | - | 548 (92.72%) | 28 (4%) | - | - | 8 (28.57%) | - | - | 20 (71.43%) |
Fox | 54 | 35 (64%) | 1 (2.86%) | 4 (11.43%) | - | 18 (51.43%) | - | 12 (34.29%) | 19 (35%) | 0 (0.00%) | 2 (10.53%) | - | 12 (63.16%) | - | 5 (26.32%) |
Zhang, Cao | 289 | 240 (83%) | 10 (4.17%) | 6 (2.50%) | - | - | - | 224 (93.33%) | 49 (16%) | 4 (8.16%) | 8 (16.33%) | - | - | - | 37 (75.51%) |
Gupta | 496 | 255 (51%) | - | - | 15 (5.88%) | - | 80 (31.37%) | 160 (62.75%) | 241 (48%) | - | - | 21 (8.71%) | 77 (31.95%) | - | 143 (59.34%) |
Soares | 1,152 | 696 (60%) | 38 (5.46%) | - | - | - | 658 (94.54%) | - | 456 (39%) | 39 (8.55%) | - | - | - | 417 (91.45%) | - |
Thompson | 470 | 301 (64%) | 39 (12.96%) | 79 (26.25%) | - | 183 (60.80%) | - | - | 169 (35%) | 27 (15.98%) | 49 (28.99%) | - | 93 (55.03%) | - | - |
Bernaola | 1,645 | 1382 (84%) | 35 (2.53%) | 146 (10.56%) | - | 1201 (86.90%) | - | - | 263 (15%) | 6 (2.28%) | 33 (12.55%) | - | 218 (82.89%) | - | - |
Islam | 654 | 631 (96%) | 103 (16.32%) | - | - | - | - | 507 (80.35%) | 23 (3%) | 3 (13.04%) | - | - | - | - | - |
Philipose | 466 | 267 (57%) | 19 (7.12%) | 204 (76.40%) | - | 44 (16.48%) | - | - | 199 (42%) | 9 (4.52%) | 137 (68.84%) | - | 33 (16.58%) | - | 20 (10.05%) |
Fillmore | 1,794 | 1566 (87%) | 408 (26.05%) | 758 (48.40%) | - | 279 (17.82%) | - | 98 (6.26%) | 228 (12%) | 44 (19.30%) | 141 (61.84%) | - | 43 (18.86%) | - | 23 (10.09%) |
Pan | 3,536 | 3302 (93%) | - | - | 862 (26.11%) | - | - | 2440 (73.89%) | 234 (6%) | - | - | 82 (35.04%) | - | - | 152 (64.96%) |
Zhao, Chen | 474 | 398 (83%) | 87 (21.86%) | - | - | - | - | 311 (78.14%) | 82 (17%) | 36 (43.90%) | - | - | - | - | 46 (56.10%) |
Holman | 10,989 | NA (NA%) | - | - | - | - | - | - | 10989 (100%) | 609 (5.54%) | 4684 (42.62%) | - | 5386 (49.01%) | - | 310 (2.82%) |
Chand | 300 | 143 (47%) | 23 (16.08%) | - | - | - | - | 120 (83.92%) | 157 (52%) | 44 (28.03%) | - | - | - | - | 113 (71.97%) |
Oliveira | 131 | 105 (80%) | - | - | 16 (15.24%) | - | 83 (79.05%) | 6 (5.71%) | 26 (19%) | - | - | 7 (26.92%) | - | 17 (65.38%) | - |
Vilar-Garcia | 328,892 | 316605 (96%) | 71215 (22.49%) | - | - | - | - | 245390 (77.51%) | 12287 (3%) | 3103 (25.25%) | - | - | - | - | 9184 (74.75%) |
Ibarra-Nava | 416,546 | 370038 (88%) | 27001 (7.30%) | - | - | - | - | 343037 (92.70%) | 46508 (11%) | 3817 (8.21%) | - | - | - | - | 426791 (917.67%) |
Rubio-Rivas | 186 | 147 (79%) | 7 (4.76%) | 32 (21.77%) | - | 108 (73.47%) | - | - | 39 (20%) | 1 (2.56%) | 6 (15.38%) | - | 32 (82.05%) | - | - |
Ren | 432 | 289 (66%) | 25 (8.65%) | - | - | 264 (91.35%) | - | - | 143 (33%) | 18 (12.59%) | - | 125 (87.41%) | - | - | - |
Ullah | 212 | 158 (74%) | 22 (13.92%) | 67 (42.41%) | - | 63 (39.87%) | - | 6 (3.80%) | 54 (25%) | 2 (3.70%) | 35 (64.81%) | - | 17 (31.48%) | - | 0 (0.00%) |
Nicholson | 1,040 | 829 (79%) | 70 (8.44%) | 163 (19.66%) | - | 320 (38.60%) | - | 276 (33.29%) | 211 (20%) | 16 (7.58%) | 68 (32.23%) | - | 65 (30.81%) | - | 62 (29.38%) |
Kalan | 193 | 188 (97%) | 14 (7.45%) | - | - | 162 (86.17%) | - | 12 (6.38%) | 5 (2%) | 0 (0.00%) | - | - | 2 (40.00%) | - | 3 (60.00%) |
Incerti | 13,658 | 11495 (84%) | 785 (6.83%) | 2450 (21.31%) | - | 5450 (47.41%) | 2810 (24.45%) | - | 2163 (15%) | 81 (3.74%) | 642 (29.68%) | - | 757 (35.00%) | 683 (31.58%) | - |
Ioannou | 10,131 | 9033 (89%) | 1054 (11.67%) | 3549 (39.29%) | - | 3339 (36.96%) | - | 1091 (12.08%) | 1098 (10%) | 81 (7.38%) | 528 (48.09%) | - | 305 (27.78%) | - | 184 (16.76%) |
Lamure | 89 | 59 (66%) | 4 (6.78%) | 16 (27.12%) | - | 31 (52.54%) | - | 8 (13.56%) | 30 (33%) | 1 (3.33%) | 13 (43.33%) | - | 12 (40.00%) | - | 4 (13.33%) |
Yadaw | 5,051 | 4635 (91%) | 162 (3.50%) | 709 (15.30%) | - | 2394 (51.65%) | - | 1370 (29.56%) | 416 (8%) | 17 (4.09%) | 105 (25.24%) | - | 196 (47.12%) | - | 98 (23.56%) |
Zinellu | 105 | 77 (73%) | 24 (31.17%) | 8 (10.39%) | - | 45 (58.44%) | - | - | 28 (26%) | 8 (28.57%) | 3 (10.71%) | - | 17 (60.71%) | - | - |
Zhang, Li | 399 | NA (NA%) | - | - | - | - | - | - | 399 (100%) | 60 (15.04%) | 186 (46.62%) | - | 148 (37.09%) | - | - |
Wang, Shu | 59 | 18 (30%) | - | - | 0 (0.00%) | - | - | 18 (100.00%) | 41 (69%) | - | - | 9 (21.95%) | - | - | 32 (78.05%) |
Wang, Zheutlin | 2,448 | 1706 (69%) | 57 (3.34%) | 315 (18.46%) | - | 954 (55.92%) | - | 380 (22.27%) | 742 (30%) | 25 (3.37%) | 197 (26.55%) | - | 354 (47.71%) | - | 166 (22.37%) |
Torres-Macho | 1,968 | 1643 (83%) | - | - | 335 (20.39%) | - | - | 1308 (79.61%) | 325 (16%) | - | - | 125 (38.46%) | - | - | 200 (61.54%) |
Raines | 440 | 408 (92%) | - | - | 222 (54.41%) | 186 (45.59%) | - | - | 32 (7%) | - | - | 28 (87.50%) | 4 (12.50%) | - | - |
Parra-Bracamonte | 331,298 | 292988 (88%) | - | - | 21269 (7.26%) | - | - | 271719 (92.74%) | 38310 (11%) | - | - | 3215 (8.39%) | - | - | 35095 (91.61%) |
Li, Long, Zhang | 954 | 876 (91%) | - | - | 48 (5.48%) | 828 (94.52%) | - | - | 78 (8%) | - | - | 8 (10.26%) | 70 (89.74%) | - | - |
Bellan | 407 | 285 (70%) | 30 (10.53%) | - | - | - | 191 (67.02%) | 64 (22.46%) | 122 (29%) | 24 (19.67%) | - | - | - | 67 (54.92%) | 31 (25.41%) |
Alharthy | 352 | 239 (67%) | 109 (45.61%) | - | - | - | 130 (54.39%) | - | 113 (32%) | 65 (57.52%) | - | - | - | 48 (42.48%) | - |
Adrish | 1,173 | 783 (66%) | - | - | 205 (26.18%) | 578 (73.82%) | - | - | 390 (33%) | - | - | 131 (33.59%) | 259 (66.41%) | - | - |
Hoertel, Sanchez, Vernet | 12,210 | 10802 (88%) | 898 (8.31%) | - | - | - | - | 9904 (91.69%) | 1408 (11%) | 204 (14.49%) | - | - | - | - | 1204 (85.51%) |
Sourij | 238 | 180 (75%) | 4 (2.22%) | 26 (14.44%) | - | 150 (83.33%) | - | - | 58 (24%) | 0 (0.00%) | 12 (20.69%) | - | 46 (79.31%) | - | - |
Simons | 446 | 318 (71%) | 30 (9.43%) | 109 (34.28%) | - | 179 (56.29%) | - | - | 128 (28%) | 12 (9.38%) | 63 (49.22%) | - | 53 (41.41%) | - | - |
Bisso | 168 | 122 (72%) | 13 (10.66%) | - | - | - | - | 109 (89.34%) | 46 (27%) | 5 (10.87%) | - | - | - | - | 39 (84.78%) |
Caliskan | 565 | 490 (86%) | 97 (19.80%) | 48 (9.80%) | - | 345 (70.41%) | - | - | 75 (13%) | 21 (28.00%) | 31 (41.33%) | - | 23 (30.67%) | - | - |
Ebrahimian | 226 | 128 (56%) | - | - | 9 (7.03%) | - | 119 (92.97%) | - | 98 (43%) | - | - | 15 (15.31%) | - | 83 (84.69%) | - |
Estiri | 16,709 | 15879 (95%) | - | - | 1304 (8.21%) | - | - | 14575 (91.79%) | 830 (4%) | - | - | 137 (16.51%) | - | - | 693 (83.49%) |
Ferrari | 198 | 165 (83%) | - | - | 27 (16.36%) | 138 (83.64%) | - | - | 33 (16%) | - | - | 14 (42.42%) | 19 (57.58%) | - | - |
Ho, Narasimhan | 4,909 | 3553 (72%) | 163 (4.59%) | 743 (20.91%) | - | 2647 (74.50%) | - | - | 1356 (27%) | 54 (3.98%) | 319 (23.53%) | - | 983 (72.49%) | - | - |
Mansour | 111 | 83 (74%) | 5 (6.02%) | - | - | - | - | 78 (93.98%) | 28 (25%) | 6 (21.43%) | - | - | - | - | 22 (78.57%) |
Park | 2,269 | 2105 (92%) | 92 (4.37%) | - | - | - | - | 2013 (95.63%) | 164 (7%) | 2 (1.22%) | - | - | - | - | 162 (98.78%) |
Quan | 2,038 | 1587 (77%) | - | - | 589 (37.11%) | - | - | 998 (62.89%) | 442 (21%) | - | - | 218 (49.32%) | - | - | 224 (50.68%) |
Saurabh | 911 | 870 (95%) | 70 (8.05%) | 4 (0.46%) | - | 796 (91.49%) | - | - | 41 (4%) | 4 (9.76%) | 2 (4.88%) | - | 35 (85.37%) | - | - |
Strangfeld | 3,729 | 3339 (89%) | - | - | 664 (19.89%) | 2190 (65.59%) | - | 485 (14.53%) | 390 (10%) | - | - | 112 (28.72%) | 198 (50.77%) | - | 80 (20.51%) |
Nezhadmoghadam | 13,367 | 7757 (58%) | 686 (8.84%) | - | - | - | - | 7071 (91.16%) | 5610 (41%) | 565 (10.07%) | - | - | - | - | 5045 (89.93%) |
Nuno | 4,730 | 4401 (93%) | 427 (9.70%) | - | - | - | - | 3974 (90.30%) | 329 (6%) | 53 (16.11%) | - | - | - | - | 276 (83.89%) |
Fernandez, Fuertes | 46 | 45 (97%) | 12 (26.67%) | - | - | - | - | 33 (73.33%) | 1 (2%) | 0 (0.00%) | - | - | - | - | 1 (100.00%) |
Dambha, Miller | 5,328 | 4684 (87%) | 447 (9.54%) | 2326 (49.66%) | - | 1912 (40.82%) | - | - | 664 (12%) | 40 (6.02%) | 388 (58.43%) | - | 216 (32.53%) | - | - |
Williamson, Tazare | 7,999 | NA (NA%) | - | - | - | - | - | - | 7999 (100%) | 737 (9.21%) | 4745 (59.32%) | - | 2499 (31.24%) | - | 18 (0.23%) |
Dayem, Ullah | 217 | 164 (75%) | 23 (14.02%) | 72 (43.90%) | - | 67 (40.85%) | - | 2 (1.22%) | 53 (24%) | 2 (3.77%) | 37 (69.81%) | - | 14 (26.42%) | - | - |
Macias, Guzman | 196 | 109 (55%) | - | - | 37 (33.94%) | - | - | 72 (66.06%) | 87 (44%) | - | - | 34 (39.08%) | - | - | 53 (60.92%) |
Martin, Vicente | 92 | 38 (41%) | 3 (7.89%) | - | - | - | - | 35 (92.11%) | 54 (58%) | 2 (3.70%) | - | - | - | - | 52 (96.30%) |
Greenbaum | 44 | 32 (72%) | 2 (6.25%) | 6 (18.75%) | - | 24 (75.00%) | - | - | 12 (27%) | 0 (0.00%) | 3 (25.00%) | - | 9 (75.00%) | - | - |
Asem | 8,162 | 7573 (92%) | 1147 (15.15%) | - | - | - | - | 6426 (84.85%) | 589 (7%) | 208 (35.31%) | - | - | - | - | 381 (64.69%) |
Gil | 186 | 174 (93%) | 42 (24.14%) | - | - | - | 132 (75.86%) | - | 12 (6%) | 4 (33.33%) | - | - | - | 8 (66.67%) | - |
Rubina | 52 | 41 (78%) | 2 (4.88%) | - | - | - | 35 (85.37%) | 4 (9.76%) | 11 (21%) | 0 (0.00%) | - | - | - | 6 (54.55%) | 5 (45.45%) |
Mann | 1,769 | 1422 (80%) | - | - | 515 (36.22%) | 840 (59.07%) | - | 67 (4.71%) | 347 (19%) | - | - | 130 (37.46%) | 163 (46.97%) | - | 54 (15.56%) |
Madakkatel | 1,953 | 1577 (80%) | 184 (11.67%) | 586 (37.16%) | - | 789 (50.03%) | - | 18 (1.14%) | 376 (19%) | 54 (14.36%) | 176 (46.81%) | - | 140 (37.23%) | - | 6 (1.60%) |
Demichev | 50 | 35 (70%) | 1 (2.86%) | 6 (17.14%) | - | 28 (80.00%) | - | - | 15 (30%) | 0 (0.00%) | 2 (13.33%) | - | 13 (86.67%) | - | - |
Velasco, Rodriguez | 2,070 | 1677 (81%) | 68 (4.05%) | - | - | - | - | 1599 (95.35%) | 393 (18%) | 17 (4.33%) | - | - | - | - | 376 (95.67%) |
Puebla, Neira | 10,216 | 10028 (98%) | 395 (3.94%) | 870 (8.68%) | - | 8763 (87.39%) | - | - | 188 (1%) | 3 (1.60%) | 47 (25.00%) | - | 138 (73.40%) | - | - |
Prats-Uribe, Xie | 1,591 | 1219 (76%) | 136 (11.16%) | 453 (37.16%) | - | 630 (51.68%) | - | - | 372 (23%) | 56 (15.05%) | 175 (47.04%) | - | 141 (37.90%) | - | - |
Peng, Lei | 622 | 547 (87%) | 48 (8.78%) | - | - | - | - | 499 (91.22%) | 75 (12%) | 14 (18.67%) | - | - | - | - | 61 (81.33%) |
Nassar | 160 | 121 (75%) | 9 (7.44%) | - | - | - | - | 112 (92.56%) | 39 (24%) | 8 (20.51%) | - | - | - | - | 31 (79.49%) |
Mendez, Dominguez | 7,064 | 6867 (97%) | 132 (1.92%) | - | - | - | - | 6735 (98.08%) | 197 (2%) | 2 (1.02%) | - | - | - | - | 195 (98.98%) |
Marimuthu | 854 | 767 (89%) | 4 (0.52%) | - | - | - | - | 763 (99.48%) | 87 (10%) | 6 (6.90%) | - | - | - | - | 81 (93.10%) |
Chetboun | 3,401 | 2892 (85%) | 190 (6.57%) | 689 (23.82%) | - | 1756 (60.72%) | - | 257 (8.89%) | 509 (14%) | 20 (3.93%) | 171 (33.60%) | - | 164 (32.22%) | - | 154 (30.26%) |
Bruce | 125 | 101 (80%) | 13 (12.87%) | - | - | - | - | 88 (87.13%) | 24 (19%) | 12 (50.00%) | - | - | - | - | 12 (50.00%) |
Bhaskaran | 1,584 | 1082 (68%) | 85 (7.86%) | 381 (35.21%) | - | 587 (54.25%) | - | 29 (2.68%) | 502 (31%) | 27 (5.38%) | 224 (44.62%) | - | 237 (47.21%) | - | 14 (2.79%) |
Bertuzzi | 17,456,515 | NA (NA%) | - | - | - | - | - | - | 17063 (0%) | 1109 (6.50%) | 10276 (60.22%) | - | 5678 (33.28%) | - | - |
Avouac | 92 | 70 (76%) | 10 (14.29%) | - | - | - | 35 (50.00%) | 25 (35.71%) | 22 (23%) | 6 (27.27%) | - | - | - | 5 (22.73%) | 11 (50.00%) |
Alsafar | 873 | 751 (86%) | 101 (13.45%) | - | - | - | - | 650 (86.55%) | 122 (13%) | 36 (29.51%) | - | - | - | - | 86 (70.49%) |
Ahmadi | 464 | 438 (94%) | 50 (11.42%) | - | - | - | 388 (88.58%) | - | 26 (5%) | 0 (0.00%) | - | - | - | 26 (100.00%) | - |
Aboueshia | 468,443 | 468056 (99%) | 48522 (10.37%) | 162807 (34.78%) | - | 256727 (54.85%) | - | - | 387 (0%) | 59 (15.25%) | 183 (47.29%) | - | 145 (37.47%) | - | - |
Figure 9. Forest plot for the risk of mortality in current vs. never smokers. The prior from the previous review version (v11) was RR = 1.12.
Figure 10. Forest plot for the risk of mortality in former smokers vs. never smokers. The prior from the previous version (v11) was RR = 1.56.
This living rapid review found uncertainty in the majority of 547 studies arising from the recording of smoking status. Notwithstanding this uncertainty, compared with overall adult national prevalence estimates, recorded current smoking rates in most studies were lower than expected. In a subset of good and fair quality studies (n = 39), current but not former smokers had a reduced risk of testing positive for SARS-CoV-2 but current smokers appeared somewhat more likely to present for testing and/or receive a test. Current compared with never smokers had an increased risk of greater disease severity. Data for current smokers on the risk of hospitalisation and mortality were inconclusive, and favoured there being no important associations. Former smokers were at increased risk of hospitalisation, disease severity and mortality compared with never smokers.
Interpretation of results from studies conducted during the first phase of the SARS-CoV-2 pandemic is complicated by several factors (see Figure 11):
Figure 11. A schematic of some of the interpretation issues for the association of smoking status and COVID-19 infection, hospitalisation, disease severity and mortality. Numbers refer to the issues listed in-text in the above section. Issues presented on the right-hand side relate directly to smoking status.
This living rapid evidence review was limited by having a single reviewer extracting data with a second independently verifying the data extracted to minimise errors, restricting the search to one electronic database and one pre-print server and by not including at least three large population surveys due to their reliance on self-reported suspected or confirmed SARS-CoV-2 infection (which means they do not meet our eligibility criteria) (Bowyer et al., 2020; Hopkinson et al., 2020; Jackson et al., 2020). We also did not include a large, UK-based, representative seroprevalence study (Ward et al., 2020) in our meta-analyses as the odds of testing positive in former smokers was not reported. However, the odds of infection for current smokers (OR = 0.64, 95% CI = 0.58-0.71) was in concordance with the pooled estimate in our meta-analysis. Population surveys – particularly with linked data on confirmed infection or antibodies – will be included in future review versions to help mitigate some of the limitations of healthcare based observational studies. The comparisons of current and former smoking prevalence in the included studies with national prevalence estimates did not adjust observed prevalence for the demographic profile of those tested/admitted to hospital. Other reviews focused on this comparison have applied adjustments for sex and age, and continue to find lower than expected prevalence – notwithstanding the issues complicating interpretation described above (Farsalinos, Barbouni, et al., 2020).
Further scientific research is needed to resolve the mixed findings summarised in our review. First, clinical trials of the posited therapeutic effect of nicotine could have important implications both for smokers and for improved understanding of how the SARS-CoV-2 virus causes disease in humans. Such trials should focus on medicinal nicotine (as smoked tobacco is a dirty delivery mechanism that could mask beneficial effects) and potentially differentiate between different modes of delivery (i.e. inhaled vs. ingested) since this can affect pharmacokinetics (Shahab et al., 2013) and potential therapeutic effects. A second research priority would be a large, representative (randomly sampled) population survey with a validated assessment of smoking status which distinguishes between recent and long-term ex-smokers – ideally biochemically verified – and assesses seroprevalence and links to health records.
In the meantime, public-facing messages about the possible protective effect of smoking or nicotine are premature. In our view, until there is further research, the quality of the evidence does not justify the huge risk associated with a message likely to reach millions of people that a lethal activity, such as smoking, may protect against COVID-19. It continues to be appropriate to recommend smoking cessation and emphasise the role of alternative nicotine products to support smokers to stop as part of public health efforts during COVID-19. At the very least, smoking cessation reduces acute risks from cardiovascular disease and could reduce demands on the healthcare system (Stead et al., 2013). GPs and other healthcare providers can play a crucial role – brief, high-quality and free online training is available at National Centre for Smoking Cessation and Training.
Across 547 studies, recorded current but not past smoking prevalence was generally lower than national prevalence estimates. Current smokers were at reduced risk of testing positive for SARS-CoV-2 and at increased risk of greater disease severity. Former smokers were at increased risk of hospitalisation, disease severity and mortality compared with never smokers.
An original short review for the Royal College of Physicians was converted to an extended living review after a request by Martin Dockrell, Tobacco Control Lead, Public Health England. All scientific decisions were made by the authors independently of funders and external organisations. The authors would like to thank Rosemary Koper for her assistance in running the electronic searches and data extraction up until v7, and all authors who responded to requests for additional data.
DS and OP have no conflicts of interest to declare. LS has received a research grant and honoraria for a talk and travel expenses from manufacturers of smoking cessation medications (Pfizer and Johnson & Johnson). JB has received unrestricted research funding to study smoking cessation from companies who manufacture smoking cessation medications. All authors declare no financial links with tobacco companies or e-cigarette manufacturers or their representatives.
DS is supported by a PhD studentship from the UK Biotechnology and Biological Sciences Research Council [BB/M009513/1]. OP receives salary support from Cancer Research UK (C1417/A22962). JB, LS, & OP are members of SPECTRUM, a UK Prevention Research Partnership Consortium (MR/S037519/1). UKPRP is an initiative funded by the UK Research and Innovation Councils, the Department of Health and Social Care (England) and the UK devolved administrations, and leading health research charities.
The most up-to-date review version is available here
All data contributing to the current and future review versions are available here
All code required to reproduce the current and future analyses are available here
C. Huang et al. (2020), Jie Li et al. (2020), Jin-jin Zhang et al. (2020), Yang et al. (2020), Guan, Ni, et al. (2020), W. Liu et al. (2020), Qi et al. (2020), Y. Huang et al. (2020), Xu et al. (2020), F. Zhou et al. (2020), R. Liu et al. (2020), Mo et al. (n.d.), Y. Shi et al. (2020), Xiaoli Zhang et al. (2020), Dong et al. (2020), S. Wan et al. (2020), X. Jin et al. (2020), R. Wang et al. (2020), Lian et al. (n.d.), Hu et al. (2020), Guan, Liang, et al. (2020), T. Chen et al. (2020), Guo et al. (2020), CDCMMWR (2020), E. S. Kim et al. (2020), Feng et al. (2020), C. Rentsch et al. (2020), Goyal et al. (2020), K. I. Zheng et al. (2020), Gold et al. (2020), Argenziano et al. (2020), Richardson et al. (2020), Fontanet et al. (2020), P. Shi et al. (2020), Hadjadj et al. (2020), Liao et al. (2020), Gil-Agudo et al. (2020), Q. Yao et al. (n.d.), Zuo, Yalavarthi, et al. (2020), Solís & Carreño (2020), Yu et al. (2020), Ziehr et al. (2020), Yi Zheng et al. (2020), Kalan et al. (2020), Kolin et al. (2020), Borobia et al. (2020), Giacomelli et al. (2020), Shah et al. (2020), Williamson et al. (2020), Allenbach et al. (2020), Robilotti et al. (2020), Lubetzky et al. (2020), Yin et al. (2020), Rica et al. (2020), Cho et al. (2020), Yanover et al. (2020), Hamer et al. (2020), Targher et al. (2020), Carrillo-Vega et al. (2020), Regina et al. (2020), Almazeedi et al. (2020), Lusignan et al. (2020), Palaiodimos et al. (2020), Mejia-Vilet et al. (2020), C. Chen et al. (2020), Jiong Li et al. (2020), Valenti et al. (2020), Feuth et al. (2020), Ge et al. (2020), Parrotta et al. (2020), Shekhar et al. (2020), Rimland et al. (2020), Basse et al. (2020), Freites et al. (2020), Alshami et al. (2020), Q. Shi et al. (2020), Al-Hindawi et al. (2020), M. A. Wu et al. (2020), L. Kim et al. (2020), Docherty et al. (2020), Petrilli et al. (2020), Klang et al. (n.d.), Vaquero et al. (2020), Ip et al. (2020), Heili-Frades (n.d.), Berumen et al. (2020), Garibaldi et al. (2020), Soto-Mota et al. (2020), Jingwen Li et al. (n.d.), Louis et al. (2020), Kuderer et al. (2020), M. Gianfrancesco et al. (2020), Chaudhry et al. (2020), Niedzwiedz et al. (2020), Valle et al. (2020), Bello-Chavolla, Bahena-López, et al. (2020), Batty et al. (2020), Israel, Feldhamer, et al. (2020), Hao et al. (2020), Lassale et al. (2020), Eugen-Olsen et al. (2020), Martinez-Portilla et al. (2020), Raisi-Estabragh et al. (n.d.), H. Luo et al. (2020), Boulware et al. (2020), Ikitimur et al. (n.d.), Sierpiński et al. (2020), B. Wang et al. (2020), Perrone et al. (2020), Sharma et al. (2020), Magagnoli et al. (2020), Ramlall et al. (2020), Giannouchos et al. (2020), Romão et al. (2020), Cen et al. (2020), Houlihan et al. (2020), Lan et al. (2020), Russell et al. (2020), Veras et al. (2020), Rossi et al. (2020), Martin-Jimenez et al. (2020), Rajter et al. (2020), Yaya Zhou et al. (2020), Woolford et al. (2020), Hultcrantz et al. (2020), Hernández-Garduño (2020), Sterlin et al. (2020), Maraschini et al. (2020), A.-L. Wang et al. (2020), McQueenie et al. (2020), Miyara et al. (2020), Apea et al. (2021), Garassino et al. (2020), Zeng et al. (2020), Suleyman et al. (2020), L. Chen et al. (2020), Kibler et al. (2020), Olivares et al. (2020), Elezkurtaj et al. (2020), Zuo, Estes, et al. (2020), Killerby (2020), Gu et al. (2020), Wei et al. (2020), Crovetto et al. (2020), Govind et al. (2020), Sisó-Almirall et al. (2020), Salton et al. (2020), Duan et al. (2020), Lenka et al. (2020), Fisman et al. (2020), Madariaga et al. (2020), C. Jin et al. (2020), Mendy et al. (2020), Sigel et al. (n.d.), Souza et al. (2020), Nguyen et al. (2020), Melo et al. (2020), Auvinen et al. (2020), Magleby et al. (n.d.), Hewitt et al. (2020), Mohamud et al. (2020), Trubiano et al. (2020), Patel et al. (2020), Merzon et al. (2020), Bello-Chavolla, Antonio-Villa, et al. (2020), Zacharioudakis et al. (2020), Antonio-Villa et al. (2020), Kimmig et al. (2020), Senkal (2020), Xie et al. (2020), Elmunzer et al. (2020), Alizadehsani et al. (2020), Maucourant et al. (2020), Fan et al. (2020), Z. Shi et al. (2020), Riley et al. (2020), Hippisley-Cox et al. (2020), Jin‐jin Zhang et al. (2020), Eiros et al. (2020), Marcos et al. (2020), Hoertel, Rico, Vernet, Beeker, et al. (2020), H. Shi et al. (2020), Hussein et al. (2020), Bian et al. (2020), Z. Zhan et al. (2020), Omrani et al. (2020), Gupta et al. (2020), Soares et al. (2020), Abolghasemi et al. (n.d.), Merkely et al. (2020), Fox et al. (n.d.), Pandolfi et al. (2020), Girardeau et al. (2020), Kurashima et al. (2020), McGrail & Edwards (2020), Martinez-Resendez et al. (2020), Hoertel, Rico, Vernet, Jannot, et al. (2020), Z.-H. Wang et al. (2020), Bernaola et al. (2020), Schneeweiss et al. (2020), Concha-Mejia & Rincon-Sanchez (2020), Izquierdo et al. (2020), Santos et al. (2020), Reiter et al. (2020), Motta et al. (2020), Altamimi et al. (2020), Thompson et al. (2020), Zobairy et al. (2020), K. Zhou et al. (2020), Kumar et al. (2020), Qu et al. (2020), Higuchi et al. (2020), Zhao et al. (2020), Fond et al. (2020), Jun et al. (2020), Morshed et al. (2020), Iversen et al. (2020), Ebinger et al. (2020), Hadi et al. (2020), Tao et al. (2020), Klang et al. (2020), J. Zhou et al. (2021), Altibi et al. (2020), Izzi-Engbeaya et al. (2020), Rizzo et al. (2020), Jehi et al. (2020), Holman et al. (2020), Ouyang et al. (2020), Valenzuela et al. (2020), Monteiro et al. (2020), Philipose et al. (2020), Weerahandi et al. (2020), Parra-Bracamonte et al. (2020), Peters et al. (2020), Islam et al. (2020), Chand et al. (2020), Aksu et al. (2020), Alkurt et al. (2020), Ward et al. (2020), Salerno et al. (2020), M. Rashid et al. (2020), Pan et al. (2020), Fillmore et al. (2020), Wei Zhou et al. (2020), Ibrahim et al. (2020), Oliveira et al. (2020), Yoo et al. (2020), T. Zhan et al. (2020), Mohamed-Hussein et al. (2020), Villar-Garcia et al. (2020), Ibarra-Nava et al. (2020), Rubio-Rivas et al. (2020), Mamtani et al. (2020), Ren, Guo, Blighe, et al. (2020), Mutambudzi et al. (2020), Yan et al. (2020), Mancilla-Galindo et al. (2020), Ullah et al. (2020), Hamadah et al. (2020), Sami et al. (2020), Pongpirul et al. (2020), Burrell et al. (2020), Nicholson et al. (2020), Ariza et al. (2020), Carrat et al. (2020), Favara et al. (2020a), Favara et al. (2020b), Invernizzi et al. (2020), Zhu et al. (2020), O’Reilly et al. (2020), Meini et al. (n.d.), Silva Neto et al. (2020), Ioannou et al. (2020), Torres-Macho et al. (2020), F. Li et al. (2020), J. G. Wang et al. (2020), Lopez-Medrano et al. (2020), Collard et al. (2020), Makaronidis et al. (2020), Yadaw et al. (2020), Talavera et al. (2020), Jakob et al. (2020), Incerti et al. (2020), J. Luo et al. (2020), Alharthy et al. (2020), Robinson et al. (2021), Adrish et al. (2020), Erber et al. (2020), Chaudhary et al. (2020), Raines et al. (2021), Roederer et al. (2021), Zinellu et al. (2021), Ramachandran et al. (2020), Lamure et al. (2020), Ghinai et al. (2020), Best et al. (2020), Savarraj et al. (n.d.), Israel, Schäffer, et al. (2020), El-Solh et al. (2020), Perico et al. (2020), Wenqian Zhou et al. (2020), Chudasama et al. (2020), Salama et al. (2021), Z. Wang et al. (2020), Yiwu Zhou et al. (2020), Hoertel, Sánchez, et al. (2020), Arleo et al. (2020), Bermejo-Martin et al. (2020), Joubert et al. (2020), Kortela et al. (2020), M. A. Gianfrancesco et al. (2020), Colaneri et al. (2021), Gallichotte et al. (2020), Lin et al. (2020), (kim_easy?)–use_2020, Galal et al. (2020), Riou et al. (2021), Sourij et al. (2020), Clavario et al. (2020), Saeed et al. (2020), Mansour et al. (2020), Cadegiani et al. (2020), Ilic et al. (2021), Benaim et al. (2020), F. K. Ho et al. (2020), Singh et al. (2020), Márquez-Salinas et al. (2020), Díez-Manglano et al. (2020), Bellan et al. (2020), Woolcott & Castilla-Bancayán (2021a), Woolcott & Castilla-Bancayán (2021b), K. Yao et al. (2021), H. Chen et al. (2020), Serling-Boyd et al. (2020), Simons, Perski, et al. (2020), Dupraz et al. (2020), Barasa et al. (2020), Ren, Guo, Tu, et al. (2020), J. Li et al. (2020), Martini et al. (2020), O’Gallagher et al. (2020), Alguwaihes et al. (2020), Zuo, Warnock, et al. (2020), Xiaomeng Zhang et al. (2020), Dai et al. (2020), Vila-Córcoles et al. (2020), Bisso et al. (2020), C. T. Rentsch et al. (2020), Thiabaud et al. (2020), Vila-Corcoles et al. (2020), Lévy et al. (2020), Kantele et al. (2020), Iftime et al. (2020), K. S. Ho et al. (2020), Caliskan & Saylan (2020), Muñoz et al. (2020), Crooks et al. (2020), Nunez-Gil et al. (2020), Núñez-Gil et al. (2021), Gori et al. (2020), Rowlands et al. (2020), Richard et al. (2020), Schubl et al. (2020), Ugur Chousein et al. (2020), Modrák et al. (2020), Kara Polat et al. (2020), Kjetland et al. (2020), Lewnard et al. (2021), Nezhadmoghadam & Tamez-Peña (2021), Covid-19 in pregnancy et al. (2021), Boyd & Martin-Loeches (2021), Paleiron et al. (2021), Ader et al. (2021), Giannini et al. (2021), Shade et al. (2021), Park et al. (2021), Ferrari et al. (2021), Y. Zhang et al. (2021), Ebrahimian et al. (2021), Vahidy et al. (2021), Mendes et al. (2021), Saurabh et al. (2021), Ayoubkhani et al. (2021), Thakur et al. (2021), Zhong et al. (2020), Cummins et al. (2021), Sun et al. (2021), Lowe et al. (2021), Caglar & Kacer (2021), De Santi et al. (2021), Quan et al. (2021), Strangfeld et al. (2021), Tardif et al. (2021), Jafari et al. (2021), Prats-Uribe, Tobed, et al. (2021), Nuño et al. (2021), Abajo et al. (2021), Mora et al. (2021), Molenaar et al. (2021), Leister et al. (2021), Didikoglu et al. (2021), Estiri et al. (2021), Tavakol et al. (2021), H. Cai et al. (2021), Lohia et al. (2021), Vila-Corcoles et al. (2021), Gégout petit et al. (2021), Q. Zhang et al. (2021), Dambha-Miller et al. (2021), Badr et al. (2021a), Badr et al. (2021b), Hoertel et al. (2021), Lombardi et al. (2021), Gharebaghi et al. (2021), Shields et al. (2021), Voruz et al. (2021), The OpenSAFELY Collaborative et al. (2021), González, Vielot, et al. (2021), Lucar et al. (2021), Drozd et al. (2021), Printza et al. (2021), Dashti et al. (2021), Nielsen et al. (2021), Peng et al. (2021), Dayem Ullah et al. (2021), Velasco-Rodríguez et al. (2021), Action to beat coronavirus/Action pour battre le coronavirus (Ab-C) Study Investigators & Jha (2021), Guzmán et al. (2021), García-Abellán et al. (2021), Martin-Vicente et al. (2021), Rogier et al. (2021), Greenbaum et al. (2021), Grint et al. (2021), Kline et al. (2021), Hausfater et al. (2021), Daugherty et al. (2021), Vanegas-Cedillo et al. (2021), Amanat et al. (2021), Yamei Zheng et al. (2021), Melotti et al. (2021), HPG23 Covid-19 Study Group et al. (2021), Martinez-Lacalzada, Viteri-Noël, et al. (2020), Martinez-Lacalzada, Adrián Viteri-Noël, et al. (2020), Q. Wang et al. (2021), Rachmawati et al. (2021a), Rachmawati et al. (2021b), Fernandez-Fuertes et al. (2021), Menges et al. (2021), Dev et al. (2021), PHOSP-COVID Collaborative Group et al. (2021), Asem et al. (2021), S. F. Lee et al. (2021), Avouac et al. (2021), (schaad_point?)–care_2021, Mok et al. (2021), Faverio et al. (2021), Bell et al. (2021), Gil et al. (2021), Galluzzi et al. (2021), Wagner et al. (2021), Mady et al. (2021), Rubina et al. (2021), Scully et al. (2021), Manohar et al. (2021), Durstenfeld et al. (2021), R. A. Rashid et al. (2021), J. Wang et al. (2021), Thomas et al. (2021), S. Li, Jun, et al. (2021), Atergeleh et al. (2021), Boscolo-Rizzo et al. (2021), Chalkias et al. (2021), Byttebier et al. (2021), Husain et al. (2021), Reese et al. (2021), Desgranges et al. (2021), S. Li, Sarangarajan, et al. (2021), Tarifi et al. (2021), Zell et al. (2021), S. C. Lee et al. (2021), Joubert et al. (2021), Halabi et al. (2021), Shiri et al. (2021), Gerhards et al. (2021), Radon et al. (2021), González, Zepeda, et al. (2021), Ahmadi et al. (2021), Ravindra et al. (2021), Mann et al. (2021), Noh et al. (2021), Bhaskaran et al. (2021), Chetboun et al. (2021), Fogh et al. (2021), Madakkatel et al. (2021), Bertuzzi et al. (2021), Röthlin Eriksen et al. (2021), Gornyk et al. (2021a), Gornyk et al. (2021b), Campbell et al. (2021), Marimuthu et al. (2021), Bruce et al. (2021), Bark et al. (2021), Jha et al. (2021), Lekoubou et al. (2021), Kahlert et al. (2021), Hirschtick et al. (2021), Y. Li et al. (2021), AlSafar et al. (2021), Wallis et al. (2021), Ayhan et al. (2021), Nanda et al. (2021), Prats-Uribe, Xie, et al. (2021), Egede et al. (2021), Kleynhans et al. (2021), Puebla Neira et al. (2021), Lassen et al. (2021), S. Chen et al. (2021), Fisher et al. (2021), Ghani et al. (2021), Andrade Barreto et al. (2021), Aabakke et al. (2021), Yozgat et al. (2021), Sandri et al. (2021), Jose et al. (2021), Herzberg et al. (2021), Han et al. (2021), Abdulamir et al. (2021), L. Chauhan et al. (2021), Barchuk et al. (2021), Patone et al. (2021), Mollan et al. (2021), Sonnweber et al. (2021), Nassar et al. (2021), Ali et al. (2021), Demichev et al. (2021), Mostafa et al. (2021), Tehrani et al. (2021a), Tehrani et al. (2021b), Amer et al. (2021), X. Wu et al. (2021), N. K. Chauhan et al. (2021), Mendez-Dominguez et al. (2021), The CONCOR-1 Study Group et al. (2021), Gebhard et al. (2021), Genecand et al. (2021), Qureshi et al. (2021), Y. I. Wan et al. (2021), Gaitán-Duarte et al. (2021), Chuo et al. (2021), Sholzberg et al. (2021), Riyahi et al. (2021), International Severe Acute Respiratory and emerging Infections Consortium, Escher, et al. (2020), International Severe Acute Respiratory and emerging Infections Consortium, Hall, et al. (2020), Pritchard et al. (2020), ISARIC Clinical Characterisation Group et al. (2020), Aboueshia et al. (2021), Matli et al. (2021), Alhamlan et al. (2021)